|
☐
|
REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
☒
|
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
||
|
For the fiscal year ended December 31, 2018
|
|
☐
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
☐
|
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
||
|
Date of event requiring this shell company report
|
|
For the transition period from
to
.
|
Title of each class
|
Name of each exchange on which registered
|
Ordinary Shares, par value NIS 1.00 per share
|
The New York Stock Exchange
|
Title of Class
|
Number of Shares Outstanding
|
Ordinary shares
|
1,304,890,778
|
PART I
|
Page
|
|||
1
|
||||
1
|
||||
1
|
||||
33
|
||||
131
|
||||
131
|
||||
187
|
||||
220
|
||||
228
|
||||
233
|
||||
233
|
||||
247
|
||||
256
|
||||
PART II
|
||||
256
|
||||
256
|
||||
257
|
||||
258
|
||||
258
|
||||
259
|
||||
259
|
||||
260
|
||||
260
|
||||
260
|
||||
262
|
||||
262
|
||||
262
|
||||
262
|
||||
FS-1
|
Bromine
|
A chemical element used as a basis for a wide variety of uses and compounds, and mainly as a component in flame retardants or fire prevention substances. Unless otherwise stated, the term “bromine” refers to elemental bromine.
|
CFR
|
Cost and freight. In a CFR transaction, the prices of goods to the customer includes, in addition to FOB expenses, marine shipping costs and all other costs that arise after the goods leave the seller’s factory gates and up to the destination port.
|
CPI
|
The Consumer Price Index, as published by the Israeli Central Bureau of Statistics.
|
Dead Sea Bromine Company
|
Dead Sea Bromine Company Ltd., included in Industrial Products segment.
|
EPA
|
US Environmental Protection Agency.
|
FAO
|
The Food and Agriculture Organization of the United Nations.
|
FOB
|
Free on board expenses are expenses for overland transportation, loading costs and other costs, up to and including the port of origin. In an FOB transaction, the seller pays the FOB expenses and the buyer pays the other costs from the port of origin onwards.
|
F&C
|
Fertilizers and Chemicals Ltd., included in Innovative Ag Solutions segment.
|
Granular
|
Fertilizer having granular particles.
|
ICL Boulby
|
A United Kingdom company included in the Potash segment.
|
ICL Iberia (Iberpotash)
|
Iberpotash S.A., a Spanish company included in Potash segment.
|
IC
|
Israel Corporation Ltd.
|
ICL Dead Sea (DSW)
|
Dead Sea Works Ltd., included in Potash segment.
|
ICL Magnesium (DSM)
|
Dead Sea Magnesium Ltd., included in Potash segment.
|
ICL Neot Hovav
|
Subsidiaries in the Neot Hovav area in the south of Israel, including facilities of Bromine Compounds Ltd. Included in Industrial Products segment.
|
ICL Rotem
|
Rotem Amfert Negev Ltd., included in Phosphate Solutions segment.
|
IFA
|
The International Fertilizers Industry Association, an international association of fertilizers manufacturers.
|
ILA
|
Israel Land Authority
|
IMF
|
International Monetary Fund.
|
K
|
The element potassium, one of the three main plant nutrients.
|
KNO
3
|
Potassium Nitrate, soluble fertilizer containing N&P used as a stand-alone product or as a key component of some water-soluble blends.
|
KOH
|
Potassium hydroxide 50% liquid.
|
N
|
The element nitrogen, one of the three main plant nutrients.
|
NYSE
|
The New York Stock Exchange.
|
P
|
The element phosphorus, one of the three main plant nutrients, which is also used as a raw material in industry.
|
Phosphate
|
Phosphate rock that contains the element phosphorus. Its concentration is measured in units of P
2
O
5
.
|
Polyhalite
|
A mineral marketed by ICL under the brand name Polysulphate™, composed of potash, sulphur, calcium, and magnesium. Used in its natural form as a fully soluble and natural fertilizer, which is also used for organic agriculture and as a raw material for production of fertilizers.
|
Polymer
|
A chemical compound containing a long chain of repeating units linked by a chemical bond and created by polymerization.
|
Potash
|
Potassium chloride (KCl), used as a plant’s main source of potassium.
|
P
2
O
5
|
Phosphorus pentoxide.
|
P
2
S
5
|
Phosphorus pentasulfide.
|
REACH
|
Registration, Evaluation
,
Authorization
and Restriction
of Chemicals, a framework within the European Union.
|
Red MOP
|
Natural or artificially reddish color MOP.
|
Salt
|
Unless otherwise specified, sodium chloride (NaCl).
|
Soluble NPK
|
Soluble fertilizer containing the three basic elements for plant development (nitrogen, phosphorus and potash).
|
SOP
|
Potassium of Sulfate or 0-0-50, used as low chloride potassium source.
|
Standard
|
Fertilizer having small particles.
|
Tami
|
Tami (IMI) Research and Development Institute Ltd., the central research institute of ICL.
|
TASE
|
Tel Aviv Stock Exchange, Ltd.
|
USDA
|
United States Department of Agriculture.
|
Urea
|
A white granular or prill solid fertilizer containing 46% nitrogen.
|
YTH/YPC
|
The Chinese partner in the Company’s joint venture YPH in China.
|
4D
|
Clean green phosphoric acid, used as a raw material for purification processes.
|
For the Year Ended December 31,
|
|||||
2018
|
2017
|
2016
|
2015
|
2014
|
|
US$ millions, except for the share data
|
Sales
|
5,556
|
5,418
|
5,363
|
5,405
|
6,111
|
Gross profit
|
1,854
|
1,672
|
1,660
|
1,803
|
2,196
|
Operating income (loss)
|
1,519
|
629
|
(3)
|
765
|
758
|
Income (loss) before income taxes
|
1,364
|
505
|
(117)
|
668
|
632
|
Net income (loss) attributable to the shareholders of the Company
|
1,240
|
364
|
(122)
|
509
|
464
|
Earnings (loss) per share (in dollars) :
|
|||||
Basic earnings (loss) per share
|
0.97
|
0.29
|
(0.10)
|
0.40
|
0.37
|
Diluted earnings (loss) per share
|
0.97
|
0.29
|
(0.10)
|
0.40
|
0.37
|
Weighted average number of ordinary shares outstanding:
|
|||||
Basic (in thousands)
|
1,277,209
|
1,276,072
|
1,273,295
|
1,271,624
|
1,270,426
|
Diluted (in thousands)
|
1,279,781
|
1,276,997
|
1,273,295
|
1,272,256
|
1,270,458
|
Dividends declared per common share (in dollars)
|
0.18
|
0.13
|
0.18
|
0.28
|
0.67
|
As at December 31,
|
|||||
2018
|
2017
|
2016
|
2015
|
2014
|
|
US$ millions
|
Statements of Financial Position Data:
|
|||||
Total assets
|
8,776
|
8,714
|
8,552
|
9,077
|
8,348
|
Total liabilities
|
4,861
|
5,784
|
5,893
|
5,889
|
5,348
|
Total equity
|
3,915
|
2,930
|
2,659
|
3,188
|
3,000
|
· |
Geological and mining conditions and/or effects of prior mining that may not be fully identified/assessed within the available data or that may differ from those based on experience;
|
· |
Assumptions concerning future prices of products, operating costs, mining technology improvements, development costs and reclamation costs; and
|
· |
Assumptions concerning future effects of regulation, including the issuance of required permits and taxes imposed by governmental agencies.
|
· |
Difficulties and costs associated with complying with a wide variety of complex laws, treaties and regulations, including the U.S. Foreign Corrupt Practices Act (the “FCPA”), the UK. Bribery Act of 2010 and Section 291A of the Israeli Penal Law;
|
· |
Unexpected changes in regulatory environments;
|
· |
Increased government ownership and regulation in the countries in which we operate;
|
· |
Political and economic instability, including civil unrest, inflation and adverse economic conditions resulting from governmental attempts to reduce inflation, such as imposition of higher interest rates and wage and price controls; and
|
· |
The imposition of tariffs, exchange controls, trade barriers, new taxes or tax rates or other restrictions, including the current trade dispute between the US and China.
|
· |
Some government programs may be discontinued, expire or be cancelled;
|
· |
Governments may initiate new legislation or amend existing legislation in order to impose additional and/or increased fiscal liabilities on our business, such as additional royalties or natural resource taxes, as has occurred in Israel;
|
· |
The applicable tax rates may increase;
|
· |
We may no longer be able to meet the requirements for continuing to qualify for some programs;
|
· |
Such programs and tax benefits may be unavailable at their current levels;
|
· |
Upon the expiration of a particular benefit, we may not be eligible to participate in a new program or qualify for a new tax benefit that would offset the loss of the expiring tax benefit.
|
· |
Changes in trade agreements between countries, such as in the trade agreements between the United States and China.
|
· |
Substantial cash expenditures;
|
· |
Dilution due to issuances of equity securities;
|
· |
The incurrence of debt and contingent liabilities, including liabilities for environmental damage caused by acquired businesses before we acquired them;
|
· |
A decrease in our profit margins;
|
· |
Impairment of intangible assets and goodwill; and
|
· |
Increased governmental oversight over the Company’s activity in certain areas.
|
· |
The composition of our Board of Directors (other than external directors, as described under
“Item 6 - Directors, Senior Management and Employees— C. Board Practices—
External Directors
”
);
|
· |
Mergers, acquisitions, divestitures or other business combinations;
|
· |
Future issuances of ordinary shares or other securities;
|
· |
Amendments to our Articles of Association, excluding provisions of the Articles of Association that were determined by virtue of the Special State Share
;
and
|
· |
Dividend distribution policy.
|
· |
Expiration or termination of licenses and/or concessions;
|
· |
General stock market conditions;
|
· |
Decisions by governmental entities that affect us;
|
· |
Variations in our and our competitors’ results of operations;
|
· |
Changes in earnings estimates or recommendations by securities analysts; and
|
· |
General market conditions and other factors, including factors unrelated to our operating performance.
|
· |
In March 2018, the Company completed the sale transaction of the fire safety and oil additives businesses, for a total consideration of $1,010 million, of which $953 million is in cash and $57 million is in the form of a long-term loan to a subsidiary of the buyer.
|
· |
In 2017, the Company completed the sale of its holdings in IDE Technologies Ltd., constituting 50% of IDE’s share capital.
|
· |
In 2016, ICL completed the sale of Clearon (chlorine-based biocide activities in USA).
|
· |
In 2015, ICL, together with YPC, completed the formation of YPH JV. YPH JV’s activities include operation of a phosphate rock mine and other phosphate operations.
In January 2016, ICL completed the investment in 15% of the issued and outstanding share capital on a fully diluted basis of YTH (Chinese traded company which holds YPH JV together with ICL).
|
· |
In 2015, ICL completed the divestiture of the following non‑core business activities: the alumina, paper and water industry (APW), the thermoplastic products for the footwear industry (Renoflex), the hygiene products for the food industry (Anti‑Germ) and the pharmaceutical and gypsum businesses (PCG).
|
· |
Access to one of the world’s richest, longest‑life and lowest‑cost sources of potash and bromine (the Dead Sea).
|
· |
Two potash mines and processing facilities in Spain
. The Company is in the
process of restructuring the operations in Spain from two sites into one site.
|
· |
Bromine compounds processing facilities located in Israel, the Netherlands and China
.
|
· |
A unique integrated phosphate value chain, from phosphate rock mines in Israel and in China to our value‑added downstream products in Israel, Europe, the United States, Brazil and China. Our specialty phosphates serve the food industry by providing texture and stability solutions to the meat, poultry, sea food, dairy and bakery markets and many industrial markets such as metal treatment, water treatment, oral care, carbonated drinks, asphalt modification, paints and coatings and more.
|
· |
Polysulphate resources in the United Kingdom
.
|
· |
Production of tailor-made, highly-effective specialty fertilizers offering both improved value to the grower and precise nutrition which is essential for plant development, optimization of crop yields and reduced environmental impacts.
|
· |
A focused and highly experienced group of technical experts developing production processes, new applications, formulations and products for our agricultural and industrial markets.
|
· |
An extensive global logistics and distribution network with operations in over 30 countries.
|
· | Polysulphate™ – polyhalite is a mineral that is exclusively mined by ICL through the Potash segment in an underground mine in the UK and is marketed under the brand name Polysulphate™. Polysulphate™ is used in its natural form as a fully soluble and natural fertilizer, which is also used for organic agriculture and as a raw material for production of fertilizers. Polysulphate™ is composed of sulphur (SO 3 48%), potash (K 2 O 14%), calcium (CaO 17%) and magnesium (MgO 6%), which are essential components for improvement of crops and agricultural products. |
· |
PotashpluS – a compressed mixture of Polysulphate™ and potash. The product includes potassium, sulphur, calcium and magnesium.
|
· |
PKPlus – a unique combination of phosphate, potash and Polysulphate™.
|
· |
NovaPhos – ensures an effective supply of slow-release phosphorus, calcium, magnesium and micronutrients for crops, specifically tailored for use in acidic soil.
|
· |
NPS – a nitrogen-phosphate fertilizer compounded with sulphur, which provides exceptional effectiveness for the enhancement of a wide range of crops through the combination of these three nutrients in one product.
|
· |
PK+Micronutrients – a tailor-made fertilizer, with precise micronutrient composition for the specific type of crop.
|
· |
Unique portfolio of mineral assets.
ICL benefits from access to one of the world’s richest, longest‑life and lowest‑cost resources of potash and bromine. ICL’s access to these resources is based on an exclusive concession from the State of Israel for extraction of minerals from the Dead Sea. ICL also holds licenses to mine potash and salts from underground mines in Spain, with vast resources. ICL is the only global producer of polyhalite, a mineral used as fertilizer and consisting potassium, Sulphur, calcium and magnesium. In addition, ICL has access to phosphate rock in the Negev Desert based on mining licenses from the State of Israel and it holds a license for mining phosphates in China. Access to these assets provides ICL with a consistent, reliable supply of raw materials, allowing for large scale-production and supporting ICL’s integrated value chain of specialty, value added products.
|
· |
Diversification into higher value‑added specialty products leveraging ICL’s integrated business model.
ICL’s integrated production processes are based on a synergistic value chain that allows it to both efficiently convert raw materials into value‑added downstream products and to utilize the by‑products. For example, in phosphates, ICL utilizes its backward integration to produce specialty phosphates used in the food industry and for industrial applications. These businesses benefit from higher growth rates, higher margins and lower volatility compared to commodity phosphates. In addition, as a by‑product of the potash production at the Dead Sea, ICL generates brines with the highest bromine concentration globally. ICL’s bromine‑based products serve various industries such as the electronics, construction, oil and gas and automotive industries.
|
· |
Leading positions in markets with high entry barriers.
ICL obtains leadership positions in many of the key markets in which it operates. It is the clear leader in the bromine market, with 40% of market capacity and about third of production and in the potash market the Dead Sea operations has a leading competitive positions. ICL also has the largest market share in specialty phosphates in the combined markets of North America, Europe and Latin America and is the sole producer of polysulphate. ICL has leadership positions in additional product lines such as phosphorous-based flame retardants, PK fertilizers in Europe and soluble phosphate‑based fertilizers.
|
· |
Strategically located production and logistics assets.
ICL benefits from the proximity of its facilities, both in Israel and Europe, to developed economies (Western Europe) and emerging markets (such as China, India and Brazil). For example, in Israel, ICL ships from two seaports: The Port of Ashdod (with access to Europe and South America) and the Port of Eilat (with access to Asia, Africa and Oceania). As a result of their geographical positions, access to these two ports provides ICL with two distinctive advantages versus its competitors: (1) it has lower plant gate‑to‑port, ocean freight, and transportation costs from ports to target markets, which lower its overall cost structure; and (2) it has faster time to markets due to its proximity to end‑markets, allowing it to opportunistically fill short lead‑time orders, strengthening its position with its customers. In addition, ICL is the sole producer with the ability to transport potash and phosphates from the same port (which it does in Israel). ICL’s sales are balanced between emerging markets (approximately 39% of 2018 sales) and developed economies (approximately 61% of 2018 sales).
|
· |
Available cash flows from operating activities and
closely monitored capital allocation approach
. Continuous focus on cash flow generation, optimization of the capital expenditures (CAPEX) and working capital as well as the implementation of efficiency measures enabled the Company to generate operating cash flow of $620 million in 2018. These cash flows were used in accordance with the Company’s strict approach in connection with allotment of equity, whereby the Company examines, on an ongoing basis, the work plan and its investments. ICL's capital allocation approach balances between driving its long‑term value creation through investments in its growth, providing a solid dividend yield while aiming to maintain an investment grade rating (BBB- by S&P and Fitch). On March 6, 2018, the Company’s Board of Directors revisited the dividend distribution policy and decided that for 2018 and 2019 calendar years the Company’s dividend payment rate will continue to be up to 50% of the adjusted net income. In 2018, the Company declared and paid total dividends of $244 million, in respect of the fourth quarter of 2017 as well as the first, second and third quarters of 2018. Dividend payments in 2018 reflects a dividend yield rate of 3.8% (based on the average share price for the year). See “Item 8 - Financial Information— A. Consolidated Statements and Other Financial Information— Dividend policy”.
|
· |
Professional expertise and culture of collaboration and determination
. ICL’s operations are managed by an international management team with extensive industry experience. ICL develops leaders with strong experience in their fields in order to drive change and innovation within the Company. ICL focuses on nurturing and empowering talent through a global platform of qualification, collaboration and communication that reinforces innovation.
|
Segment Information
|
Sub-business line
|
Product
|
Primary Applications
|
Primary End‑Markets
|
Flame retardants
|
Bromine-, Phosphorus- and magnesium Based Flame Retardants
|
Additives used in plastic, building materials and textile production
|
Electronics, automotive, building and construction, furniture and textiles
|
Industrial solutions
|
Elemental Bromine
|
Chemical reagent
|
Tire manufacturing, pharmaceuticals and agro
|
Phosphorus-Based Industrial Compounds
|
Fire resistant fluids in turbines & power generation hydraulic systems and phosphorous-based inorganic intermediates
|
Power plants and agro
|
|
Organic Bromine Compounds
|
Insecticides, solvents for chemical synthesis and chemical intermediates
|
Pharmaceuticals and agro
|
|
Clear Brines
|
Oil and gas drillings
|
Oil and gas
|
|
Merquel
|
Mercury emission control
|
Emission control in coal‑fired power plants
|
|
Bromine‑Based Biocides
|
Water treatment and disinfection
|
Swimming pools, cooling towers, paper plants and oil and gas drillings
|
|
Specialty minerals
|
Magnesia Products
|
Pharma and food, transformer steel, catalysts fuel and oil additives.
|
Food additives, multivitamins, transformer steel, automotive rubber and plastic, health care
|
Solid MgCl
2
, KCl
|
Deicing, food, oil drilling, pharma
|
Deicing, sodium replacement, KCl for drugs. multivitamins, oil drilling companies, small industrial niche markets
|
· |
The relatively low average cost of potash production at the Dead Sea by using the sun as a solar energy source in the evaporation process.
|
· |
Logistical advantages due to its geographical location, access to nearby ports in Israel and Europe and relative proximity to its customers, which are reflected in particularly competitive marine and overland shipping costs and delivery times.
|
· |
Climate advantages due to the hot and dry climate of the Dead Sea that enable the Company to store, at very low cost, a large quantity of potash in an open area thereby allowing it to constantly produce at Sodom at full capacity, independent of fluctuations in global potash demand.
|
· |
A professional agronomic sales team that focuses on individually‑tailored agronomic consulting to customers based on an analysis of the different growing conditions of each particular customer.
|
· |
A leading R&D set‑up in the area of potash production.
|
· |
Synergies between the various production plants in Sodom site.
|
· |
ICL is the sole producer of Polysulphate™ worldwide.
|
· |
ICL Boulby's infrastructure supporting Polysulphate production (previously used for potash production) is already in place, including mine, shaft and transportation logistics.
|
· |
The ability to increase production at a relatively low capital expenditure.
|
· |
The Polysulphate™ and Polysulphate™-based fertilizers, which include different compounds of phosphorus, sulphur, magnesium and calcium, are tailored for various types of soil and a wide range of crops, achieved high performance in enhancing crops, improving yields and increasing fertilizer efficiency.
|
· |
Polysulphate™ contributes to and follows the main market trends in the fields of increased nutrient-use efficiency, low carbon footprint and organic fertilizers.
|
· |
The FertilizerpluS product line is part of ICL’s strong market position in fertilizers.
|
· |
The FertilizerpluS product line has an inherent potential
for the development of new products and applications.
|
· |
PotashpluS – a compressed mixture of Polysulphate™ and potash. The product includes potassium, sulphur, calcium and magnesium and is marketed by the Potash segment. In the third quarter of 2018, the segment finalized the industrialization process for the production of PotashpluS and in 2019 plans to increase significantly the production and the sales quantities of the product.
|
· |
PKpluS – a unique combination of phosphate, potash and Polysulphate™. In 2018, the Company, through the Phosphate Solutions segment, sold the product in commercial quantities and in 2019 plans to increase the production and the sales quantities of the product.
|
· |
An integrated value chain uses the phosphate rock mined in Israel (ICL Rotem) as well as in China (YPH) for the production of its green phosphoric acid, which serves mainly as a raw material for the production of the segment's products and for the production of ICL's specialty fertilizers business products.
|
· |
Logistical advantages due to its geographical location, close proximity to ports in Israel and Europe and relative proximity to its customers. In addition, ICL is a unique global fertilizer producer that is able to combine potash and phosphate fertilizers in the same shipment, which enables it to service smaller customers, particularly in Brazil and the United States.
|
· |
A professional agronomic sales team that focuses on individually‑tailored agronomic consulting to customers based on analysis of their specific combination of agricultural products and growing conditions.
|
· |
Phosphate Solutions segment is the only fully integrated global producer of downstream phosphate-based products and its geographical diversification provides a competitive advantage in logistics, as a supplier to global food companies.
|
· |
As a result of the acquisition of YPH, the JV in China, ICL has an integrative phosphate platform in China with better access to the Chinese market. In addition, Phosphate Solutions segment enjoys a competitive cost advantage with respect to its phosphate activities due to access to low‑cost phosphate rock with long‑term reserves, as well as low‑cost green phosphoric acid.
|
· |
Everris
, a company that manufactures and sells high‑quality controlled‑release, slow‑release and soluble fertilizers,
|
· |
Fuentes Fertilizantes
, a leading company in Spain that manufactures and distributes liquid and soluble fertilizers, NPK compounds and conventional fertilizers,
|
· |
ICL Belgium
, a manufacturer of soluble NPK fertilizer components,
|
· |
AmegA
, which develops advanced solutions for water conservation.
|
· |
YPH
in China also manufactures specialty fertilizers, contributing to the business line’s growth in Asia.
|
· |
Controlled‑release fertilizers (CRF) allow accurate release of nutrients over time. CRF’s have a special coating that allows prolonged release of nutrients over several weeks and up to 18 months - compared to regular fertilizers that dissolve in the soil and are immediately available. ICL Innovative Ag Solutions has leading global brand-name products such as, Osmocote, Agroblen and Agrocote. Osmocote is the most used controlled‑release fertilizers by ornamental growers worldwide. The brand is known to deliver high quality ornamental plants due to its consistent release of nutrients and unique patterned and programmed release technologies. ICL continues to invest in new technologies as well as field trials to test and confirm the high reliability of the release. During the past few years, ICL developed several new technologies such as the “Dual Coating Technology” (which optimizes the release to ornamental plants) and the “E-Max Release Technology” (a new coating technology with improved release characteristics, mainly for urea). Furthermore, ICL is also selling slow‑release fertilizers (SRF) which, due to their low solubility and hydrolysis, release nutrients slowly (generally up to a period of 2 months). Main market for this is in the Turf and Amenity market.
|
· |
Soluble fertilizers, which are fully water‑soluble, and fully‑soluble NPK compound fertilizers, are commonly used for fertilization through drip irrigation systems to optimize fertilizer efficiency in the root zone and to maximize yields. These fully soluble fertilizers are also sometimes used for foliar applications. ICL's well-known brands for fertigation are Peters, Universol, Agrolution, NovaNPK and Novacid. ICL develops specific formulations for different applications and circumstances. There are specific formulations for specific crops, greenhouses and/or open fields, as well as for different water types.
|
· |
ICL is also selling ‘Straight fertilizers’ which are crystalline, free‑flowing and high purity phosphorus soluble fertilizers such as MKP, MAP and PeKacid. PeKacid is the only solid highly acidifying, water soluble fertigation product that contains both phosphorus and potassium. The product is ideal for specific water conditions where an acidifying effect is required as well as keeping the dripping lines clean.
|
· |
Liquid fertilizers are used for intensive agriculture and are integrated in irrigation systems (mainly drip systems). The product line includes mostly tailor‑made formulations designed for specific soil & water/climate conditions and crop needs.
|
· |
Peat, a growing medium for various crops, where generally controlled‑release fertilizers and plant‑protection products are added too. Specific formulations of growing media are designed for specific plant needs, such as greenhouse bedding plants and outdoor nurseries. A well-known ICL brand is the “Levington” brand. Inclusion of growing media products in the portfolio in the UK allows ICL to offer an effective total solution to bedding and pot plant growers and nurseries.
|
· |
Water conservation and soil conditioning products is a new product line developed by ICL's IAS segment. Water conservation products are used in professional turf to keep water in the root-zone. A key brand is H2Pro. These products significantly reduce irrigation requirements. This new technology is also used in agriculture to allow better water availability around the root-zone of the crops.
|
· |
A strong, efficient and integrated supply chain with in-house access to high quality raw materials, such as phosphate and potash, which is based on an extensive product portfolio and multi-location production.
|
· |
Unique R&D and product development activities, creating a strong platform for future growth in controlled-release fertilizers, fertigation, foliar soluble fertilizers, enhanced nutrients, water efficiency and innovative next generation products.
|
· |
Added value production process technology – custom-made formulations to meet our customers’ unique needs.
|
· |
Highly skilled global agronomic sales team providing professional advice and consultation and Distributor loyalty.
|
· |
Full product portfolio (one-stop shop).
|
· |
ICL’s well-known and leading brands.
|
· |
Tetrabromobisphenol A (TBBPA) flame retardant, is under review as part of the Chemicals Regulation in Europe (REACH). The results of the review are expected in 2021. During 2018, TBBPA was nominated for review under the European directive on the restriction of the use of certain hazardous substances in electrical and electronic equipment (RoHS). The assessment is expected to be completed by the end of 2019. In October 2018, the California Office of Environmental Health and Hazard Assessment (OEHHA) added TBBPA to the Proposition 65 list, this process does not have a significant impact on
the
Industrial Products
segment
.
|
· |
Hypobromous Acid (HOBr): The Netherlands has filed a Registry of Intent (ROI) to the European Chemicals Agency (ECHA), with a proposed classification of HOBr as a reproductive toxin category 1B under the Classification, Labelling & Packaging (CLP) EU Regulation. HOBr is the active biocide formed from a few products of
the
Industrial Products
segment
. If this proposal will be accepted and becomes officially binding, it may have significant implications on the bromine-based biocidal products in the EU.
|
· |
Ammonium Bromide: Sweden has filed a dossier supporting proposed classification as reproductive toxin category 1B under the Classification, Labelling & Packaging (CLP) EU Regulation. If this proposal will be accepted and becomes officially binding, it may have significant implications on the bromides use in the EU (biocides and as chemicals).
|
· |
Biocides: in a number of countries, a biocidal substance and any product containing it must be registered prior to import or sale in those countries. Sale is limited to those commercial uses for which registration has been granted in a given country. The registration is generally for a limited time and needs to be renewed in order to continue selling. In the EU, biocides are regulated by the Biocides Products Regulation (BPR) under the EU Chemicals Agency (ECHA). All of
the
Industrial
Products segment's
biocide registration submissions under the BPR are currently in the stage of evaluation by the relevant Member State performing the review.
|
· |
Additional specific products of
the
Industrial Products
segment
are in the process of evaluation under the Chemical Regulation in the EU (REACH), For some products, there are draft or final decisions by ECHA to perform more studies, a process that will take a few years until the evaluation is completed.
|
C. ORGANIZATIONAL STRUCTURE
|
· |
Israel: under the Israeli Dead Sea Concession Law, 1961, as amended in 1986 (the “Concession Law”), we have lease rights until 2030 for the salt and carnallite ponds, pumping facilities and productions plants at Sodom. We have other production facilities in Israel, situated on land with a long‑term lease, including the plants at Mishor Rotem, the Oron and Zin sites of Phosphate Solutions segment (Oron is under an extension process), production facilities at Naot Hovav of Industrial Products segment (leased until 2024
-
2048), as well as production, storage and transportation facilities together with chemicals and research laboratories at Kiryat Ata that belong to Innovative Ag Solutions segment (leased until 2046
-
2049). We also use warehouses and loading and unloading sites at the Ashdod (leased until 2030) and Eilat ports (negotiations are underway to extend the agreement).
|
· |
Europe:
|
· |
North and South America:
|
· |
Asia:
|
Property Type
|
Location
|
Size (square feet)
|
Products
|
Owned/Leased
|
Plant
|
Mishor Rotem, Israel
|
27,094,510
|
Phosphate Solutions products
|
Owned on leased land
|
Plant
|
Mishor Rotem, Israel
|
10,763,910
|
Industrial Products products
|
Owned on leased land
|
Plant
|
Neot Hovav, Israel
|
9,601,591
|
Industrial Products products
|
Owned on leased land
|
Plant
|
Zin, Israel
|
8,484,123
|
Phosphate Solutions products
|
Owned on leased land
|
Plant
|
Kiryat Ata, Israel
|
6,888,903
|
Innovative Ag Solutions products
|
Leased
|
Plant
|
Oron, Israel
|
4,413,348 (not including phosphate reserve)
|
Phosphate Solutions products
|
Owned on leased land
|
Plant
|
Sodom, Israel
|
13,099,679 (not including ponds and Magnesium factory)
|
Potash products
|
Owned on leased land
|
Plant
|
4,088,800
|
Magnesium products (Potash segment)
|
Owned on leased land
|
|
Plant
|
2,326,060
|
Industrial Products products
|
Owned on leased land
|
|
Conveyor belt
|
1,970,333
|
Transportation facility for Potash
|
Owned on leased land
|
|
Pumping station
|
920,314
|
Pumping station for Potash segment
|
Owned on leased land
|
|
Plant
|
667,362
|
Industrial Products products
|
Owned on leased land
|
|
Power plant
|
645,856
|
Power and steam production for Potash segment
|
Owned on leased land
|
|
Warehouse and loading facility
|
Ashdod, Israel
|
664,133
|
Warehouse for Potash and Phosphate Solutions products
|
Leased
|
Office
|
Beer Sheva, Israel
|
495,883
|
Industrial Products
|
Owned
|
Plant
|
Mishor Rotem, Israel
|
430,355
|
Phosphate Solutions products
|
Owned on leased land
|
Warehouse and loading facility
|
Eilat, Israel
|
152,557
|
Warehouse for Potash and Phosphate Solutions products
|
Leased
|
Headquarters
|
Tel Aviv, Israel
|
25,318
|
Company headquarters
|
Leased
|
Plant
|
Catalonia, Spain
|
48,491,416
|
Mines, manufacturing facilities and warehouses for Potash
|
Owned
|
Plant
|
Totana, Spain
|
2,210,261
|
Innovative Ag Solutions products
|
Owned
|
Plant
|
Cartagena, Spain
|
209,853
|
Innovative Ag Solutions products
|
Owned
|
Warehouse and loading facility
|
Cartagena, Spain
|
184,342
|
Storage for Innovative Ag Solutions products
|
Leased
|
Plant
|
Jiaxing, China
|
828,017
|
Industrial Products products
|
Owned on leased land
|
Plant
|
Shan Dong, China
|
692,045
|
Industrial Products products
|
Owned on leased land
|
Plant
|
Kunming, Yunnan, China
|
458,394
|
Production Plant of Phosphate Solutions
|
Owned on leased land
|
Plant
|
Lian Yungang, China
|
358,793
|
Industrial Products products
|
Owned on leased land
|
Plant
|
Kunming, Yunnan, China
|
290,420
|
Phosphate Solutions products
|
Owned on leased land
|
Pumping station
|
Kunming, Yunnan, China
|
2,231
|
A pumping station for Phosphate Solutions
|
Owned on leased land
|
Peat Moor
|
Nutberry and Douglas Water, United Kingdom
|
17,760,451
|
Peat mine -Innovative Ag Solutions
|
Owned
|
Plant
|
Cleveland, United Kingdom
|
13,239,609
|
Polysulphate products (Potash segment)
|
Owned
|
Peat Moor
|
Creca, United Kingdom
|
4,305,564
|
Peat mine - Innovative Ag Solutions
|
Leased
|
Plant
|
Nutberry, United Kingdom
|
322,917
|
Innovative Ag Solutions products
|
Owned
|
Plant
|
Daventry, United Kingdom
|
81,539
|
Innovative Ag solutions products
|
Owned and leased
|
Plant
|
Terneuzen, the Netherlands
|
1,206,527
|
Industrial Products products
|
Owned
|
Plant
|
Heerlen, the Netherlands
|
481,802
|
Innovative Ag solutions products
|
Owned and leased
|
Plant
|
Amsterdam, the Netherlands
|
349,827
|
Phosphate Solutions products and logistics center
|
Owned on leased land
|
European Headquarters
|
Amsterdam, the Netherlands
|
59,055
|
European Company headquarters
|
Leased
|
Plant
|
Gallipolis Ferry, West Virginia, United States
|
1,742,400
|
Industrial Products products
|
Owned
|
Plant
|
Lawrence, Kansas, United States
|
179,689
|
Phosphate Solutions products
|
Owned
|
Plant
|
Carondelet, Missouri, United States
|
172,361
|
Phosphate Solutions products
|
Owned
|
Plant
|
North Charleston, South Carolina, United States
|
100,000
|
Innovative Ag solutions products
|
Leased
|
Plant
|
Summerville, South Carolina, United States
|
40,000
|
Innovative Ag solutions products
|
Leased
|
US headquarters
|
St. Louis, Missouri, United States
|
45,595
|
US Company headquarters
|
Leased
|
Plant
|
Ludwigshafen, Germany
|
6,996,541
|
Phosphate Solutions products and Infrastructure
|
Owned
|
Plant
|
Ladenburg, Germany
|
1,569,764
|
Phosphate Solutions products
|
Owned
|
Plant
|
Bitterfeld, Germany
|
514,031
|
Industrial Products products
|
Owned
|
Plant
|
Hemmingen, Germany
|
175,042
|
Phosphate Solutions products
|
Owned
|
Plant
|
Cajati, Brazil
|
413,959
|
Phosphate Solutions products
|
Owned
|
Plant
|
Sao Jose dos Campos, Brazil
|
Phosphate plant: 137,573 Blending plant: 80,729
|
Phosphate Solutions products
|
Owned on (free of charge) leased land
|
Plant
|
Belgium
|
128,693
|
Innovative Ag solutions products
|
Owned
|
Plant
|
Calais, France
|
546,290
|
Industrial Products products
|
Owned
|
Plant
|
Nuevo Leon, Mexico
|
152,408
|
Phosphate Solutions products
|
Owned
|
Plant
|
Bandırma, Turkey
|
375,187
|
Phosphate Solutions products
|
Owned
|
Plant
|
Hartberg, Austria
|
692,937
|
Phosphate Solutions products
|
Owned
|
Plant
|
Heatherton, Australia
|
64,583
|
Phosphate Solutions products
|
Leased
|
Israel
|
Total in Israel
|
Out of Israel
|
Total
|
|
Year Ended December 31,
|
$ millions
|
2018
|
71
|
*62
|
133
|
4
|
137
|
2017
|
64
|
*68
|
132
|
4
|
136
|
2016
|
58
|
-
|
58
|
9
|
67
|
Year Ended December 31,
|
|||
2018
|
2017
|
2016
|
Millions of metric
tonnes
produced
|
8
|
7
|
9
|
Grade (% P
2
O
5
before/after beneficiation)
|
26/32
|
26/32
|
26/32
|
Year Ended December 31,
|
|||
2018
|
2017
|
2016
|
|
thousands of
metric tonnes
|
thousands of
metric tonnes
|
thousands of
metric tonnes
|
Phosphate Rock
|
3,550
|
3,332
|
3,947
|
Green Phosphoric Acid
|
560
|
575
|
602
|
Fertilizers
|
988
|
957
|
890
|
White Phosphoric Acid
|
162
|
148
|
161
|
MKP
|
70
|
68
|
47
|
Year Ended December 31,
|
|||
2018
|
2017
|
2016
|
Sallent
|
|||
Ore processed (in millions of metric tonnes)
|
2
|
2
|
2
|
Grade (% KCl)
|
23%
|
23%
|
23%
|
Suria
|
|||
Ore processed (in millions of metric tonnes)
|
2
|
2
|
2
|
Grade (% KCl)
|
25%
|
24%
|
26%
|
Total
|
|||
Ore processed (in millions of metric tonnes)
|
4
|
4
|
4
|
Year Ended December 31,
|
|||
2018*
|
2017
|
2016
|
Potash Ore (millions of metric tonnes)
|
1
|
1
|
2
|
Grade (% KCl)
|
35%
|
36%
|
36%
|
Grade (% insoluble)
|
9%
|
11%
|
11%
|
Year Ended December 31,
|
|||
2018
|
2017
|
2016
|
Polyhalite Ore (millions of metric tonnes)
|
0.4
|
0.5
|
0.2
|
Year Ended December 31,
|
|||
2018
|
2017
|
2016
|
Millions of metric tonnes produced
|
2.15
|
1.95
|
2.20
|
Grade (% P
2
O
5
before/after beneficiation)
|
20.7/28.98
|
21.3/29.6
|
20.4/29.2
|
Year Ended December 31,
|
|||
2018
|
2017
|
2016
|
|
thousands of metric tonnes
|
thousands of metric tonnes
|
thousands of metric tonnes
|
Phosphate Rock
|
1,725
|
1,545
|
1,798
|
Green Phosphoric Acid
|
635
|
572
|
617
|
Fertilizers
|
621
|
335
|
790
|
White Phosphoric Acid (TG)
|
65
|
61
|
37
|
· |
Proven (measured) reserves.
Reserves for which (1) quantity is computed from information received from explorations, channels, wells and drillings; grade and/or quality are computed from the results of detailed sampling and (2) the sites for inspection, sampling and measurement are spaced so closely to each other so that the geologic character is well defined so the size, shape, depth and mineral content of reserves can be reliably determined.
|
· |
Probable (indicated) reserves. Reserves for which quantity and grade and/or quality are computed from information similar to that used for proven (measured) reserves, but the sites for survey, sampling, and measurement are further apart or are otherwise less efficiently spaced. The degree of assurance, although lower than that for proven (measured) reserves, is high enough to assume continuity between points of observation.
|
Category
|
White Phosphate
|
Low Organic Phosphate
|
High Organic Phosphate
|
Bituminous Phosphate
|
Recoverable Reserves
|
Average Grade
|
|
(millions of metric tonnes)
|
(%P
2
O
5
)
|
Rotem
|
Proven
|
-
|
10
|
-
|
-
|
10
|
26%
|
Zin
|
Proven
|
-
|
16
|
15
|
3
|
34
|
25%
|
Oron
|
Proven
|
14
|
4
|
-
|
-
|
18
|
23%
|
Total (Proven) (1)
|
14
|
30
|
15
|
3
|
62
|
· |
Low-organic phosphate—1.7 million metric tonnes per year
|
· |
High-organic phosphate—1.1 million metric tonnes per year
|
· |
Bituminous phosphate—0.3 million metric tonnes per year
|
Category
|
Low Organic Phosphate
|
Average Grade
|
|
(millions of metric tonnes)
|
(% P
2
O
5
)
|
Block 1
|
Proven
|
3
|
21%
|
Block 2
|
Proven
|
5
|
21%
|
Block 3
|
Proven
|
30
|
22%
|
Block 4
|
Proven
|
17
|
22%
|
Total (Proven)
|
55
|
(1) |
In February 2018, the Company entered into two supply agreements with Tamar and “Leviathan” reservoir (hereinafter – the Agreements), to secure its gas supply needs until the end of 2025 or until the entry of the “Karish” and “Tanin” reservoirs into service, whichever occurs first. The gas price in the Agreements is in accordance with the gas price formulas stipulated under the government’s gas outline. The Company anticipates that the scope of the annual gas consumption will be about 0.75 BCM.
|
$ per tonne
|
1-12/2018
|
1-12/2017
|
% vs 2017
|
DAP (Bulk CFR India Spot)
|
423
|
363
|
17%
|
TSP (Granular Bulk FOB Morocco Spot)
|
338
|
277
|
22%
|
MAP (Granular Bulk CFR Brazil Spot)
|
438
|
369
|
19%
|
Phosphate Rock (68-72% BPL) (FOB Morocco Contract)
|
91
|
90
|
1%
|
For the Year Ended December 31,
|
|||||
2018
|
2017
|
2016
|
2015
|
2014
|
|
US$ millions
|
Operating income (loss)
|
1,519
|
629
|
(3)
|
765
|
758
|
Impact of employee strike (1)
|
-
|
-
|
-
|
248
|
17
|
Capital (gain) loss (2)
|
(841)
|
(54)
|
1
|
(215)
|
(36)
|
Impairment of assets (3)
|
19
|
32
|
489
|
90
|
71
|
Provision for early retirement and dismissal of employees (4)
|
7
|
20
|
39
|
48
|
-
|
Provision for legal claims (5)
|
31
|
25
|
5
|
38
|
149
|
Provision for historical waste removal and site closure costs (6)
|
18
|
-
|
51
|
20
|
-
|
Other
|
-
|
-
|
-
|
-
|
1
|
Total adjustments to operating income (loss)
|
(766)
|
23
|
585
|
229
|
202
|
Adjusted operating income
|
753
|
652
|
582
|
994
|
960
|
Net income (loss) attributable to the shareholders of the Company
|
1,240
|
364
|
(122)
|
509
|
464
|
Total adjustments to operating income (loss)
|
(766)
|
23
|
585
|
229
|
202
|
Adjustments to finance expenses (7)
|
10
|
-
|
38
|
-
|
31
|
Total tax impact of the above operating income & finance expenses adjustments
|
(7)
|
(4)
|
(81)
|
(58)
|
(64)
|
Tax assessment and deferred tax adjustments (8)
|
-
|
6
|
36
|
19
|
62
|
Adjustments attributable to the non-controlling interests
|
-
|
-
|
(5)
|
-
|
-
|
Total adjusted net income - shareholders of the Company
|
477
|
389
|
451
|
699
|
695
|
For the Years Ended December 31,
|
%
Increase
(Decrease)
|
||
2018
|
2017
|
||
$ millions
|
$ millions
|
Sales
|
5,556
|
5,418
|
3%
|
Cost of sales
|
3,702
|
3,746
|
(1)%
|
Gross profit
|
1,854
|
1,672
|
11%
|
Selling, transport and marketing expenses
|
798
|
746
|
7%
|
General and administrative expenses
|
257
|
261
|
(2)%
|
Research and development expenses
|
55
|
55
|
-
|
Other expenses
|
84
|
90
|
(7)%
|
Other income
|
(859)
|
(109)
|
688%
|
Operating income
|
1,519
|
629
|
141%
|
Finance expenses, net
|
158
|
124
|
27%
|
Share in earnings of equity-accounted investees
|
3
|
-
|
-
|
Income before income taxes
|
1,364
|
505
|
170%
|
Provision for income taxes
|
129
|
158
|
(18)%
|
Net income
|
1,235
|
347
|
256%
|
Net income attributable to the shareholders of the Company
|
1,240
|
364
|
241%
|
Earnings per share attributable to the shareholders of the Company:
|
|||
Basic earnings per share (in dollars)
|
0.97
|
0.29
|
235%
|
Diluted earnings per share (in dollars)
|
0.97
|
0.29
|
235%
|
Sales
|
Expenses
|
Operating income
|
||
$
millions
|
YTD 2017 figures
|
5,418
|
(4,789)
|
629
|
|
Total adjustments YTD 2017 *
|
-
|
23
|
23
|
|
Adjusted YTD 2017 figures
|
5,418
|
(4,766)
|
652
|
|
Divested businesses 2017
|
(343)
|
221
|
(122)
|
|
Adjusted YTD 2017 figures (excluding divested businesses)
|
5,075
|
(4,545)
|
530
|
|
Quantity
|
(87)
|
77
|
(10)
|
|
Price
|
419
|
-
|
419
|
|
Exchange rate
|
99
|
(93)
|
6
|
|
Raw materials
|
-
|
(88)
|
(88)
|
|
Energy
|
-
|
(2)
|
(2)
|
|
Transportation
|
-
|
(41)
|
(41)
|
|
Operating and other expenses
|
-
|
(64)
|
(64)
|
|
Adjusted YTD 2018 figures (excluding divested businesses)
|
5,506
|
(4,756)
|
750
|
|
Divested businesses 2018
|
50
|
(47)
|
3
|
|
Adjusted YTD 2018 figures
|
5,556
|
(4,803)
|
753
|
|
Total adjustments YTD 2018 *
|
-
|
766
|
766
|
|
YTD 2018 figures
|
5,556
|
(4,037)
|
1,519
|
- |
Sales
– the Company sales increased by $138 million compared to 2017.
The increase derives mainly from an increase in the selling prices of potash (a $42 increase in the average realized price per tonne compared to the corresponding period last year), phosphate fertilizers, phosphate-based acids and food additives (as part of the value-focused strategy), specialty agriculture products and a positive price impact throughout most of Industrial Products segment’s business lines
(see 'Price' above), as well as a positive exchange rate contribution, mainly due to the average upward revaluation of the euro against the dollar (see ‘Exchange rate’ above) and an increase in the quantities sold of dairy proteins, bromine- and phosphorous-based flame retardants and specialty agriculture products (part of the change in the ‘Quantity’ line above).
|
- |
Cost of sales
– the cost of sales decreased by $44 million compared to 2017. The decrease derives mainly from the divestiture of the Fire Safety, Oil Additives and Rovita businesses (see 'Divested businesses' rows above) together with a decline in the quantities sold of potash, phosphate fertilizers and phosphate-based acids and food additives (see ‘Quantity’ above).
|
- |
Selling and marketing
– selling and marketing expenses increased by $52 million compared to 2017. The increase derives mainly from an increase in marine transportation prices and exchange rate fluctuations (see ‘Transportation’ and ‘Exchange rate’ above).
|
- |
General and administrative
– general and administrative expenses decreased by $4 million compared to 2017. The company successfully maintained low level of general and administrative expenses following the efficiency measures that took place in 2017.
|
- |
Other income, net
- other income, net, increased by $756 million compared to 2017. The increase derives mainly from capital gain recorded from the sale transaction of the Fire Safety and Oil Additives businesses, partly offset by capital gains recorded in the previous year related to divestiture of businesses, mainly IDE (see ‘Adjustments to reported operating and net income – Non-GAAP financial measures’ above).
|
Europe
|
1,970
|
1,918
|
Asia
|
1,488
|
1,342
|
North America
|
978
|
1,175
|
South America
|
712
|
666
|
Rest of the world
|
408
|
317
|
Total
|
5,556
|
5,418
|
2018
|
2017
|
|
$ millions
|
$ millions
|
Total Sales
|
1,296
|
1,193
|
Sales to external customers
|
1,281
|
1,179
|
Sales to internal customers
|
15
|
14
|
Segment profit
|
350
|
303
|
Depreciation and Amortization
|
63
|
61
|
Capital expenditures
|
50
|
49
|
Europe
|
473
|
456
|
Asia
|
399
|
351
|
North America
|
347
|
327
|
South America
|
21
|
18
|
Rest of the world
|
41
|
27
|
Total
|
1,281
|
1,179
|
Sales
|
Expenses
|
Operating income
|
||
$ millions
|
YTD 2017 figures
|
1,193
|
(890)
|
303
|
|
Quantity
|
22
|
(19)
|
3
|
|
Price
|
70
|
-
|
70
|
|
Exchange rate
|
11
|
(11)
|
-
|
|
Raw materials
|
-
|
(13)
|
(13)
|
|
Energy
|
-
|
(2)
|
(2)
|
|
Transportation
|
-
|
1
|
1
|
|
Operating and other expenses
|
-
|
(12)
|
(12)
|
|
YTD 2018 figures
|
1,296
|
(946)
|
350
|
- |
Quantity
– the positive impact on the segment’s profit derives mainly from an increase in the quantities sold of bromine-based flame retardants, phosphorous‑based flame retardants and industrial solutions and magnesia products, partly offset by a decrease in the quantities sold of bromine-based industrial solutions.
|
- |
Price
– the positive impact on the segment’s profit derives mainly from an increase in the selling prices of bromine-based industrial solutions and flame retardants, phosphorous-based flame retardants and magnesia products.
|
- |
Exchange rate
– the average upward revaluation of the euro against the dollar which increased the Company's revenue was fully offset by the average upward revaluation of the euro and the shekel against the dollar which increased production costs.
|
- |
Raw materials
–the negative impact on the segment’s profit derives mainly from an increase in the prices of raw materials used for bromine- and phosphorous-based flame retardants.
|
- |
Operating and other expenses
– the negative impact on the segment's profit derives mainly from inventory write-off and higher labor costs.
|
2018
|
2017
|
|
$ millions
|
$ millions
|
Total sales
|
1,623
|
1,383
|
Potash sales to external customers
|
1,280
|
1,119
|
Potash sales to internal customers
|
79
|
71
|
Other and eliminations*
|
264
|
193
|
Gross profit
|
696
|
539
|
Segment profit
|
393
|
282
|
Depreciation and Amortization
|
141
|
128
|
Capital expenditures
|
356
|
270
|
Average realized price (in $)**
|
278
|
236
|
Asia
|
518
|
432
|
South America
|
406
|
347
|
Europe
|
396
|
327
|
North America
|
107
|
116
|
Rest of the world
|
54
|
36
|
Total
|
1,481
|
1,258
|
Sales
|
Expenses
|
Operating income
|
||
$
millions
|
YTD 2017 figures
|
1,383
|
(1,101)
|
282
|
|
Quantity
|
21
|
(25)
|
(4)
|
|
Price
|
197
|
-
|
197
|
|
Exchange rate
|
22
|
(27)
|
(5)
|
|
Energy
|
-
|
(3)
|
(3)
|
|
Transportation
|
-
|
(32)
|
(32)
|
|
Operating and other expenses
|
-
|
(42)
|
(42)
|
|
YTD 2018 figures
|
1,623
|
(1,230)
|
393
|
- |
Quantity
– the moderate negative impact on the segment’s profit derives mainly from a product and site mix, due to increased sales of lower margin products, including electricity surplus from the new power plant in Sodom and Polysulphate.
|
- |
Price
– the positive impact on the segment’s profit derives from the increase in potash selling prices.
|
- |
Exchange rate
– the negative impact on the segment’s profit derives mainly from the average upward revaluation of the euro against the dollar.
|
- |
Transportation
– the negative impact on the segment’s profit derives mainly from an increase in marine transportation prices.
|
- |
Operating and other expenses
– the negative impact on the segment’s profit derives mainly from a capital gain due to sale of an office building in Israel which was recorded last year, an increase in royalties, as a result of higher revenue, higher depreciation expenses, expenses recorded in connection with DSW's collective labor agreement and higher operational costs, mainly as a result of annual production record level of potash in Israel.
|
Thousands of Tonnes
|
2018
|
2017
|
Production
|
4,880
|
4,773
|
Total sales (including internal sales)
|
4,895
|
5,039
|
Closing inventory
|
385
|
400
|
2018
|
2017
|
|
$ millions
|
$ millions
|
Total Sales
|
2,099
|
2,037
|
Sales to external customers
|
2,001
|
1,938
|
Sales to internal customers
|
98
|
99
|
Segment profit
|
208
|
149
|
Depreciation and Amortization
|
172
|
172
|
Capital expenditures
|
180
|
154
|
Europe
|
696
|
730
|
Asia
|
465
|
457
|
North America
|
405
|
368
|
South America
|
264
|
274
|
Rest of the world
|
171
|
109
|
Total
|
2,001
|
1,938
|
Sales
|
Expenses
|
Operating income
|
||
$
millions
|
YTD 2017 figures
|
2,037
|
(1,888)
|
149
|
|
Divested businesses 2017
|
(32)
|
36
|
4
|
|
YTD 2017 figures (excluding divested businesses)
|
2,005
|
(1,852)
|
153
|
|
Quantity
|
(108)
|
98
|
(10)
|
|
Price
|
142
|
-
|
142
|
|
Exchange rate
|
44
|
(33)
|
11
|
|
Raw materials
|
-
|
(62)
|
(62)
|
|
Energy
|
-
|
1
|
1
|
|
Transportation
|
-
|
(10)
|
(10)
|
|
Operating and other expenses
|
-
|
(14)
|
(14)
|
|
YTD 2018 figures (excluding divested businesses)
|
2,083
|
(1,872)
|
211
|
|
Divested businesses 2018
|
16
|
(19)
|
(3)
|
|
YTD 2018 figures
|
2,099
|
(1,891)
|
208
|
- |
Divested businesses
– sale of the assets and business of Rovita at the beginning of the third quarter of 2018.
|
- |
Quantity
– the negative impact on the segment’s profit derives mainly from a decrease in phosphate-based acids and food additives, together with phosphate fertilizers quantities sold, which was partly offset by an increase in dairy proteins quantities sold.
|
- |
Price
– the segment benefited from a positive price impact throughout most of the phosphate chain. The increase derives mainly from selling prices of phosphate fertilizers, together with phosphate-based acids, food additives and salts (mainly as part of value-focused strategy).
|
- |
Exchange rate
– the positive impact on the segment’s profit derives mainly from the average upward revaluation of the euro against the dollar increasing revenues. This increase was partly offset by the average upward revaluation of the euro and the Chinese yuan against the dollar increasing production costs.
|
- |
Raw materials
– the negative impact on the segment’s profit derives mainly from higher sulphur prices which increased the costs of the main raw materials throughout the phosphate value chain.
|
- |
Transportation
– the negative impact on the segment’s profit derives mainly from an increase in marine transportation prices.
|
- |
Operating and other expenses
– the negative impact on the segment’s profit derives mainly from an insurance income in Israel which was recorded last year and inventory write-off, partly offset by lower operational costs as a result of implementation of efficiency measures and an environment-related provision which was recorded last year.
|
Thousands of tonnes
|
2018
|
2017
|
Phosphate rock
|
||
Production
|
5,006
|
4,877
|
Green phosphoric acid
|
||
Used for production of phosphate commodities
|
552
|
451
|
Used for production of phosphate specialties
|
305
|
281
|
Other
|
17
|
28
|
Phosphate fertilizers
|
||
Production
|
2,304
|
2,094
|
Sales*
|
2,269
|
2,291
|
Pure phosphoric acid
|
||
Production
|
289
|
275
|
2018
|
2017
|
|
$ millions
|
$ millions
|
Total Sales
|
741
|
692
|
Sales to external customers
|
719
|
671
|
Sales to internal customers
|
22
|
21
|
Segment profit
|
57
|
56
|
Depreciation and Amortization
|
19
|
19
|
Capital expenditures
|
15
|
12
|
Europe
|
359
|
324
|
Asia
|
105
|
99
|
North America
|
97
|
87
|
South America
|
21
|
22
|
Rest of the world
|
137
|
139
|
Total
|
719
|
671
|
Sales
|
Expenses
|
Operating income
|
||
$
millions
|
YTD 2017 figures
|
692
|
(636)
|
56
|
|
Quantity
|
17
|
(13)
|
4
|
|
Price
|
13
|
-
|
13
|
|
Exchange rate
|
19
|
(17)
|
2
|
|
Raw materials
|
-
|
(14)
|
(14)
|
|
Energy
|
-
|
-
|
-
|
|
Transportation
|
-
|
-
|
-
|
|
Operating and other expenses
|
-
|
(4)
|
(4)
|
|
YTD 2018 figures
|
741
|
(684)
|
57
|
- |
Quantity
– the positive impact on the segment's profit derives mainly from specialty agriculture products, largely from liquid NPK, straight fertilizers and water-soluble NPK
.
|
- |
Price
– the positive impact on the segment's profit derives mainly from an increase in the selling prices of straight fertilizers
.
|
- |
Exchange rate
– the positive impact on the segment's profit derived mainly from the average upward revaluation of the euro against the dollar which increased revenue more than it contributed to the increase in production costs
.
|
- |
Raw materials
– the negative impact on the segment's profit derives mainly from an increase in most of the segment's raw materials, mainly ammonia and caustic soda
.
|
For the Years Ended December 31,
|
%
Increase
(Decrease)
|
||
2017
|
2016
|
||
$ millions
|
$ millions
|
sales
|
Sales
|
5,418
|
5,363
|
1%
|
Cost of sales
|
3,746
|
3,703
|
1%
|
Gross profit
|
1,672
|
1,660
|
1%
|
Selling, transport and marketing expenses
|
746
|
722
|
3%
|
General and administrative expenses
|
261
|
321
|
(19)%
|
Research and development expenses
|
55
|
73
|
(25)%
|
Other expenses
|
90
|
618
|
(85)%
|
Other income
|
(109)
|
(71)
|
54%
|
Operating income (loss)
|
629
|
(3)
|
-
|
Finance expenses, net
|
124
|
132
|
(6)%
|
Share in earnings of equity-accounted investees
|
-
|
18
|
-
|
Income (loss) before income taxes
|
505
|
(117)
|
-
|
Provision for income taxes
|
158
|
55
|
187%
|
Net income (loss)
|
347
|
(172)
|
-
|
Net income (loss) attributable to the shareholders of the Company
|
364
|
(122)
|
-
|
Earnings (losses) per share attributable to the shareholders of the Company:
|
|||
Basic earnings (losses) per share (in dollars)
|
0.29
|
(0.10)
|
-
|
Diluted earnings (losses) per share (in dollars)
|
0.29
|
(0.10)
|
-
|
Sales
|
Expenses
|
Operating income
|
||
$ millions
|
YTD 2016 figures
|
5,363
|
(5,366)
|
(3)
|
|
Total adjustments YTD 2016*
|
-
|
585
|
585
|
|
Adjusted YTD 2016 figures
|
5,363
|
(4,781)
|
582
|
|
Quantity
|
52
|
(1)
|
51
|
|
Price
|
(6)
|
-
|
(6)
|
|
Exchange rate
|
9
|
(56)
|
(47)
|
|
Raw materials
|
-
|
25
|
25
|
|
Energy
|
-
|
(21)
|
(21)
|
|
Transportation
|
-
|
(12)
|
(12)
|
|
Operating and other expenses
|
-
|
80
|
80
|
|
Adjusted YTD 2017 figures
|
5,418
|
(4,766)
|
652
|
|
Total adjustments YTD 2017*
|
-
|
(23)
|
(23)
|
|
YTD 2017 figures
|
5,418
|
(4,789)
|
629
|
- |
Sales
– the company sales increased by $55 million compared to 2016. The quantity‑related increase derives mainly from an increase in the quantities sold of fire safety products (which were divested
at
the end of the first quarter of 2018), phosphate acids, bromine-based industrial solutions (mainly clear brine fluids), bromine‑based flame retardants and specialty agriculture
products
. The increase was partly offset by a decline in the quantities sold of phosphate rock, phosphate fertilizers and dairy proteins.
|
- |
Cost of sales
– the cost of sales increased by $43 million compared to 2016. The increase derives mainly from the upward revaluation of the shekel against the dollar increasing production costs (see ‘Exchange rate’ above), higher energy prices in Israel, higher electricity costs in Europe (see ‘Energy’ above), inventory write-offs in ICL Potash, mainly in Europe and an increase in royalties paid due to higher revenues (see ‘Other’ above). The increase was partly offset by a decline in raw materials prices, mainly commodity
fertilizer
prices used in the specialty fertilizers business and sulphur prices used mainly in the phosphate value chain (see ‘Raw materials’ above).
|
- |
Selling and marketing
– selling and marketing expenses increased by $24 million compared to 2016. The increase derives mainly from an increase in marine transportation prices and exchange rate fluctuations, partly offset by a decrease in quantities sold of products of the Phosphate commodities business (see ‘Transportation’ and ‘Exchange rate’ above).
|
- |
General and administrative
– general and administrative expenses decreased by $60 million compared to 2016. The decrease derives mainly from cost-saving measures and a reduction of professional services throughout the Company (see ‘Operating and other expenses’ above).
|
- |
Other expenses, net
- other expenses, net, decreased by $566 million compared to 2016. The decrease derives mainly from capital gains recorded this year related to divestiture of businesses (mainly IDE
)
,
together with non-operational expenses in the corresponding period last year, mainly from impairment of assets related to the Harmonization Project and to discontinuance of the activities of Allana Affar in Ethiopia (see ‘Adjustments to reported operating and net income – Non-GAAP financial measures’ above).
|
Europe
|
1,918
|
1,863
|
Asia
|
1,342
|
1,275
|
North America
|
1,175
|
1,141
|
South America
|
666
|
588
|
Rest of the world
|
317
|
496
|
Total
|
5,418
|
5,363
|
2017
|
2016
|
|
$ millions
|
$ millions
|
Total Sales
|
1,193
|
1,120
|
Sales to external customers
|
1,179
|
1,111
|
Sales to internal customers
|
14
|
9
|
Segment profit
|
303
|
286
|
Depreciation and Amortization
|
61
|
52
|
Capital expenditures
|
49
|
38
|
Europe
|
456
|
424
|
Asia
|
351
|
301
|
North America
|
327
|
330
|
South America
|
18
|
24
|
Rest of the world
|
27
|
32
|
Total
|
1,179
|
1,111
|
Sales
|
Expenses
|
Operating income
|
||
$
millions
|
YTD 2016 figures
|
1,120
|
(834)
|
286
|
|
Quantity
|
57
|
(21)
|
36
|
|
Price
|
12
|
-
|
12
|
|
Exchange rate
|
4
|
(16)
|
(12)
|
|
Raw materials
|
(1)
|
(1)
|
|
|
Energy
|
(2)
|
(2)
|
|
|
Transportation
|
(1)
|
(1)
|
|
|
Operating and other expenses
|
(15)
|
(15)
|
|
|
YTD 2017 figures
|
1,193
|
(890)
|
303
|
-
|
Quantity
– the positive impact on the segment's profit derives mainly from an increase in the quantities sold of bromine-based flame retardants and bromine-based industrial solutions (mainly clear brine fluids).
|
-
|
Price
– the positive impact on the sales and on the segment's profit derives mainly from an increase in the selling prices of phosphorous-based flame retardants and bromine-based industrial solutions.
|
-
|
Exchange rate
– the negative impact on the segment's profit derives mainly from the upward revaluation of the shekel against the dollar increasing production costs, partly offset by the upward revaluation of the euro against the dollar increasing revenues.
|
-
|
Operating and other expenses
- the negative impact on the segment's profit derives mainly from an increase in the royalties as a result of the increase in sales and from expenses recorded in relation with an extension of work agreement.
|
2017
|
2016
|
|
$ millions
|
$ millions
|
Total sales
|
1,383
|
1,338
|
Potash sales to external customers
|
1,119
|
1,085
|
Potash sales to internal customers
|
71
|
80
|
Other and eliminations*
|
193
|
173
|
Gross profit
|
539
|
499
|
Segment profit
|
282
|
282
|
Depreciation and Amortization
|
128
|
127
|
Capital expenditures
|
270
|
311
|
Average realized price (in $)**
|
236
|
226
|
Asia
|
432
|
395
|
South America
|
347
|
267
|
Europe
|
327
|
354
|
North America
|
116
|
93
|
Rest of the world
|
36
|
104
|
Total
|
1,258
|
1,213
|
Sales
|
Expenses
|
Operating income
|
||
$
millions
|
YTD 2016 figures
|
1,338
|
(1,056)
|
282
|
|
Quantity
|
1
|
9
|
10
|
|
Price
|
41
|
-
|
41
|
|
Exchange rate
|
3
|
(14)
|
(11)
|
|
Energy
|
(11)
|
(11)
|
|
|
Transportation
|
(28)
|
(28)
|
|
|
Operating and other expenses
|
(1)
|
(1)
|
|
|
YTD 2017 figures
|
1,383
|
(1,101)
|
282
|
- |
Operating and other expenses
- the negative impact on the segment’s profit derives mainly from an increase in inventory write-offs (mainly in Europe) and an increase in royalties and sales commissions. This negative impact was partly offset by expenses recorded last year in connection with DSW's collective labor agreement and a capital gain due to sale of an office building in Israel.
|
Thousands of Tonnes
|
2017
|
2016
|
Production
|
4,773
|
5,279
|
Total sales (including internal sales)
|
5,039
|
5,165
|
Closing inventory
|
400
|
666
|
2017
|
2016
|
|
$ millions
|
$ millions
|
Total Sales
|
2,037
|
2,186
|
Sales to external customers
|
1,938
|
2,082
|
Sales to internal customers
|
99
|
104
|
Segment profit
|
149
|
224
|
Depreciation and Amortization
|
172
|
203
|
Capital expenditures
|
154
|
237
|
Europe
|
730
|
697
|
Asia
|
457
|
501
|
North America
|
368
|
379
|
South America
|
274
|
276
|
Rest of the world
|
109
|
229
|
Total
|
1,938
|
2,082
|
Sales
|
Expenses
|
Operating income
|
||
$ millions
|
YTD 2016 figures
|
2,186
|
(1,962)
|
224
|
|
Quantity
|
(109)
|
73
|
(36)
|
|
Price
|
(46)
|
-
|
(46)
|
|
Exchange rate
|
6
|
(33)
|
(27)
|
|
Raw materials
|
15
|
15
|
|
|
Energy
|
(8)
|
(8)
|
|
|
Transportation
|
16
|
16
|
|
|
Operating and other expenses
|
11
|
11
|
|
|
YTD 2017 figures
|
2,037
|
(1,888)
|
149
|
- |
Operating and other expenses
- the positive impact on the segment’s profit derives mainly from a decrease in depreciation expenses due to lower production (lower stripping costs), a decrease in royalties paid and an insurance income in Israel, partly offset by an environment related provision.
|
Thousands of tonnes
|
2017
|
2016
|
Phosphate rock
|
||
Production
|
4,877
|
5,744
|
Green phosphoric acid
|
||
Used for production of phosphate commodities
|
451
|
645
|
Used for production of phosphate specialties
|
281
|
261
|
Other
|
28
|
28
|
Phosphate fertilizers
|
||
Production
|
2,094
|
2,725
|
Sales*
|
2,291
|
2,645
|
Pure phosphoric acid
|
||
Production
|
275
|
266
|
2017
|
2016
|
|
$ millions
|
$ millions
|
Total Sales
|
692
|
661
|
Sales to external customers
|
671
|
632
|
Sales to internal customers
|
21
|
29
|
Segment profit
|
56
|
55
|
Depreciation and Amortization
|
19
|
17
|
Capital expenditures
|
12
|
7
|
Europe
|
324
|
314
|
Asia
|
99
|
72
|
North America
|
87
|
100
|
South America
|
22
|
19
|
Rest of the world
|
139
|
127
|
Total
|
671
|
632
|
Sales
|
Expenses
|
Operating income
|
||
$
millions
|
YTD 2016 figures
|
661
|
(606)
|
55
|
|
Quantity
|
46
|
(39)
|
7
|
|
Price
|
(12)
|
-
|
(12)
|
|
Exchange rate
|
(3)
|
1
|
(2)
|
|
Raw materials
|
12
|
12
|
|
|
Energy
|
-
|
-
|
|
|
Transportation
|
-
|
-
|
|
|
Operating and other expenses
|
(4)
|
(4)
|
|
|
YTD 2017 figures
|
692
|
(636)
|
56
|
Year Ended December 31,
|
|||
2018
|
2017
|
2016
|
|
$ millions
|
$ millions
|
$ millions
|
Net cash provided by operating activities
|
620
|
847
|
966
|
Net cash provided by (used in) investing activities
|
331
|
(333)
|
(800)
|
Net cash used in financing activities
|
(894)
|
(511)
|
(239)
|
Issuer
|
European bank (1)
|
Group of twelve international banks (2)
|
European bank (3)
|
Date of the credit facility
|
March 2014
|
March 2015
|
December 2016
|
Date of credit facility termination
|
March 2019
|
March 2023
|
May 2025
|
The amount of the credit facility
|
USD 35 million
Euro 100 million
|
USD 1,200 million
|
USD 100 million
|
Credit facility has been utilized
|
Euro 40 million
|
USD 200 million
|
USD 70 million
|
Interest rate
|
Up to 33% use of the credit: Libor/Euribor + 0.70%.
From 33% to 66% use of the credit: Libor/Euribor + 0.80%
66% or more use of the credit: Libor/Euribor + 0.95%
|
Libor + 0.45% + spread
|
|
Loan currency type
|
USD and Euro loans
|
USD and Euro loans
|
USD loans
|
Pledges and restrictions
|
Financial covenants - see Section D, a cross-default mechanism and a negative pledge.
|
Financial covenants - see Section D, a cross-default mechanism and a negative pledge.
|
Financial covenants - see Section D and a negative pledge.
|
Non-utilization fee
|
0.32%
|
0.21%
|
0.30%
|
(1)
|
After the date of the report, the Company elected not to realize the option of revolving credit facility extension, and to repay the utilized credit facility on the date of its termination.
|
(2)
|
In October 2018, the Company entered into an agreement according to which, its commitment under certain revolving credit facility agreements will be reduced by a total aggregate amount of $655 million, to an amount of $1.2 billion.
|
(3)
|
In June 2018, the maturity date of the credit facility was extended to 2025. In November 2018, the credit facility was reduced from $136 million to $100 million. As at the date of the report, the Company utilized $70 million of that credit facility.
|
Instrument type
|
Loan date
|
Original principal (millions)
|
Currency
|
Carrying amount
($
millions
)
|
Interest rate
|
Principal repayment date
|
Additional information
|
Loan-Israeli institutions
|
November 2013
|
300
|
Israeli Shekel
|
67
|
4.74% (1)
|
2015-2024
(annual installment)
|
Partially prepaid
|
Debentures (private offering) – 3 series
|
January 2014
|
84
145
46
|
U.S Dollar
|
84
144
46
|
4.55%
5.16%
5.31%
|
January 2021
January 2024
January 2026
|
|
Loan-international institutions
|
July 2014
|
27
|
Euro
|
25
|
2.33%
|
2019-2024
|
Partially prepaid
|
Debentures - Series D
|
December 2014
|
800
|
U.S Dollar
|
182
|
4.50%
|
December 2024
|
(2)
|
Loan - European Bank
|
December 2014
|
161
|
Brazilian Real
|
19
|
CDI+1.35%
|
2015-2021
(Semiannual installment)
|
|
Debentures - Series E
|
April 2016
|
1,569
|
Israeli Shekel
|
416
|
2.45%
|
2021- 2024
(annual installment)
|
|
Loan - others
|
April - October, 2016
|
600
|
Chinese Yuan Renminbi
|
29
|
5.23%
|
2019
|
(3)
|
Loan - Asian Banks
|
June - October, 2018
|
600
|
Chinese Yuan Renminbi
|
87
|
4.79% - 5.44%
|
2019
|
|
Loan - Asian Bank
|
April 2018
|
400
|
Chinese Yuan Renminbi
|
58
|
CNH Hibor + 0.50%
|
2019
|
|
Debentures - Series F
|
May 2018
|
600
|
U.S Dollar
|
596
|
6.38%
|
May 2038
|
(4)
|
Loan - European Bank
|
December 2018
|
70
|
U.S Dollar
|
70
|
Libor + 0.66%
|
December 2021
|
· |
New Flame retardants for Printed wire boards: Development of new phosphorus‑based solutions for PWB according to new emerged demands from the market e.g. Polyquel® P100. This is a polymeric halogen free flame-retardant active ester curing agent for epoxy laminates with superior performance.
|
· |
Brominated polymeric flame retardants: Development of the next generation polymeric/active brominated flame retardants which are more environmentally friendly and future substitutes for threatened products.
|
· |
Flame retardants for polyurethanes: development of new phosphorus‑based solutions and integrated phosphorus/bromine solutions as flame-retardants for the polyurethane market (flexible and rigid foam). VeriQuel F100 is a new flexible halogen free active flame retardant for flexible polyurethane being launched to the market.
|
· |
Textiles: continuing development of TexFRon®, a series of textile flame‑retardant products. The series includes TexFRon 9001, the FR acrylic binder TexFRon P
and the low-melt polymeric TexFRon 4002. Additionally, it includes TexFRon AG and TexFRon 5001, both are non-halogen flame retardants. TexFRon®
4002 is an effective and environmentally friendly solution for diverse textile products, replacing DECA and offering a transparent and laundry‑durable solution that is not currently available in the market. In addition, unique ATO-free (Antimony Trioxide) flame‑retardant systems were introduced to the market. These green solutions created interest among the Company's customers and are being commercially evaluated; TexFRon 4002 and TexFRon 5001 are Oeko-Tex® certified.
|
· |
Energy storage: continued development of bromine‑based energy storage solutions for Br-Battery companies, using diverse compounds.
|
· |
Ecological research to reduce emissions
:
e.g. wastewater management, air emissions and solid/organic waste reuse.
|
· |
Biocides: continued development of new materials for water treatment and prevention of biofilm in industrial water cooling systems and pulp & paper plants.
|
· |
Phosphorus‑based products: development of new phosphorus‑based solutions for hydraulic fluids.
|
· |
Magnesia-based products: development of formulations in order to fulfil unmet needs in the markets, such as replacing aluminum products in deodorants and zinc oxide in several consumer products.
|
· |
Support of production: improving product quality
,
production cost
,
energy saving, recycling and waste treatment. C
hanging and improving processes while using the principles of green chemistry.
|
· |
Trouble shooting and equipment maintenance cycle improvement using better
construction materials
preventing
of accelerated corrosion, wear and tear, and equipment adaptation.
|
· |
Activities of efficiency and synergy measures in order to increase potash production and reducing cost per tonne at the potash and magnesium plants in Sodom;
|
· |
Advancement of research regarding environmental protection, including development of methods for treating and reducing effluents;
|
· |
Analysis of alternative methods for increasing the production capacity of carnallite at the evaporation ponds;
|
· |
Implementation of the recommendations of the R&D department designed to clear bottlenecks, focused on the flotation and compaction areas, with the purpose of increasing the production capacity in Spain;
|
· |
PotashpluS compaction – commissioning of operation at the compaction facility and optimization of the compaction process parameters;
|
· |
PotashpluS granulation – development is carried out at IFDC (International Fertilizer Development Center) and is currently at the stage of increasing production capacity to 400 kg per hour. This being a preliminary stage prior to development unto production on a full industrial scale;
|
· |
Granular Polysulphate – optimization of the process on two aspects: output and quality, as well as implementation of a new organic coating.
|
· |
The segment continues to check the adaptation of various potential types of phosphate rock (bituminous and brown phosphates) for the production of phosphoric acid and its downstream products as part of an effort to utilize and increase existing phosphate reserves. In 2019 the segment will further analyze these types of phosphate including R&D, pilots, plant testing activities and its economic feasibility.
|
· |
Improvement of processes and reduction of costs in the production plants;
|
· |
Research regarding environmental protection, including development of methods for treating and reducing effluents;
|
· |
Development of applications for water conservation and improving availability of the fertilizers around the root;
|
· |
Development of a new PK fertilizer fully soluble;
|
· |
Implementation of software to track global product life cycle to support global visibility of projects and formulas
;
|
· |
The R&D unit continuously looks out for new areas of innovation, for example to translate megatrends like sodium reduction with the target to create a full product portfolio based on ICL’s mineral tool box. This trend is relevant for processed meat applications. Furthermore, the segment participates in the trend of meat substitutes to complement a competitive product portfolio for classical phosphate customers in the meat, poultry and seafood industries
;
|
· |
Successful launch of the phosphate-based additive HALOX® CW-314 into the paints & coatings market. The additive is enhancing the infrared (IR) reflectance and thermal emissivity of elastomeric roof coating while maintaining the dirt pick-up resistance (DPUR) and prevention of mildew growth
;
and
|
· |
At the end of 2018, the R&D departments for food specialties and industrial phosphate applications were integrated into one support platform. The technical capabilities and the project portfolio were streamlined to fulfill the actual business needs and to realize financial synergies
.
|
· |
Improvement of product portfolio with new product formulations; Mainly tailored formulations on customer demand
|
· |
Development of improved production options for HiPeaK;
|
· |
Development of controlled‑release NPK fertilizers with a quicker fully degradable coating;
|
· |
Development of applications for water conservation and improving availability of the fertilizers around the root; and
|
· |
Initiation and development of new technologies to increase nutrient use efficiency.
|
· |
Fyrol® - a brand name for a range of phosphorus-containing flame retardants targeting flexible and rigid polyurethane foam applications.
|
· |
Joha® - a global trademark for dairy specialties, which specializes in emulsifying salts for processed cheese.
|
· |
Merquel® - a line of inorganic brominated salts which can be used to control mercury emissions from coal power plants.
|
· |
Osmocote® - a leading brand in the area of controlled released fertilizers which uses innovative technologies and is used globally by container nursery stocks, pot- plant growers and more.
|
· |
Peters® - a brand of water soluble fertilizers, specifically designed for bedding-, pot- and container nursery plants.
|
· |
Tari® - a brand in the meat industry as well as in the artisan business which focuses on the production and processing of meat products with functional additives, spices and flavors.
|
· |
Brifisol® - a global brand in the meat and seafood industries, which concentrates in improving texture by adding cryoprotectant for frozen food products such as meat, shrimp, fish filets and more.
|
D. TREND INFORMATION
|
As at December 31, 2018
|
|||||
Total
amount (2) |
12 months
or less
|
1-2
years
|
3-5
years
|
More than
5 years
|
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
Credit from banks and others (not including current maturities)
|
556
|
556
|
-
|
-
|
-
|
Trade payables
|
715
|
715
|
-
|
-
|
-
|
Other payables
|
330
|
330
|
-
|
-
|
-
|
Operating lease obligations
|
359
|
50
|
45
|
103
|
161
|
Purchase obligations(1)
|
3,033
|
646
|
192
|
606
|
1,589
|
Employee Benefits
|
526
|
25
|
80
|
126
|
295
|
Long-term debt and debentures
|
2,855
|
152
|
453
|
1,084
|
1,166
|
Total
|
8,374
|
2,474
|
770
|
1,919
|
3,211
|
(1)
|
This information excludes agreements in the ordinary course of business for purchases within the next twelve months.
|
(2)
|
The amounts presented, including long-term items, are presented in nominal values (and
include
estimated interest, so that they differ from their carrying amount).
|
As at December 31, 2018
|
|||||
Total
amount
|
12 months
or less
|
1-2
years
|
3-5
Years
|
More than
5 years
|
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
Financial liabilities – derivative instruments utilized for economic hedging
|
|||||
Foreign currency and interest derivative instruments
|
16
|
16
|
-
|
-
|
-
|
Derivative instruments on energy and marine transport
|
5
|
4
|
1
|
-
|
-
|
21
|
20
|
1
|
-
|
-
|
G. SAFE HARBOR
|
A . |
DIRECTORS AND OFFICERS
|
Name
|
Age
|
Commencement date as director
|
Johanan Locker
|
62
|
April 2016 and as Chairman of the Board since August 2016
|
Aviad Kaufman
|
48
|
March 2014
|
Avisar Paz
|
62
|
April 2001
|
Lior Reitblatt
|
61
|
November 2017
|
Nadav Kaplan
(1)
|
73
|
August 2018
|
Ovadia Eli
|
74
|
August 2011
|
Reem Aminoach
|
58
|
March 2017
|
Ruth Ralbag
|
58
|
January 2018
|
Sagi Kabla
|
42
|
February 2016
|
Yoav Doppelt
(2)
|
50
|
December 2018
|
(1) |
On August 20, 2018, the annual General Meeting of the Company's shareholders appointed Dr. Nadav Kaplan as an external director of the Company, for a first three-year term of office. For further details about Dr. Kaplan, see below.
|
(2) |
On December 12, 2018, the Board of Directors appointed Mr. Yoav Doppelt as a director of the Company,
until
the next annual General Meeting. For further details about Mr. Doppelt, see below.
|
(3) |
On January 10, 2018, Mr. Shimon Eckhaus ceased serving as a director of the Company.
|
(4) |
On February 13, 2018, Mr. Geoffery Merszei ceased serving as a director of the Company.
|
(5) |
On February 26, 2018, Mr. Yaacov Dior ceased serving as an external director of the Company.
|
(6) |
On August 29, 2018. Dr. Miriam Haran ceased serving as an external director of the Company.
|
Name
|
Age
|
Position
|
Raviv Zoller
(1)
|
55
|
President & Chief Executive Officer
|
Anat Tal-Ktalav
(2)
|
50
|
President, ICL Industrial Products Division
|
Charles M. Weidhas
|
59
|
Chief Operating Officer
|
Eli Glazer
(2)
|
62
|
President, ICL Innovative Agro Solutions Division
|
Ilana Fahima
(3)
|
53
|
Executive Vice President, Global Human Resources
|
Kobi Altman
|
50
|
Chief Financial Officer
|
Lilach Geva-Harel
(4)
|
42
|
Senior Vice President, Global General Counsel
|
Miri Mishor
(2)
|
55
|
Senior Vice President, Global Information Technology
|
Noam Goldstein
(2)
|
58
|
President, ICL Potash Division
|
Ofer Lifshitz
(2)
|
60
|
President, ICL Phosphate Solutions Division
|
Rani Lobenstein
|
47
|
Senior Vice President, Corporate Relations
|
Amir Meshulam
(5)
|
42
|
Senior Vice President, Global Internal Auditor
|
(1) | Mr. Raviv Zoller entered into office as CEO of the Company on May 14, 2018, replacing the Company's Acting CEO, Mr. Asher Grinbaum. |
(2) |
Further to the structural adjustments of the Company's business segments (see Note 5 to our Audited Financial Statements), as of August 31, 2018, Mr. Noam Goldstein serves as President of the Potash Segment, Ms. Anat Tal as President of the Industrial Products Segment, Mr. Ofer Lifshitz as President of the Phosphate Solutions Segment, and Mr. Eli Glazer as President of the Innovative Ag Solutions Segment. In addition, as of August 31, 2018 Mr. Noam Goldstein, Ms. Anat Tal and Ms. Miri Mishor, SVP Global IT are considered executive officeholders of the Company.
|
(3) |
On November 1, 2018, Mrs. Ilana Fahima joined ICL as EVP, Global HR, replacing Mr. Yakir Menashe which assumed the position of EVP, Global Procurement as of such date. As of the date of her appointment, Mrs. Fahima is considered as an executive officeholder of the Company. Mrs. Fahima's terms of Compensation as well as her entitlement to the insurance, indemnification and exemption arrangements as are currently in effect for the Company’s Executive Officers, were approved by the Company's HR & Compensation Committee and Board of Directors on October 25, 2018 and October 31, 2018, respectively.
|
(4) |
On February 1, 2019, Mrs. Lilach Geva Harel joined ICL as SVP, Global General Counsel, replacing Ms. Lisa Haimovitz. As of the date of her appointment, Mrs. Geva Harel is considered as an executive officeholder of the Company. Mrs. Geva Harel's terms of Compensation as well as her entitlement to the insurance, indemnification and exemption arrangements as are currently in effect for the Company’s Executive Officers, were approved by the Company's HR & Compensation Committee and Board of Directors on December 25 and 27, 2018, respectively.
|
(5) |
see C. Board Practices – Internal Auditor.
|
Grant for Year
|
Offerrees
|
Allocation Date
|
Type of Equity
(2)
|
Dates of Organs' Approvals
|
Grant Value (ILS)
|
Grant Amount
|
Exceptions & Comments
|
|
2018
|
each of our directors who serve from time to time (excluding the Chairman of the Board)
|
10.1.2018
|
restricted shares
|
HR & Comp. Committee – 27.11.17
Board – 5.12.17
Shareholders (Annual GM) – 10.1.18
|
310,000
|
22,080
|
1. |
Our former board members, Messrs. Geoffery Merszei and Yaacov Dior, whose term of office ended on February 13 and 26, respectively, were entitled to 2,057 and 2,843 Restricted Shares, reflecting their entitlement to the relative portion of the 2018 Grant.
|
2. |
Dr. Miriam Haran, whose term of office ended in August 2018, was allocated 14,793 restricted shares.
|
|||||||
3. |
Dr. Nadav Kaplan was allocated 5,930 restricted shares on August 20, 2018
.
|
|||||||
4. |
Mr. Yoav Doppelt was allocated 758 restricted shares on December 12, 2018.
|
|||||||
5. |
Messrs. Kaufman, Paz and Kabla waived in advance their entitlement to the equity compensation per 2018.
|
|||||||
2019
|
each of our directors who serve from time to time (excluding the Chairman of the Board & Office Holders of IC)
|
1.1.2019
|
restricted shares
|
HR & Comp. Committee & Board – 19.6.18
Shareholders (Annual GM) – 20.8.18
|
310,000
|
14,623
|
(1) |
The annual
base
salary for the officers in the above table was calculated according to their actual term of office in the Company in 2018.
|
(2) |
The salary
items (compensation)
component set out in the above table includes all of the following components:
gross
salary,
employer
social benefits, customary social and related provisions, company car, relocation expenses, rent and indemnification for tax payments in case of
relocation
, payments during advance notice period pursuant to the terms of employment agreements, inasmuch as relevant, and reimbursement of telephone expenses. The compensation is in accordance with the Company's Compensation Policy.
|
(3) |
The bonuses to officer holders for 2018, including the top-five earners in 2018, were approved by our HR & Compensation Committee and Board of Directors on February 4 and 5, 2019, respectively. The bonuses approved are in accordance with the provisions of our Compensation Policy, unless otherwise specifically mentioned.
|
(4) |
The expense or income for the share-based payment component was calculated according to IFRS.
|
(5) |
Mr. Raviv Zoller entered into office as the Company's President & CEO on May 14, 2018. Mr. Zoller’s terms of employment were approved by our HR & Compensation Committee and Board of Directors on February 22 and 25, 2018, respectively, and by the general meeting of our shareholders on April 24, 2018, and they are as follows: (a) annual base salary of NIS 2,400 thousand (approximately $67
0
thousand), indexed to the Israeli Consumer Price Index (CPI). Mr. Zoller's annual base salary as of December 31, 2018 is NIS 2,433 thousand (approximately $650 thousand); (b) annual cash bonus in accordance with ICL’s bonus plan and Compensation Policy. Mr. Zoller’s Target Bonus was set at NIS 2,500 thousand (approximately $695 thousand), with the maximum annual bonus set at the amount of NIS 3,750 thousand (approximately $1,040 thousand); (c) an annual equity compensation entitlement at the amount of NIS 4,000 thousand (approximately $1,110 thousand), as well as an annual equity grant for 2018 at a total amount of NIS 4,000 thousand (approximately $1,110 thousand), which was granted to Mr. Zoller upon his entry into office, comprising half of options exercisable into Company shares at a value of NIS 2,000 thousand (approximately $555 thousand), and half of restricted shares at a value of NIS 2,000 thousand (approximately $555 thousand).
For
details regarding the equity compensation granted to Mr. Zoller for 2018, see
to the description of
the equity compensation
grants, set forth
in the table
and respective foot notes
below
;
(d) Mr. Zoller will be entitled to an advance notice period of 12 months in case of termination by the Company (not for cause) and will be required to give the Company a 6 months advance notice in case he resigns. During such advance notice period Mr. Zoller may be required to continue working for ICL, and therefore Mr. Zoller would continue to be entitled to all of his compensation terms, excluding an annual bonus in respect of the advanced notice period and excluding an equity grant, to the extent granted during such advance notice period; (e) in addition, in case of termination of office, Mr. Zoller will be entitled to an additional severances equal to his last his last base salary multiplied by the number of years that he served as ICL’s President & CEO; (f) Mr. Zoller is entitled to all other cash and non-cash benefits payable to our senior executives pursuant to our policies in effect from time to time, including but not limited to, pension, study fund, disability insurance, company car, etc., as well as the exemption, insurance and indemnification arrangements applying to the Company’s office holders
.
|
(6) |
The annual bonus for 2018 to Mr. Zoller, as specified in the table above, reflects the outcome of implementation of the annual bonus formula as provided in the Company’s compensation policy and described in the “Annual Bonus” section below with respect to Mr. Zoller's actual term of office in 2018 (i.e. beginning May 14, 2018), as approved by our HR & Compensation Committee and Board of Directors on February 4 and 5, 2019, respectively.
|
(7) |
Mr. Johanan Locker serves as director in the Company as of April 20, 2016, and as Chairman of our Board of Directors (at a scope of no less than 90% of a full-time position) as of August 15, 2016. Mr. Locker’s compensation terms were approved by our HR & Compensation Committee and Board of Directors on April 19, 2016, and on April 20, 2016, respectively, and by the general meeting of our shareholders on August 29, 2016, as follows: (1) annual base salary of NIS 1,920 thousand (approximately $535 thousand)
.
Mr. Locker's annual base salary as of December 31, 2018 has not changed; (2) annual cash bonus according to ICL’s bonus plan and compensation policy – the target bonus was set at NIS 1,900 thousand (approximately $530 thousand); (3) annual equity compensation entitlement at the amount of NIS 1,800 thousand (approximately $500 thousand). For details regarding an additional equity compensation granted to Mr. Locker in 2018,
see
to the description of the equity compensation grants, set forth in the table and respective foot notes below; (4) Mr. Locker will be entitled to an advance notice period of 12 months and will be required to give the Company a 6 months advance notice in case he resigns. During such advance notice period Mr. Locker may be required to continue working for ICL and therefore Mr. Locker would continue to be entitled to all of his compensation terms, including annual bonus; (5) in addition, in case of termination of service, Mr. Locker will be entitled to an additional severances equal to his last monthly salary multiplied by the number of years that he served as ICL’s Executive Chairman; (6) Mr. Locker is entitled to all other cash and non-cash benefits payable to our senior executives pursuant to our policies in effect from time to time, including but not limited to, pension, study fund, disability insurance, company car, etc.
|
(8) |
On February 4 and 5, 2019, our HR & Compensation Committee and Board of Directors approved, respectively, the annual bonus for 2018 to Mr. Locker, as further detailed in the “Annual Bonus” section below. In addition, at the same dates, the HR & Compensation Committee and Board of Directors, further resolved to grant a special bonus to Mr. Locker for 2018, in an amount equals to three (3) monthly salaries, or. NIS 480,000 (
approximately
$134 thousand). The special bonus is subject to approval of the general meeting of our shareholders, and thus is not reflected in the table above.
|
(9) |
Mr. Charles Weidhas serves as Chief Operating Officer (COO) as of July 1, 2016. Mr. Weidhas’ employment contract is for an unlimited period and may be terminated by either party at any time by prior written notice. Mr. Weidhas is entitled to an advanced notice period and adjustment period of 6 months each and is entitled to life insurance and health insurance for himself and his family. Beginning on October 13, 2013, and for a period of 5 years thereafter, which was extended for an additional year by the HR & Compensation Committee and Board of Directors on October 25 and 31, 2018, respectively, Mr. Weidhas is entitled to reimbursement of his rent. As of March 2016, Mr. Weidhas’ monthly base salary is paid in U.S. dollars. As of 31 December 2017, Mr. Weidhas’ monthly base salary is approximately $30,468. Mr. Weidhas is also entitled, as long as he resides in Israel, to maintain the net amount in respect of all payments made to him as would be obtained in the United States (tax equalization). In addition to the amount provided regularly for pension fund and severance pay, Mr. Weidhas is entitled to additional severance pay equal to his last salary multiplied by the number of his years of employment
with
ICL
in Israel
. For details regarding Mr. Weidhas annual bonus for 2018, see the “Annual Bonus” section below.
|
(10) |
Mr. Asher Grinbaum served as Acting CEO of ICL between September 11, 2016 and May 13, 2018. During his service as Acting CEO, Mr. Grinbaum’s terms of employment remained similar to the terms he had in in his previous position in the Company – Executive Vice President and Chief Operating Officer (COO). Mr. Grinbaum’s employment agreement (including amendments thereto), provided that Mr. Grinbaum’s base salary will be updated twice a year according to the rise in the Consumer Price Index in the months that passed since such previous update. According to Mr. Grinbaum's employment agreement and the salary updates pursuant thereto, as decided by our Board of Directors from time to time, Mr. Grinbaum’s monthly base salary, as of December 31, 2018, was NIS 137,774 (approximately $35,600). Mr. Grinbaum's annual base salary in the above table was calculated according to the actual term of office in the Company in 2018, i.e. the relative portion calculated until the last day in office, May 13, 2018. Subsequent to his retirement on May 13, 2018, and pursuant to his employment agreement, Mr. Grinbaum was entitled to an accrued vacation period, between May 14, 2018 and July 16, 2018, which was followed by a 6 months advanced notice period. In the course of the two periods thereof, employer-employee relations continued to apply, and
ceased
on January 16, 2019
.
The Company has booked full provisions respecting the base salary for the remaining period of 2018
already
as of December 31,2017, as well as for the accrued vacation period, the advanced notice period and Mr. Grinbaum's retirement benefits, except for the Special Bonus, as defined herein below
.
Therefore, all amounts that have been previously recorded in 2017 are not included in the table above.
|
(11) |
The bonus amount in the above table includes: (A) an annual bonus for 2018, in an amount of NIS 1,570,000 (approximately $440,000), that was calculated in accordance with the Annual Bonus Calculation Formula and the provisions of our Compensation Policy, following the approval of HR & Compensation Committee and Board of Directors on February 4 and 5, 2019, respectively. In respect of the accrued vacation period and the advanced notice period, no Specific Personal Measurables (KPIs) were applied. For further details, see the “Annual Bonus” section below; (B) a Special Bonus in an amount of NIS 1,800,000 (approximately $500,550), that was granted to Mr. Grinbaum in light of his exceptional contribution and remarkable efforts when serving as our Acting CEO
,
as further set forth in the Proxy Statement for the Company's Annual General Meeting that was held on August 20, 2018. The Special Bonus was approved by the general meeting of our shareholders on August 20, 2018, following approval by our Compensation Committee and Board of Directors on June 19, 2018, and on February 4 and 5, 2019, respectively.
According to the Company's Compensation Policy, the maximum special bonus payout with respect to the CEO in any given year cannot exceed the difference between three base monthly salaries and the non-measurable components of the annual bonus payout. In addition, the maximum special bonus payout in any given year with respect to any Executive Officer cannot exceed 6 base monthly salaries. Therefore, the special bonus to Mr. Grinbaum was approved by the general meeting of our shareholders in a deviation from the Company's Compensation Policy, according to section 272(C) to the Israeli Companies Law.
|
(12) |
Mr. Kobi Altman serves as ICL’s Chief Financial Officer (CFO) as of April 1, 2015. Mr. Altman’s employment agreement provides that Mr. Altman’s
base
salary will be updated twice a year according to the rise in the Consumer Price Index in the months that passed since such previous update. The employment contract is for an unlimited period and may be terminated by either party at any time by advance written notice. Mr. Altman is entitled to an advance notice period of 6 months. According to the employment contract and the salary updates, as decided by our Board of Directors from time to time, Mr. Altman’s monthly
base
salary, as of December 31, 2018, is approximately NIS 117,000 (approximately $31,215). In addition, Mr. Altman is entitled to all benefits customary in the Company, such as regular provisions for pension and severance, disability fund, company car, etc. Shortly after beginning his employment, in April 2015, Mr. Altman was granted a special equity
grant
(as a signing bonus) of 59,391 restricted shares, the value thereof at the grant date was NIS 1,600 thousand, which vested in April 2018.
|
Year of grant
|
Approval dates
|
Offeree
|
Allocation date
|
Quantity of option warrants
|
Quantity of restricted shares
|
NIS exercise price (subject to adjustments)
|
Quantity of valid option warrants as at February 20, 2019
|
Weighted economic value of each option warrant
(4)
|
Fair value of restricted shares
|
Exercise price of option warrants
|
Share price
|
Quantity of option warrants expired as at February 20, 2019
|
Notes
|
On date immediately preceding allocation (NIS)
|
as at February 20, 2019 (NIS)
|
||||||||||||
2014
|
Raviv Zoller
|
NA
|
|||||||||||
Johanan Locker
|
NA
|
||||||||||||
Charles Weidhas
|
September 27, 2014
|
95,129
|
22,250
|
28
.71
|
63,418
|
6.57
|
28.09
|
25.289
|
20.2
|
31,711
|
Exercise price of the option warrants is
25.2
% higher than the share price on February 20, 2019; hence the option warrants are “out of the money”.
|
||
Asher Grinbaum
(1)
|
September 27, 2014
|
95,129
|
22,250
|
28
.71
|
63,418
|
6.57
|
28.09
|
25.289
|
20.2
|
31,711
|
|||
Kobi Altman
|
NA
|
||||||||||||
2015
|
Compensation Committee and Board: May 10 and 12, 2015, respectively
|
Raviv Zoller
|
NA
|
Exercise price of the option warrants is
27.8%
higher than the share price on February
20
, 2019; hence the option warrants are “out of the money”.
|
|||||||||
Johanan Locker
|
NA
|
||||||||||||
Charles Weidhas
|
July 8, 2015
|
137,363
|
23,200
|
27.
76
|
45,787
|
4.55
|
26.94
|
25.829
|
20.2
|
91,576
|
|||
Asher Grinbaum
(1)
|
July 8, 2015
|
137,363
|
23,200
|
27.
76
|
45,787
|
4.55
|
26.94
|
25.829
|
20.2
|
91,576
|
|||
Kobi Altman
|
July 8, 2015
|
137,363
|
82,591
(2)
|
27.
76
|
45,787
|
4.55
|
26.94
|
25.829
|
20.2
|
91,576
|
Year of grant
|
Approval dates
|
Offeree
|
Allocation date
|
Quantity of option warrants
|
Quantity of restricted shares
|
NIS exercise price (subject to adjustments)
|
Quantity of valid option warrants as at February 20, 2019
|
Weighted economic value of each option warrant
(4)
|
Fair value of restricted shares
|
Exercise price of option warrants
|
Share price
|
Quantity of option warrants expired as at February 20, 2019
|
Notes
|
On eve of allocation (NIS)
|
as at February 20, 2019 (NIS)
|
||||||||||||
2016
|
Compensation Committee and Board: May 16 and 17, 2016, respectively. Respecting Mr. Locker, general meeting approval: August 29, 2016
|
Raviv Zoller
|
NA
|
Exercise price of the option warrants is
22.8
% lower respecting Mr. Locker,
19.6
% lower respecting Mr. Grinbaum and
22.2
% lower respecting all others, than the share price on February 20, 2019
,
hence the option warrants are
"in
the money
".
|
|||||||||
Johanan Locker
|
August 29, 2016
|
186,335
|
55,215
|
17.05
|
186,335
|
4.19
|
15.42
|
15.595
|
20.2
|
-
|
|||
Charles Weidhas
|
June 30, 2016
|
133,747
|
39,632
|
17.05
|
133,747
|
4.83
|
16.3
|
15.716
|
20.2
|
-
|
|||
Asher Grinbaum
(1)
|
February 14, 2017
|
114,065
|
37,592
|
17.22
|
114,065
|
5
.83
|
17.69
|
16.233
|
20.2
|
-
|
|||
Kobi Altman
|
June 30, 2016
|
145,549
|
43,129
|
17.05
|
85,549
(5)
|
4.83
|
16.3
|
15.716
|
20.2
|
-
|
|||
2017
|
Compensation Committee and Board: June 19 and 20, 2017, respectively. Respecting Mr. Locker, general meeting approval: August 2, 2017
|
Raviv Zoller
|
NA
|
Exercise price of the option warrants is
22
% lower respecting Mr. Locker and
28.5
% lower respecting all others, than the share price on February 20, 2019
,
hence the option warrants are
"in
the money
".
|
|||||||||
Johanan Locker
|
August 2, 2017
|
164,916
|
52,910
|
16.49
|
164,916
|
5.46
|
17.01
|
15.744
|
20.2
|
-
|
|||
Charles Weidhas
|
June 20, 2017
|
128,627
|
42,089
|
15.31
|
128,627
|
5.17
|
15.8
|
14.448
|
20.2
|
-
|
|||
Asher Grinbaum
(1)
(3)
|
June 20, 2017
|
128,627
|
42,089
|
15.31
|
128,627
|
5.17
|
15.8
|
14.448
|
20.2
|
-
|
|||
Kobi Altman
|
June 20, 2017
|
128,627
|
42,089
|
15.31
|
128,627
|
5.17
|
15.8
|
14.448
|
20.2
|
-
|
(5) |
On November 4, 2018, Mr. Altman exercised 60,000 option warrants. The exercise price as at the date of the sale was NIS 15.97 (approximately $4.26), and the share price as at that date was NIS 21.86 (approximately $5.83). The amount of shares that derived from the exercise of the options and that was immediately sold reflected the difference between the exercise price and the share price
at the relevant date
(net exercise).
|
(6) |
On June 19, 2018, our HR & Compensation Committee and our Board of Directors, approved and on August 20, 2018, our general meeting of shareholders approved an issuance to Mr. Locker, of options in a total value of NIS 2,400,000 (approximately $662,983), comprising of NIS 900,000 (approximately $248,619) as in the previous year, and an additional amount of Options for 2018 in the amount of NIS 1,500,000 (approximately $414,365), and of restricted shares in a total value of NIS 900,000 ($248,619), as in the previous year.
|
(1) |
The Articles of Association of the Company and its Israeli subsidiaries include provisions that permit exemption, indemnification and insurance of the liability of officers, all in accordance with the provisions of the Israeli Companies Law.
|
Number of meetings in
reported year
|
Average Attendance
|
|
General Board Meetings
|
16
|
97%
|
Audit & Accounting Committee
|
13
|
91%
|
Financing Committee
|
4
|
100%
|
Operations Committee
|
4
|
92%
|
Compensation Committee
|
11
|
100%
|
Environment Committee
|
4
|
94%
|
2018
|
2017
|
2016
|
Phosphate Solutions
|
5,259
|
5,533
|
6,274
|
Potash
|
2,855
|
3,109
|
3,196
|
Industrial Products
|
1,675
|
1,697
|
1,710
|
Innovative Ag Solutions
|
1,182
|
1,163
|
1,081
|
Global functions and headquarters
|
1,154
|
1,158
|
1,253
|
Total employees
|
12,125
|
12,660
|
13,514
|
2018
|
2017
|
2016
|
Israel
|
4,672
|
4,673
|
4,861
|
China
|
2,467
|
2,413
|
2,816
|
Spain
|
1,179
|
1,281
|
1,294
|
Germany
|
860
|
1,012
|
1,157
|
UK
|
659
|
836
|
827
|
USA
|
728
|
817
|
895
|
Netherlands
|
627
|
626
|
639
|
Brazil
|
276
|
280
|
264
|
France
|
125
|
125
|
127
|
Other
|
532
|
597
|
634
|
Total employees
|
12,125
|
12,660
|
13,514
|
Grant date
|
Employees entitled
|
Number of instruments (thousands)
|
Issuance's details
|
Instrument terms
|
Vesting conditions
|
Expiration date
|
August 6, 2014
|
Officers and senior employees
|
3,993
|
An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan, to 450 ICL officers and senior employees in Israel and overseas.
|
Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company. In case of on the exercise date the closing price of an ordinary share is higher than twice the exercise price (the “Share Value Cap”), the number of the exercised shares will be reduced so that the product of the exercised shares actually issued to an offeree multiplied by the share closing price will equal to the product of the number of exercised options multiplied by the Share Value Cap.
|
3 equal tranches:
(1) One third on December 1, 2016
(2) One third on December 1, 2017
(3) One third on December 1, 2018
|
Two years from the vesting date.
|
December 11, 2014
|
Former CEO
|
367
|
An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan.
|
|||
May 12, 2015
|
Officers and senior employees
|
6,729
|
An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan, to 550 ICL officers and senior employees in Israel and overseas.
|
Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company.
|
3 equal tranches:
(1) one third at the end of 12 months after the grant date
(2) one third at the end of 24 months after the grant date
(3) one third at the end of 36 months after the grant date
|
The first and second tranches is at the end of 36 months after the grant date for the third tranche is at the end of 48 months after the grant date.
|
June 29, 2015
|
Former CEO
|
530
|
An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan.
|
|||
Former Chairman of BOD
|
404
|
|||||
June 30, 2016
|
Officers and senior employees
|
3,035
|
An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan, to 90 ICL officers and senior employees in Israel and overseas.
|
June 30, 2023
|
||
September 5, 2016
|
Former CEO
|
625
|
An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan.
|
|||
Chairman of BOD
|
186
|
|||||
February 14, 2017
|
Former CEO
|
114
|
An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan.
|
February 14, 2024
|
||
June 20, 2017
|
Officers and senior employees
|
6,868
|
An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan to 498 ICL officers and senior employees in Israel and overseas.
|
June 20, 2024
|
||
August 2, 2017
|
Chairman of BOD
|
165
|
An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan.
|
Grant date
|
Employees entitled
|
Number of instruments (thousands)
|
Issuance's details
|
Instrument terms
|
Vesting conditions
|
Expiration date
|
March 6, 2018
|
Officers and senior employees
|
5,554
|
An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan (as amended) to 508 ICL officers and senior employees in Israel and overseas, ICL CEO and Chairman of the BOD.
|
Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company.
|
3 equal tranches:
(1) one third at the end of 12 months after the grant date
(2) one third at the end of 24 months after the grant date
(3) one third at the end of 36 months after the grant date
|
March 6, 2025
|
May 14, 2018
|
CEO
|
385
|
May 14, 2025
|
|||
August 20, 2018
|
Chairman of BOD
|
403
|
August 20, 2025
|
Grant date
|
Employees entitled
|
Number of instruments (thousands)
|
Vesting conditions (*)
|
Instrument terms
|
Additional Information
|
Fair value at the grant date (Million)
|
August 6, 2014
|
Officers and senior employees
|
922
|
3 equal tranches:
(1) One third on December 1, 2016
(2) One third on December 1, 2017
(3) One third on December 1, 2018
|
An issuance for no consideration, under the 2014 Equity Compensation Plan, to 450 ICL officers and senior employees in Israel and overseas.
|
The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the date approval of the BOD and/or the date of the approval of the General Meeting where required).
|
8.4
|
December 11, 2014
|
Former CEO
|
86
|
An issuance for no consideration, under the 2014 Equity Compensation Plan.
|
|||
February 26, 2015
|
ICL’s Directors (excluding ICL's CEO)
|
99
|
3 tranches:
(1) 50% will vest August 28, 2015
(2) 25% will vest February 26, 2017
(3) 25% will vest February 26, 2018
|
An issuance for no consideration, under the 2014 Equity Compensation Plan, to 11 ICL Directors.
|
0.7
|
|
May 12, 2015
|
Officers and senior employees
|
1,194
|
3 equal tranches:
(1) one third at the end of 12 months after the grant date
(2) one third at the end of 24 months after the grant date
(3) one third at the end of 36 months after the grant date
|
An issuance for no consideration, under the 2014 Equity Compensation Plan, to 550 ICL officers and senior employees in Israel and overseas.
|
9.7
|
|
June 29, 2015
|
Former CEO
|
90
|
An issuance for no consideration, under the 2014 Equity Compensation Plan.
|
|||
Former Chairman of the BOD
|
68
|
|||||
December 23, 2015
|
ICL’s Directors (excluding ICL's CEO & Chairman of the BOD)
|
121
|
3 equal tranches:
(1) One third on December 23, 2016
(2) One third on December 23, 2017
(3) One third on December 23, 2018
|
An issuance for no consideration, under the 2014 Equity Compensation Plan, to 8 ICL Directors.
|
0.5
|
Grant date
|
Employees entitled
|
Number of instruments (thousands)
|
Vesting conditions (*)
|
Instrument terms
|
Additional Information
|
Fair value at the grant date (Million)
|
June 30, 2016
|
Officers and senior employees
|
990
|
3 equal tranches:
(1) one third at the end of 12 months after the grant date
(2) one third at the end of 24 months after the grant date
(3) one third at the end of 36 months after the grant date
|
An issuance for no consideration, under the 2014 Equity Compensation Plan, to 90 ICL officers and senior employees in Israel and overseas.
|
The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the date approval of the BOD and/or the date of the approval of the General Meeting where required).
|
4.8
|
September 5, 2016
|
Chairman of the BOD
|
55
|
An issuance for no consideration, under the 2014 Equity Compensation Plan.
|
|||
Former CEO
|
185
|
|||||
January 3, 2017
|
ICL’s Directors (excluding ICL's Chairman of the BOD)
|
146
|
An issuance for no consideration, under the 2014 Equity Compensation Plan, to 8 ICL Directors.
The value includes a reduction of 5% from the value of the equity compensation, pursuant to the decision of the directors in March 2016, to reduce their annual compensation for 2016 and 2017.
|
0.6
|
||
February 14, 2017
|
Former CEO
|
38
|
An issuance for no consideration, under the 2014 Equity Compensation Plan.
|
0.2
|
||
June 20, 2017
|
Officers and Senior employees
|
2,211
|
An issuance for no consideration, under the 2014 Equity Compensation Plan, to 494 ICL officers and senior employees in Israel and overseas.
|
10
|
||
August 2, 2017
|
Chairman of BOD
|
53
|
An issuance for no consideration, under the 2014 Equity Compensation Plan.
|
0.3
|
||
January 10, 2018
|
ICL’s Directors (excluding ICL's CEO & Chairman of the BOD)
|
137
|
An issuance for no consideration, under the 2014 Equity Compensation Plan, to 7 ICL Directors.
|
0.6
|
Grant date
|
Employees entitled
|
Number of instruments (thousands)
|
Vesting conditions (*)
|
Instrument terms
|
Additional Information
|
Fair value at the grant date (Million)
|
March 6, 2018
|
Officers and senior employees
|
1,726
|
3 equal tranches:
(1) one third at the end of 12 months after the grant date
(2) one third at the end of 24 months after the grant date
(3) one third at the end of 36 months after the grant date
|
An issuance for no consideration, under the 2014 Equity Compensation Plan (as amended).
|
The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the date approval of the BOD and/or the date of the approval of the General Meeting where required).
|
8
|
May 14, 2018
|
CEO
|
121
|
0.6
|
|||
August 20, 2018
|
Chairman of BOD
|
47
|
0.2
|
|||
ICL’s Directors (excluding ICL's CEO & Chairman of the BOD)
|
88
|
Acceleration at January 2019.
|
0.4
|
Ordinary Shares
Beneficially Owned (1) |
Special State
Share |
|||
Shareholders
|
Number
|
%
|
Number
|
%
|
Israel Corporation Ltd.
(2)
|
587,178,761
|
45.86%**
|
-
|
-
|
State of Israel
(3)
|
-
|
-
|
1
|
100%
|
Johanan Locker
|
155,369
|
*
|
-
|
-
|
Avisar Paz
|
-
|
*
|
-
|
-
|
Aviad Kaufman
|
-
|
*
|
-
|
-
|
Sagi Kabla
|
-
|
*
|
-
|
-
|
Ovadia Eli
|
79,199
|
*
|
-
|
-
|
Nadav Kaplan
|
20,553
|
*
|
-
|
-
|
Lior Reitblatt
|
95,553
|
*
|
-
|
-
|
Reem Aminoach
|
36,703
|
*
|
-
|
-
|
Ruth Ralbag
|
36,703
|
*
|
-
|
-
|
Yoav Doppelt
|
15,381
|
*
|
-
|
-
|
Raviv Zoller
|
120,919
|
*
|
-
|
-
|
Kobi Altman
|
211,703
|
*
|
-
|
-
|
Lilach Geva Harel
|
-
|
*
|
-
|
-
|
Ilana Fahima
|
-
|
*
|
-
|
-
|
Rani Lobenstein
|
30,190
|
*
|
-
|
-
|
Charles Weidhas
|
171,065
|
*
|
-
|
-
|
Ofer Lifshitz
|
131,108
|
*
|
-
|
-
|
Eli Glazer
|
163,979
|
*
|
-
|
-
|
Noam Goldstein
|
55,327
|
*
|
-
|
-
|
Anat Tal-Ktalav
|
55,327
|
*
|
-
|
-
|
Amir Meshulam
|
20,793
|
*
|
-
|
-
|
· |
The composition of our Board of Directors (other than external directors, as described under “Item 6. Directors, Senior Management and Employees—C. Board Practices—External Directors”);
|
· |
Mergers or other business combinations;
|
· |
Certain future issuances of ordinary shares or other securities; and
|
· |
Amendments to our Articles of Association, excluding provisions of the Articles of Association that were determined by the Special State Share.
|
1. |
We obtain shipping services from Zim, an affiliate of Israel Corporation, and paid them about $8 million in each of the years 2016, 2017 and 2018.
|
2. |
We purchase Sulfur from Oil Refineries Ltd., a subsidiary of Israel Corporation, and paid them about $2 million, $2.5 million and $3.2 million, in 2016, 2017 and 2018, respectively.
|
3. |
We provide transportation services to ZIM, an affiliate of Israel Corporation, and were paid by them about $2.1 million, $1.6 million and $1.4 million in 2016, 2017 and 2018, respectively.
|
4. |
We sell distilled water from Oil Refineries Ltd., a subsidiary of Israel Corporation, and were paid about $2 million in 2018.
|
Sales
|
5
|
8
|
35
|
Cost of sales
|
19
|
97
|
113
|
Selling, transport and marketing expenses
|
7
|
8
|
7
|
Financing expenses (income), net
|
3
|
(9)
|
-
|
General and administrative expenses
|
1
|
1
|
1
|
Management fees to the parent company
|
1
|
1
|
1
|
As at December 31
|
||
2018
|
2017
|
|
$ millions
|
$ millions
|
Other current assets
|
28
|
38
|
Other current liabilities
|
7
|
191
|
A. |
CONSOLIDATED STATEMENTS AND OTHER FINANCIAL INFORMATION
|
1. |
The Company and the main operational companies in Israel (DSW, Rotem, Bromine, DSM, BCL and F&C), along with most of the other companies in Israel, have received final tax assessments up to and including 2011. The main subsidiaries outside of Israel have final tax assessments up to and including 2011
and 2012
.
|
2. |
Israel - In December 2018, the Israeli Tax Authorities (hereinafter - the ITA) rejected the company's objection relating to an assessment issued to the Company and to certain Israeli subsidiaries, and demanded an additional tax payment, for the years 2012‑2014, in the amount of $
73
million. The Company disputes the assessment and filed an appeal to the Jerusalem District Court. In the Company’s estimation, it
is more likely than not that
its
claims will be accepted
.
|
3. |
The company's subsidiary in Belgium recognized a notion deduction on its capital based on its interpretation of the Belgian tax law, which was validated by the Court of Appeals in Belgium. The tax authorities dispute the eligibility of the deduction by appealing to the Supreme Court against the Court of Appeals' resolution and issuing tax assessments in a total amount of $27 million for the years commencing 2010. The Company believes, it is more likely than not that its tax position will also be accepted by the Supreme Court.
|
4. |
Currently, the Company is also under tax audits in Spain and Germany for the years 2012‑2015. As at the date of the report, there are no additional tax payment requests from the tax authorities
, excluding immaterial amounts in Germany.
The Company believes that the provisions in its books are sufficient.
|
1. |
On July 10 and 19, 2016, two applications for certification of derivative actions were filed with the Economic Division of the Tel-Aviv District Court by two of our shareholders, with respect to the annual bonuses granted for the years 2014 and 2015 to our top-five highest-paid senior officers, including our CEO and Chairman of the Board at the time, alleging that such bonuses were granted in a manner deviating from our compensation policy and contrary to the Company’s best interest.
|
2. |
On December 8, 2016, the Company received a motion for disclosure and review of documents, in accordance with Section 198A of the Israeli Companies Law. The motion was filed in the District Court in Tel Aviv by a shareholder of the Company, as a preliminary proceeding towards an application for certification of a derivative action with regard to the manner of management and discontinuation of the Harmonization Project (the global ERP project), which he claimed allegedly led to write-off of the amount invested in the project. On January 17, 2018, the Court denied the motion and imposed upon the applicant the legal expenses incurred by the respondent and its attorneys’ fees. To the best of the Company’s knowledge, on February 15, 2018 an application for permission to appeal was filed with the Supreme Court regarding the District Court’s decision to deny the motion. On October 11, 2018, the Supreme Court has rejected the application for permission to appeal, and imposed upon the applicant the legal expenses and attorney’s fees incurred by the respondent. For details regarding an application for certification of a class action against the Company concerning ICL's IT (Harmonization) Project that was filed by the same shareholder, and for details regarding a law suit filed by the Company against IBM due to the Failure of the said IT Project, see Note 20 to our Audited Financial Statements.
|
3. |
On January 10, 2018, an application for certification of a derivative action was filed by a shareholder of Oil Refineries Ltd. (“Bazan”) with the Tel Aviv-Yafo District Court, against former and current board members of Bazan, OPC Energy Ltd. OPC Rotem Ltd., OPC Hadera Ltd. and the Company, (hereinafter, jointly: the “Additional Companies”), and against Israel Corporation Ltd., Mr. Idan Ofer and Mr. Ehud Angel (the “Application”).
|
4. |
According to the announcement issued by the Company on May 10, 2017, ICL Europe Coöperatief U.A. (“ICL Europe”), a subsidiary of the Company, filed a Notice of Arbitration against the Federal Democratic Republic of Ethiopia ("Ethiopia") under the Agreement of Encouragement and Reciprocal Protection of Investments between the Ethiopia and the Kingdom of the Netherlands ("the Ethiopia- Netherlands BIT"). A three-member arbitration tribunal ("Tribunal") was constituted under the Arbitration Rules of the United Nations Commission on International Trade Law ("UNCITRAL Rules") to hear the case, which is being administered by the Permanent Court of Arbitration located in The Hague, the Netherlands. Following ICL Europe's filing of Notice of Arbitration on May 10, 2017 and Ethiopia's response thereto on June 12, 2017, ICL Europe submitted to the Tribunal on June 19, 2018 its Statement of Claim seeking compensation in the amount of $181
million
plus interest for damage its claims as a result of Ethiopia's coercive, arbitrary, discriminatory and unlawful conduct, culminating in the imposition without legal basis of a purported tax on ICL Europe's indirectly owned Ethiopian company, Allana Potash Afar Plc, and Ethiopia's violation of multiple provisions of the Ethiopia- Netherlands BIT, including the requirements to accord fair and equitable treatment to ICL Europe's investment, to provide full protection and security to ICL Europe's investment and not to expropriate unlawfully ICL Europe's investment. Ethiopia submitted to the Tribunal on October 19, 2018
,
its Statement of Defense and Objections to Jurisdiction. Among other things, Ethiopia argues that ICL Europe failed to make its investment in compliance with Ethiopian law and that the Tribunal lacks jurisdiction under the Ethiopia-Netherlands BIT as a result, that the challenged tax was lawful and does not provide a basis for presenting a claim under the Ethiopia- Netherlands BIT and that ICL terminated its investment for reasons unrelated to any of the alleged unlawful acts and omissions of Ethiopia.
|
A. |
OFFER AND LISTING DETAILS
|
· |
certain financial institutions
;
|
· |
dealers or traders in securities that use a mark-to-market method of tax accounting
;
|
· |
persons holding ordinary shares as part of a “straddle” or integrated transaction or persons entering into a constructive sale with respect to the ordinary shares
;
|
· |
persons whose functional currency for U.S. federal income tax purposes is not the U.S. dollar
;
|
· |
entities classified as partnerships for U.S. federal income tax purposes
;
|
· |
tax exempt entities, “individual retirement accounts” or “Roth IRAs
"
:
|
· |
Persons who acquired our ordinary shares pursuant to the exercise of an employee stock option or otherwise as compensation;
|
· |
persons that own or are deemed to own 10% or more of our stock by vote or value; or
|
· |
persons holding our ordinary shares in connection with a trade or business conducted outside of the United States.
|
· |
a citizen or individual resident of the United States
;
|
· |
a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United States, any state therein or the District of Columbia; or
|
· |
an estate or trust the income of which is subject to U.S. federal income taxation regardless of its source
.
|
Increase (decrease)
in fair value
|
Fair value
|
Increase (decrease)
in fair value
|
|||
USD/NIS
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
Type of instrument
|
Increase of 10%
|
Increase of 5%
|
Decrease of 5%
|
Decrease of 10%
|
Cash and cash equivalents
|
(0.2)
|
(0.1)
|
1.8
|
0.1
|
0.2
|
Short term deposits and loans
|
0.0
|
0.0
|
0.1
|
0.0
|
0.0
|
Trade receivables
|
(5.5)
|
(2.9)
|
60.2
|
3.2
|
6.7
|
Receivables and debit balances
|
(1.1)
|
(0.6)
|
11.8
|
0.6
|
1.3
|
Long-term deposits and loans
|
(0.1)
|
(0.1)
|
1.5 | 0.1 | 0.2 |
Credit from banks and others
|
2.8
|
1.4
|
(30.3)
|
(1.6)
|
(3.4)
|
Trade payables
|
24.1
|
12.6
|
(265.1)
|
(14.0)
|
(29.5)
|
Other payables
|
17.5
|
9.2
|
(192.3)
|
(10.1)
|
(21.4)
|
Long-term loans
|
6.6
|
3.5
|
(73.0)
|
(3.8)
|
(8.1)
|
Fixed rate debentures (series E)
|
38.8
|
20.3
|
(426.8)
|
(22.5)
|
(47.4)
|
Options
|
(74.8)
|
(40.9)
|
(13.8)
|
19.1
|
43.4
|
Forward
|
(32.0)
|
(16.7)
|
1.6
|
18.5
|
39.1
|
Swap
|
(47.6)
|
(24.9)
|
14.7
|
27.6
|
58.2
|
Total
|
(71.5)
|
(39.2)
|
(909.6)
|
17.2
|
39.3
|
Increase (decrease)
in fair value
|
Fair value
|
Increase (decrease)
in fair value
|
|||
EUR/USD
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
Type of instrument
|
Increase of 10%
|
Increase of
5%
|
Decrease of 5%
|
Decrease of 10%
|
Cash and cash equivalents
|
(1.9)
|
(1.0)
|
21.3
|
1.1
|
2.4
|
Short term deposits and loans
|
(0.2)
|
(0.1)
|
2.7
|
0.1
|
0.3
|
Trade receivables
|
(20.2)
|
(10.6)
|
221.9
|
11.7
|
24.7
|
Receivables and debit balances
|
(1.1)
|
(0.6)
|
11.7
|
0.6
|
1.3
|
Long-term deposits and loans
|
(0.1)
|
(0.1)
|
1.1
|
0.1
|
0.1
|
Credit from banks and others
|
15.1
|
7.9
|
(166.4)
|
(8.8)
|
(18.5)
|
Trade payables
|
17.1
|
8.9
|
(187.6)
|
(9.9)
|
(20.8)
|
Other payables
|
4.2
|
2.2
|
(46.0)
|
(2.4)
|
(5.1)
|
Long-term loans from banks
|
0.5
|
0.3
|
(5.4)
|
(0.3)
|
(0.6)
|
Options
|
4.6
|
2.1
|
1.3
|
(1.8)
|
(3.7)
|
Forward
|
9.5
|
4.5
|
2.5
|
(4.1)
|
(7.7)
|
Swap
|
33.6
|
16.8
|
(1.0)
|
(16.8)
|
(33.6)
|
Total
|
61.1
|
30.3
|
(143.9)
|
(30.5)
|
(61.2)
|
Increase (decrease)
in fair value
|
Fair value
|
Increase (decrease)
in fair value
|
|||
GBP/USD
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
Type of instrument
|
Increase of 10%
|
Increase of
5%
|
Decrease of 5%
|
Decrease of 10%
|
Cash and cash equivalents
|
(0.4)
|
(0.2)
|
4.4
|
0.2
|
0.5
|
Trade receivables
|
(5.5)
|
(2.9)
|
60.3
|
3.2
|
6.7
|
Receivables and debit balances
|
0.0
|
0.0
|
0.4
|
0.0
|
0.0
|
Credit from banks and others
|
1.7
|
0.9
|
(18.7)
|
(1.0)
|
(2.1)
|
Trade payables
|
2.1
|
1.1
|
(22.7)
|
(1.2)
|
(2.5)
|
Other payables
|
0.6
|
0.3
|
(6.6)
|
(0.3)
|
(0.7)
|
Options
|
(1.3)
|
(0.6)
|
(0.1)
|
0.4
|
0.8
|
Forward
|
(3.5)
|
(1.7)
|
0.3
|
1.5
|
2.9
|
Total
|
(6.3)
|
(3.1)
|
17.3
|
2.8
|
5.6
|
Increase (decrease)
in fair value
|
Fair value
|
Increase (decrease)
in fair value
|
|||
GBP/EUR
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
Type of instrument
|
Increase of 10%
|
Increase of
5%
|
Decrease of 5%
|
Decrease of 10%
|
Forward
|
(3.7)
|
(1.9)
|
0.3
|
2.1
|
4.5
|
Increase (decrease)
in fair value
|
Fair value
|
Increase (decrease)
in fair value
|
|||
BRL/USD
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
Type of instrument
|
Increase of 10%
|
Increase of
5%
|
Decrease of 5%
|
Decrease of 10%
|
Cash and cash equivalents
|
(0.5)
|
(0.2)
|
5.0
|
0.3
|
0.6
|
Trade receivables
|
(2.3)
|
(1.2)
|
25.2
|
1.3
|
2.8
|
Trade payables
|
1.0
|
0.5
|
(10.9)
|
(0.6)
|
(1.2)
|
Other payables
|
0.2
|
0.1
|
(2.2)
|
(0.1)
|
(0.2)
|
Long-term loans from banks
|
1.7
|
0.9
|
(19.1)
|
(1.0)
|
(2.1)
|
Total
|
0.1
|
0.1
|
(2.0)
|
(0.1)
|
(0.1)
|
Increase (decrease)
in fair value
|
Fair value
|
Increase (decrease)
in fair value
|
|||
CNY/USD
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
Type of instrument
|
Increase of 10%
|
Increase of
5%
|
Decrease of 5%
|
Decrease of 10%
|
Cash and cash equivalents
|
(3.4)
|
(1.8)
|
37.2
|
2.0
|
4.1
|
Trade receivables
|
(6.5)
|
(3.4)
|
71.5
|
3.8
|
7.9
|
Trade payables
|
6.5
|
3.4
|
(71.9)
|
(3.8)
|
(8.0)
|
Other payables
|
1.8
|
0.9
|
(19.4)
|
(1.0)
|
(2.2)
|
Credit from banks and others
|
16.7
|
8.8
|
(184.0)
|
(9.7)
|
(20.4)
|
Forward
|
(2.6)
|
(1.4)
|
(0.1)
|
1.5
|
3.2
|
Long-term loans (CNY)
|
0.1
|
0.0
|
(0.7)
|
0.0
|
(0.1)
|
Total
|
12.6
|
6.5
|
(167.4)
|
(7.2)
|
(15.5)
|
Increase (decrease)
in fair value
|
Fair value
|
Increase (decrease)
in fair value
|
|||
USD/NIS
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
Type of instrument
|
Increase of 10%
|
Increase of 5%
|
Decrease of 5%
|
Decrease of 10%
|
Cash and cash equivalents
|
(0.1)
|
(0.1)
|
1.4
|
0.1
|
0.1
|
Short term deposits and loans
|
0.0
|
0.0
|
0.1
|
0.0
|
0.0
|
Trade receivables
|
(5.9)
|
(3.0)
|
59.0
|
3.0
|
5.9
|
Receivables and debit balances
|
(3.9)
|
(2.0)
|
39.4
|
2.0
|
3.9
|
Credit from banks and others
|
3.3
|
1.6
|
(32.7)
|
(1.6)
|
(3.3)
|
Trade payables
|
28.9
|
14.4
|
(288.8)
|
(14.4)
|
(28.9)
|
Other payables
|
9.6
|
4.8
|
(96.3)
|
(4.8)
|
(9.6)
|
Long-term loans
|
7.8
|
4.1
|
(86.0)
|
(4.5)
|
(9.6)
|
Fixed rate debentures (series E)
|
42.8
|
22.4
|
(470.9)
|
(24.8)
|
(52.3)
|
Options
|
(35.6)
|
(9.1)
|
3.2
|
20.5
|
50.0
|
Forward
|
(39.1)
|
(20.5)
|
1.8
|
22.7
|
47.8
|
Swap
|
(52.9)
|
(27.4)
|
64.0
|
31.7
|
66.2
|
Total
|
(45.1)
|
(14.8)
|
(806.0)
|
29.9
|
70.2
|
Increase (decrease)
in fair value
|
Fair value
|
Increase (decrease)
in fair value
|
|||
EUR/USD
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
Type of instrument
|
Increase of 10%
|
Increase of
5%
|
Decrease of 5%
|
Decrease of 10%
|
Cash and cash equivalents
|
(1.8)
|
(0.9)
|
17.9
|
0.9
|
1.8
|
Short term deposits and loans
|
(0.1)
|
0.0
|
0.7
|
0.0
|
0.1
|
Trade receivables
|
(24.6)
|
(12.3)
|
246.4
|
12.3
|
24.6
|
Receivables and debit balances
|
(0.1)
|
0.0
|
0.9
|
0.0
|
0.1
|
Long-term deposits and loans
|
(0.1)
|
(0.1)
|
1.1
|
0.1
|
0.1
|
Credit from banks and others
|
15.8
|
7.9
|
(157.6)
|
(7.9)
|
(15.8)
|
Trade payables
|
18.2
|
9.1
|
(182.1)
|
(9.1)
|
(18.2)
|
Other payables
|
7.7
|
3.8
|
(76.9)
|
(3.8)
|
(7.7)
|
Long-term loans from banks
|
2.9
|
1.4
|
(29.0)
|
(1.4)
|
(2.9)
|
Options
|
5.7
|
2.8
|
(1.8)
|
(3.1)
|
(6.7)
|
Forward
|
35.0
|
16.6
|
(2.6)
|
(15.0)
|
(28.7)
|
Swap
|
5.3
|
2.7
|
(0.6)
|
(2.5)
|
(5.1)
|
Total
|
63.9
|
31.0
|
(183.6)
|
(29.5)
|
(58.4)
|
Increase (decrease)
in fair value
|
Fair value
|
Increase (decrease)
in fair value
|
|||
GBP/USD
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
Type of instrument
|
Increase of 10%
|
Increase of
5%
|
Decrease of 5%
|
Decrease of 10%
|
Cash and cash equivalents
|
(0.7)
|
(0.3)
|
6.7
|
0.3
|
0.7
|
Trade receivables
|
(4.8)
|
(2.4)
|
47.8
|
2.4
|
4.8
|
Receivables and debit balances
|
0.0
|
0.0
|
0.1
|
0.0
|
0.0
|
Credit from banks and others
|
2.0
|
1.0
|
(20.3)
|
(1.0)
|
(2.0)
|
Trade payables
|
2.3
|
1.2
|
(23.0)
|
(1.2)
|
(2.3)
|
Other payables
|
1.5
|
0.7
|
(14.7)
|
(0.7)
|
(1.5)
|
Options
|
-
|
-
|
-
|
-
|
-
|
Forward
|
2.6
|
1.2
|
0.1
|
(1.1)
|
(2.2)
|
Total
|
2.9
|
1.4
|
(3.3)
|
(1.3)
|
(2.5)
|
Increase (decrease)
in fair value
|
Fair value
|
Increase (decrease)
in fair value
|
|||
GBP/EUR
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
Type of instrument
|
Increase of 10%
|
Increase of
5%
|
Decrease of 5%
|
Decrease of 10%
|
Forward
|
2.2
|
1.2
|
0.1
|
(1.3)
|
(2.7)
|
Increase (decrease)
in fair value
|
Fair value
|
Increase (decrease)
in fair value
|
|||
BRL/USD
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
Type of instrument
|
Increase of 10%
|
Increase of
5%
|
Decrease of 5%
|
Decrease of 10%
|
Cash and cash equivalents
|
(0.7)
|
(0.3)
|
6.5
|
0.3
|
0.7
|
Trade receivables
|
(3.1)
|
(1.5)
|
30.8
|
1.5
|
3.1
|
Trade payables
|
1.5
|
0.8
|
(15.5)
|
(0.8)
|
(1.5)
|
Other payables
|
0.2
|
0.1
|
(1.9)
|
(0.1)
|
(0.2)
|
Long-term loans from banks
|
3.0
|
1.5
|
(30.0)
|
(1.5)
|
(3.0)
|
Total
|
0.9
|
0.6
|
(10.1)
|
(0.6)
|
(0.9)
|
Increase (decrease)
in fair value
|
Fair value
|
Increase (decrease)
in fair value
|
|||
CNY/USD
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
Type of instrument
|
Increase of 10%
|
Increase of
5%
|
Decrease of 5%
|
Decrease of 10%
|
Cash and cash equivalents
|
(2.2)
|
(1.1)
|
21.6
|
1.1
|
2.2
|
Trade receivables
|
(9.2)
|
(4.6)
|
91.7
|
4.6
|
9.2
|
Trade payables
|
8.5
|
4.3
|
(85.3)
|
(4.3)
|
(8.5)
|
Other payables
|
2.1
|
1.0
|
(20.8)
|
(1.0)
|
(2.1)
|
Credit from banks and others
|
17.3
|
8.7
|
(173.3)
|
(8.7)
|
(17.3)
|
Forward
|
3.1
|
1.6
|
(0.7)
|
(1.8)
|
(3.8)
|
Long-term loans (CNY)
|
9.8
|
4.9
|
(98.1)
|
(4.9)
|
(9.8)
|
Total
|
29.4
|
14.8
|
(264.9)
|
(15.0)
|
(30.1)
|
Increase (decrease)
in fair value
|
Fair value
|
Increase (decrease)
in fair value
|
|||
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
|
Type of instrument
|
Increase of
1%
|
Increase of 0.5%
|
Decrease of 0.5%
|
Decrease of 1%
|
Fixed-USD interest debentures
|
77.5
|
40.0
|
(1,068.9)
|
(42.7)
|
(88.4)
|
Swap transactions
|
7.7
|
3.9
|
0.4
|
(4.0)
|
(8.2)
|
NIS/USD swap
|
17.6
|
8.9
|
14.7
|
(9.1)
|
(18.4)
|
EUR/USD swap
|
(0.2)
|
(0.1)
|
(1.0)
|
0.1
|
0.2
|
Total
|
102.8
|
52.8
|
(1,054.8)
|
(55.8)
|
(115.0)
|
Fixed-USD interest debentures
|
58.2
|
29.6
|
(1,107.9)
|
(30.7)
|
(62.4)
|
Swap transactions
|
10.1
|
5.1
|
(2.7)
|
(5.3)
|
(10.8)
|
NIS/USD swap
|
33.1
|
22.4
|
64.0
|
(11.7)
|
(23.6)
|
Total
|
101.4
|
57.1
|
(1,046.6)
|
(47.7)
|
(96.8)
|
Sensitivity to changes in the shekel interest rate
|
Increase (decrease)
in fair value
|
Fair value
|
Increase (decrease)
in fair value
|
||
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
|
Type of instrument
|
Increase of
1%
|
Increase of 0.5%
|
Decrease of 0.5%
|
Decrease of 1%
|
Fixed-interest long-term loan
|
2.7
|
1.4
|
(73.0)
|
(1.4)
|
(2.9)
|
Fixed rate debentures (series E)
|
14.5
|
7.4
|
(426.8)
|
(7.5)
|
(15.3)
|
NIS/USD swap
|
(18.5)
|
(9.4)
|
14.7
|
9.6
|
19.5
|
Total
|
(1.3)
|
(0.6)
|
(485.1)
|
0.7
|
1.3
|
Fixed-interest long-term loan
|
3.7
|
1.9
|
(86.0)
|
(2.0)
|
(4.0)
|
Fixed rate debentures (series E)
|
20.1
|
10.2
|
(470.9)
|
(10.5)
|
(21.3)
|
NIS/USD swap
|
(25.9)
|
(13.1)
|
64.0
|
13.5
|
27.5
|
Total
|
(2.1)
|
(1.0)
|
(492.9)
|
1.0
|
2.2
|
Increase (decrease)
in fair value
|
Fair value
|
Increase (decrease)
in fair value
|
|||
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
|
Type of instrument
|
Increase of
10%
|
Increase of 5%
|
Decrease of 5%
|
Decrease of 10%
|
Energy hedges
|
1.5
|
0.8
|
(3.0)
|
(0.9)
|
(2.0)
|
Increase (decrease)
in fair value
|
Fair value
|
Increase (decrease)
in fair value
|
|||
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
|
Type of instrument
|
Increase of
10%
|
Increase of 5%
|
Decrease of 5%
|
Decrease of 10%
|
Energy hedges
|
2.1
|
1.0
|
2.2
|
(1.0)
|
(1.9)
|
Increase (decrease)
in fair value
|
Fair value
|
Increase (decrease)
in fair value
|
|||
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
|
Type of instrument
|
Increase of
10%
|
Increase of 5%
|
Decrease of 5%
|
Decrease of 10%
|
Marine shipping hedges
|
2.7
|
1.3
|
(2.2)
|
(1.3)
|
(2.7)
|
Increase (decrease)
in fair value
|
Fair value
|
Increase (decrease)
in fair value
|
|||
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
|
Type of instrument
|
Increase of
10%
|
Increase of 5%
|
Decrease of 5%
|
Decrease of 10%
|
Marine shipping hedges
|
2.2
|
1.1
|
1.9
|
(1.0)
|
(2.1)
|
· |
pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect transactions and dispositions of our assets;
|
· |
provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements, in accordance with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with authorization of our management and directors; and
|
· |
provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.
|
2018
|
2017
|
|
US$ thousands
|
US$ thousands
|
Audit fees(1)
|
4,897
|
5,132
|
Audit-related fees(2)
|
192
|
395
|
Tax fees(3)
|
1,751
|
1,473
|
Total
|
6,840
|
7,000
|
· |
Majority Independent Board.
Under Section 303A.01 of the NYSE Listed Company Manual (the “LCM”), a U.S. domestic listed company, other than a controlled company, must have a majority of independent directors. six of our ten directors are not considered independent directors under Israeli law whether due to their relationship with the Company, our controlling shareholder or the length of their tenure on our Board of Directors.
|
· |
Nominating/Corporate Governance Committee.
Under Section 303A.04 of the LCM, a U.S. domestic listed company, other than a controlled company, must have a nominating/corporate governance committee composed entirely of independent directors. Our controlling shareholder, Israel Corporation, has significant control over the appointment of our directors.
|
· |
Equity Compensation Plans.
Under Section 303A.08 of the LCM, shareholders must be given the opportunity to vote on all equity‑compensation plans and material revisions thereto, with certain limited exemptions as described therein. We follow the requirements of the Israeli Companies Law, under which approval of equity compensation plans and material revisions thereto is within the authority of our HR & Compensation Committee and the Board of Directors. However, under the Israeli Companies Law, any compensation to directors, the chief executive officer or a controlling shareholder or another person in which a controlling shareholder has a personal interest, including equity compensation plans, generally requires the approval of the compensation committee, the board of directors and the shareholders, in that order. The compensation of directors and officers is generally required to comply with a shareholder‑approved compensation policy, which is required, among other things, to include a monetary cap on the value of equity compensation that may be granted to any director or officer.
|
· |
Shareholder Approval of Securities Issuances
. Under Section 312.03 of the LCM, shareholder approval is a prerequisite to (a) issuing common stock, or securities convertible into or exercisable for ordinary shares, to a related party, a subsidiary, affiliate or other closely related person of a related party or any company or entity in which a related party has a substantial interest, if the number of ordinary shares to be issued exceeds either 1% of the number of ordinary shares or 1% of the voting power outstanding before the issuance, and (b) issuing ordinary shares, or securities convertible into or exercisable for ordinary shares, if the ordinary share has, or will have upon issuance, voting power equal to or in excess of 20% of the voting power outstanding before the issuance or the number of ordinary shares to be issued is equal to or in excess of 20% of the number of ordinary shares before the issuance, in each case subject to certain exceptions. We seek shareholder approval for all corporate actions requiring such approval under the requirements of the Israeli Companies Law, which are different from the requirements for seeking shareholder approval under Section 312.03 of the LCM. Under the Israeli Companies Law, shareholder approval is a prerequisite to any extraordinary transaction with a controlling shareholder or in which a controlling shareholder has a personal interest. Under the Israeli Companies Law, shareholder approval is also a prerequisite to a private placement of securities if it will cause a person to become a controlling shareholder or in case all of the following conditions are met:
|
· |
The securities issued amount to 20% or more of the company’s outstanding voting rights before the issuance;
|
· |
Some or all of the consideration is other than cash or listed securities or the transaction is not on market terms; and
|
· |
The transaction will increase the relative holdings of a 5% shareholder or will cause any person to become, as a result of the issuance, a 5% shareholder.
|
* |
Incorporated by reference to our registration statement on Form F-1 (file no. 333- 198711), as amended.
|
** |
Incorporated by reference to our annual report on Form 20-F (file no. 001-13742) for the year ended December 31, 2016, dated March 16, 2017.
|
*** |
Incorporated by reference to our annual report on Form 20-F (file no. 001-13742) for the year ended December 31, 2015, dated March 16, 2016.
|
**** |
Incorporated by reference to our annual report on Form 20-F (file no. 001-13742) for the year ended December 31, 2017, dated March 7, 2018.
|
|
ISRAEL CHEMICALS LTD.
|
|
||
|
By:
|
/s/ Kobi Altman
|
|
|
|
|
Name:
|
Kobi Altman
|
|
|
|
Title:
|
Chief Financial Officer
|
|
|
By:
|
/s/ Aya Landman
|
|
|
|
|
Name:
|
Aya Landman
|
|
|
|
Title:
|
Global Company Secretary
|
|
Somekh Chaikin
KPMG Millennium Tower
17 Ha'arba'a Street, PO Box 609
Tel Aviv 61006 Israel
|
Telephone
972 3 684 8000
Fax 972 3 684 8444
Internet www.kpmg.co.il
|
2018
|
2017
|
||
Note
|
$ millions
|
$ millions
|
Current assets
|
|||
Cash and cash equivalents
|
121
|
83
|
|
Short-term investments and deposits
|
92
|
90
|
|
Trade receivables
|
990
|
932
|
|
Inventories
|
6
|
1,290
|
1,226
|
Assets held for sale
|
-
|
169
|
|
Other receivables
|
7,14
|
295
|
225
|
Total current assets
|
2,788
|
2,725
|
|
Non-current assets
|
|||
Investments in equity-accounted investees
|
30
|
29
|
|
Investments at fair value through other comprehensive income
|
145
|
212
|
|
Deferred tax assets
|
17
|
122
|
132
|
Property, plant and equipment
|
11
|
4,663
|
4,521
|
Intangible assets
|
12
|
671
|
722
|
Other non-current assets
|
9,14,18
|
357
|
373
|
Total non-current assets
|
5,988
|
5,989
|
|
Total assets
|
8,776
|
8,714
|
|
Current liabilities
|
|||
Short-term credit
|
15
|
610
|
822
|
Trade payables
|
715
|
790
|
|
Provisions
|
19
|
37
|
78
|
Liabilities held for sale
|
-
|
43
|
|
Other current liabilities
|
14,16
|
647
|
595
|
Total current liabilities
|
2,009
|
2,328
|
|
Non-current liabilities
|
|||
Long-term debt and debentures
|
15
|
1,815
|
2,388
|
Deferred tax liabilities
|
17
|
297
|
228
|
Long-term employee liabilities
|
18
|
501
|
640
|
Provisions
|
19
|
229
|
193
|
Other non-current liabilities
|
10
|
7
|
|
Total non-current liabilities
|
2,852
|
3,456
|
|
Total liabilities
|
4,861
|
5,784
|
|
Equity
|
21
|
||
Total shareholders’ equity
|
3,781
|
2,859
|
|
Non-controlling interests
|
134
|
71
|
|
Total equity
|
3,915
|
2,930
|
|
Total liabilities and equity
|
8,776
|
8,714
|
2018
|
2017
|
2016
|
||
Note
|
$ millions
|
$ millions
|
$ millions
|
Sales
|
22
|
5,556
|
5,418
|
5,363
|
Cost of sales
|
22
|
3,702
|
3,746
|
3,703
|
Gross profit
|
1,854
|
1,672
|
1,660
|
|
Selling, transport and marketing expenses
|
22
|
798
|
746
|
722
|
General and administrative expenses
|
22
|
257
|
261
|
321
|
Research and development expenses
|
22
|
55
|
55
|
73
|
Other expenses
|
22
|
84
|
90
|
618
|
Other income
|
22
|
(859)
|
(109)
|
(71)
|
Operating income (loss)
|
1,519
|
629
|
(3)
|
|
Finance expenses
|
214
|
229
|
157
|
|
Finance income
|
(56)
|
(105)
|
(25)
|
|
Finance expenses, net
|
22
|
158
|
124
|
132
|
Share in earnings of equity-accounted investees
|
3
|
-
|
18
|
|
Income (loss) before income taxes
|
1,364
|
505
|
(117)
|
|
Provision for income taxes
|
17
|
129
|
158
|
55
|
Net income (loss)
|
1,235
|
347
|
(172)
|
|
Net loss attributable to the non-controlling interests
|
(5)
|
(17)
|
(50)
|
|
Net income (loss) attributable to the shareholders of the Company
|
1,240
|
364
|
(122)
|
|
Earnings (losses) per share attributable to the shareholders of the Company:
|
24
|
|||
Basic earnings (losses) per share (in dollars)
|
0.97
|
0.29
|
(0.10)
|
|
Diluted earnings (losses) per share (in dollars)
|
0.97
|
0.29
|
(0.10)
|
|
Weighted-average number of ordinary shares outstanding:
|
24
|
|||
Basic (in thousands)
|
1,277,209
|
1,276,072
|
1,273,295
|
|
Diluted (in thousands)
|
1,279,781
|
1,276,997
|
1,273,295
|
2018
|
2017
|
2016
|
|
$ millions
|
$ millions
|
$ millions
|
Net income (loss)
|
1,235
|
347
|
(172)
|
Components of other comprehensive income that will be reclassified subsequently to net income (loss)
|
|||
Currency translation differences
|
(95)
|
152
|
(90)
|
Changes in fair value of derivatives designated as a cash flow hedge
|
-
|
-
|
(1)
|
Net changes of investments at fair value through other comprehensive income
|
-
|
(57)
|
17
|
Tax income (expenses) relating to items that will be reclassified subsequently to net income (loss)
|
-
|
5
|
(5)
|
(95)
|
100
|
(79)
|
|
Components of other comprehensive income that will not be reclassified to net income (loss)
|
|||
Net changes of investments at fair value through other comprehensive income
|
(58)
|
-
|
-
|
Actuarial gains (losses) from defined benefit plans
|
56
|
(17)
|
(48)
|
Tax income (expense) relating to items that will not be reclassified to net income (loss)
|
(3)
|
3
|
8
|
(5)
|
(14)
|
(40)
|
|
Total comprehensive income (loss)
|
1,135
|
433
|
(291)
|
Comprehensive loss attributable to the non-controlling interests
|
(9)
|
(13)
|
(59)
|
Comprehensive income (loss) attributable to the shareholders of the Company
|
1,144
|
446
|
(232)
|
Attributable to the shareholders of the Company
|
Non- controlling interests
|
Total equity
|
|||||||
Share capital
|
Share premium
|
Cumulative translation adjustment
|
Capital reserves
|
Treasury shares, at cost
|
Retained earnings
|
Total shareholders’ equity
|
|||
$ millions
|
For the year ended December 31, 2018
|
|||||||||
Balance as at January 1, 2018
|
545
|
186
|
(333)
|
30
|
(260)
|
2,691
|
2,859
|
71
|
2,930
|
Share-based compensation
|
1
|
7
|
-
|
11
|
-
|
-
|
19
|
-
|
19
|
Dividends
|
-
|
-
|
-
|
-
|
-
|
(241)
|
(241)
|
(1)
|
(242)
|
Capitalization of subsidiary debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
73
|
73
|
Comprehensive income (loss)
|
-
|
-
|
(91)
|
(58)
|
-
|
1,293
|
1,144
|
(9)
|
1,135
|
Balance as at December 31, 2018
|
546
|
193
|
(424)
|
(17)
|
(260)
|
3,743
|
3,781
|
134
|
3,915
|
Attributable to the shareholders of the Company
|
Non- controlling interests
|
Total equity
|
|||||||
Share capital
|
Share premium
|
Cumulative translation adjustment
|
Capital reserves
|
Treasury shares, at cost
|
Retained earnings
|
Total shareholders’ equity
|
|||
$ millions
|
For the year ended December 31, 2017
|
|||||||||
Balance as at January 1, 2017
|
544
|
174
|
(481)
|
79
|
(260)
|
2,518
|
2,574
|
85
|
2,659
|
Share-based compensation
|
1
|
12
|
-
|
3
|
-
|
-
|
16
|
-
|
16
|
Dividends
|
-
|
-
|
-
|
-
|
-
|
(177)
|
(177)
|
(1)
|
(178)
|
Comprehensive income (loss)
|
-
|
-
|
148
|
(52)
|
-
|
350
|
446
|
(13)
|
433
|
Balance as at December 31, 2017
|
545
|
186
|
(333)
|
30
|
(260)
|
2,691
|
2,859
|
71
|
2,930
|
Attributable to the shareholders of the Company
|
Non- controlling interests
|
Total equity
|
|||||||
Share capital
|
Share premium
|
Cumulative translation adjustment
|
Capital reserves
|
Treasury shares, at cost
|
Retained earnings
|
Total shareholders’ equity
|
|||
$ millions
|
For the year ended December 31, 2016
|
|||||||||
Balance as at January 1, 2016
|
544
|
149
|
(400)
|
93
|
(260)
|
2,902
|
3,028
|
160
|
3,188
|
Share-based compensation
|
*-
|
25
|
-
|
(10)
|
-
|
-
|
15
|
-
|
15
|
Dividends
|
-
|
-
|
-
|
-
|
-
|
(222)
|
(222)
|
(4)
|
(226)
|
Changes in equity of equity-accounted investees
|
-
|
-
|
-
|
(15)
|
-
|
-
|
(15)
|
-
|
(15)
|
Non-controlling interests in business combinations from prior periods
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(12)
|
(12)
|
Comprehensive loss
|
-
|
-
|
(81)
|
11
|
-
|
(162)
|
(232)
|
(59)
|
(291)
|
Balance as at December 31, 2016
|
544
|
174
|
(481)
|
79
|
(260)
|
2,518
|
2,574
|
85
|
2,659
|
2018
|
2017
|
2016
|
|
$ millions
|
$ millions
|
$ millions
|
Cash flows from operating activities
|
|||
Net income (loss)
|
1,235
|
347
|
(172)
|
Adjustments for:
|
|||
Depreciation and amortization
|
403
|
390
|
401
|
Impairment of non-current assets
|
17
|
28
|
5
|
Exchange rate and interest expenses, net
|
35
|
137
|
76
|
Share in earnings of equity-accounted investees, net
|
(3)
|
-
|
(18)
|
Loss (gain) from divestiture of businesses
|
(841)
|
(54)
|
1
|
Capital losses
|
-
|
-
|
432
|
Share-based compensation
|
19
|
16
|
15
|
Deferred tax expenses (income)
|
76
|
(46)
|
(2)
|
(294)
|
471
|
910
|
|
Change in inventories
|
(115)
|
57
|
70
|
Change in trade and other receivables
|
(104)
|
21
|
150
|
Change in trade and other payables
|
(36)
|
(45)
|
(90)
|
Change in provisions and employee benefits
|
(66)
|
(4)
|
98
|
Net change in operating assets and liabilities
|
(321)
|
29
|
228
|
Net cash provided by operating activities
|
620
|
847
|
966
|
Cash flows from investing activities
|
|||
Proceeds from deposits, net
|
(3)
|
(65)
|
(198)
|
Purchases of property, plant and equipment and intangible assets
|
(572)
|
(457)
|
(632)
|
Proceeds from divestiture of businesses net of transaction expenses
|
* 902
|
6
|
17
|
Proceeds from sale of equity-accounted investee
|
-
|
168
|
-
|
Dividends from equity-accounted investees
|
2
|
3
|
12
|
Proceeds from sale of property, plant and equipment
|
2
|
12
|
5
|
Other
|
-
|
-
|
(4)
|
Net cash provided by (used in) investing activities
|
331
|
(333)
|
(800)
|
Cash flows from financing activities
|
|||
Dividends paid to the Company's shareholders
|
(241)
|
(237)
|
(162)
|
Receipt of long-term debt
|
1,746
|
966
|
1,278
|
Repayment of long-term debt
|
(2,115)
|
(1,387)
|
(1,365)
|
Short-term credit from banks and others, net
|
(283)
|
147
|
14
|
Other
|
(1)
|
-
|
(4)
|
Net cash used in financing activities
|
(894)
|
(511)
|
(239)
|
Net change in cash and cash equivalents
|
57
|
3
|
(73)
|
Cash and cash equivalents as at the beginning of the year
|
83
|
87
|
161
|
Net effect of currency translation on cash and cash equivalents
|
(24)
|
(2)
|
(1)
|
Cash and cash equivalents included as part of assets held for sale
|
5
|
(5)
|
-
|
Cash and cash equivalents as at the end of the year
|
121
|
83
|
87
|
For the year
ended 31, December
|
|||
2018
|
2017
|
2016
|
|
$ millions
|
$ millions
|
$ millions
|
Income taxes paid, net of refunds
|
56
|
127
|
84
|
Interest paid
|
103
|
111
|
112
|
1. |
Subsidiary – a company over which the Company has control and the financial statements of which are fully consolidated with the Company's statements as part of the consolidated financial statements.
|
2. |
Investee company – Subsidiaries and companies, including a partnership or joint venture, the Company's investment in which is accounted for, directly or indirectly, using the equity method.
|
3. |
Related party – Within its meaning in IAS 24 (2009), “Related Party Disclosures”.
|
1. |
Initial application of IFRS 9 (2014), Financial Instruments
|
2. |
IFRS 15, Revenue from Contracts with Customers
|
1. |
Business combinations
|
2. |
Subsidiaries
|
3. |
Structured entities
|
4. |
Non-controlling interests
|
4. |
Non-controlling interests (cont’d)
|
5. |
Loss of control
|
6. |
Transactions eliminated in consolidation
|
7. |
Investment in associates and joint ventures
|
1. |
Transactions in foreign currency
|
2. |
Foreign operations
|
2. |
Foreign operations (cont'd)
|
1. |
Non-derivative financial assets (IFRS9)
|
1. |
Non-derivative financial assets (IFRS9) (cont'd)
|
2. |
Non-derivative financial liabilities
|
2. |
Non-derivative financial liabilities (cont'd)
|
3. |
Derivative financial instruments
|
3. |
Derivative financial instruments (cont'd)
|
4. |
CPI-linked assets and liabilities not measured at fair value
|
5. |
Share capital
|
1. |
Recognition and measurement
|
2. |
Subsequent Costs (after initial recognition)
|
3. |
Depreciation
|
In Years
|
|
Land development, roads and structures
|
15-30
|
Facilities, machinery and equipment (1)
|
8-25
|
Dams and ponds (2)
|
20-40
|
Heavy mechanical equipment, train cars and tanks
|
5-15
|
Office furniture and equipment, motor vehicles, computer equipment and other
|
3-10
|
1. |
Goodwill
|
2. |
Costs of exploration and evaluation of resources
|
3. |
Research and development
|
4. |
Other intangible assets
|
5. |
Subsequent costs
|
6. |
Amortization
|
6. |
Amortization (cont'd)
|
In Years
|
|
Concessions – over the balance of the concession granted to the companies
|
|
Software costs
|
3-10
|
Trademarks
|
15-20
|
Customer relationships
|
15-25
|
Agreements with suppliers and non-competition agreement
|
10-15
|
Patents
|
7-20
|
1. |
Non-derivative Financial assets
|
2. |
Non-financial assets
|
I. |
Impairment (cont'd)
|
2. |
Non-financial assets (cont'd)
|
I. |
Impairment (cont'd)
|
3. |
Investments in associates and joint ventures
|
(1) |
Current service costs – the increase in the present value of the liability deriving from employees’ service in the current period.
|
(2) |
The net financing income (expenses) are calculated by multiplying the net defined benefit liability (asset) by the discount rate used for measuring the defined benefit liability, as determined at the beginning of the annual reporting period.
|
(3) |
Exchange rate differences;
|
(4) |
Past service costs and plan reduction – the change in the present value of the liability in the current period as a result of a change in post-employment benefits attributed to prior periods.
|
(1) |
Warranty
|
(2) |
Provision for environmental costs
|
(3) |
Restructuring
|
(4) |
Site restoration
|
(5) |
Legal claims
|
(a) |
The parties to the contract have approved the contract (in writing, orally or according to other customary business practices) and they are committed to satisfying the obligations attributable to them;
|
(b) |
ICL can identify the rights of each party in relation to the goods or services that will be transferred;
|
(c) |
ICL can identify the payment terms for the goods or services that will be transferred;
|
(d) |
The contract has a commercial substance (i.e. the risk, timing and amount of the entity’s future cash flows are expected to change as a result of the contract); and
|
(e) |
It is probable that the consideration, to which ICL is entitled to in exchange for the goods or services transferred to the customer, will be collected.
|
(a) |
Negotiations were held on the contracts as one package with a single commercial purpose;
|
(b) |
The amount of the consideration in one contract depends on the price or performance of a different contract; or
|
(c) |
The goods or services promised in the contracts (or certain goods or services promised in each one of the contracts) are a single performance obligation.
|
(a) |
Goods or services (or a bundle of goods or services) that are distinct; or
|
(b) |
A series of distinct goods or services that are substantially the same and have the same pattern of transfer to the customer.
|
1) |
Not applying the requirement to recognize a right-of-use asset and a lease liability in respect of short-term leases of up to one year. Furthermore, not applying the requirement to recognize a right-of-use asset and a lease liability for leases that end within 12 months from the date of initial application.
|
2) |
Not separating non-lease components from lease components and instead accounting for all the lease components and related non-lease components as a single lease component.
|
3) |
Relying on a previous assessment of whether an arrangement contains a lease in accordance with current guidance, IAS 17, Leases, and IFRIC 4, Determining whether an Arrangement contains a Lease, with respect to agreements that exist at the date of initial application.
|
4) |
Not applying the requirement to recognize a right-of-use asset and a lease liability in respect of leases where the underlying asset has a low value.
|
Industrial Products
|
Potash
|
Phosphate Solutions
|
Innovative Ag Solutions
|
Other
Activities
|
Reconciliation
|
Consolidated
|
|
$ millions
|
For the year ended December 31, 2018
|
|||||||
Sales to external parties
|
1,281
|
1,481
|
2,001
|
719
|
74
|
-
|
5,556
|
Inter-segment sales
|
15
|
142
|
98
|
22
|
5
|
(282)
|
-
|
Total sales
|
1,296
|
1,623
|
2,099
|
741
|
79
|
(282)
|
5,556
|
Segment profit
|
350
|
393
|
208
|
57
|
9
|
(7)
|
1,010
|
General and administrative expenses
|
(257)
|
||||||
Other income not allocated to the segments
|
766
|
||||||
Operating income
|
1,519
|
||||||
Financing expenses, net
|
(158)
|
||||||
Share in earnings of equity-accounted investee
|
3
|
||||||
Income before income taxes
|
1,364
|
||||||
Capital expenditures
|
50
|
356
|
180
|
15
|
1
|
3
|
605
|
Depreciation, amortization and impairment
|
63
|
141
|
172
|
19
|
4
|
21
|
420
|
Industrial Products
|
Potash
|
Phosphate Solutions
|
Innovative Ag Solutions
|
Other
Activities
|
Reconciliation
|
Consolidated
|
|
$ millions
|
For the year ended December 31, 2017
|
|||||||
Sales to external parties
|
1,179
|
1,258
|
1,938
|
671
|
372
|
-
|
5,418
|
Inter-segment sales
|
14
|
125
|
99
|
21
|
12
|
(271)
|
-
|
Total sales
|
1,193
|
1,383
|
2,037
|
692
|
384
|
(271)
|
5,418
|
Segment profit
|
303
|
282
|
149
|
56
|
127
|
(4)
|
913
|
General and administrative expenses
|
(261)
|
||||||
Other expenses not allocated to the segments
|
(23)
|
||||||
Operating income
|
629
|
||||||
Financing expenses, net
|
(124)
|
||||||
Income before income taxes
|
505
|
||||||
Capital expenditures
|
49
|
270
|
154
|
12
|
19
|
3
|
507
|
Depreciation, amortization and impairment
|
61
|
128
|
172
|
19
|
8
|
30
|
418
|
Industrial Products
|
Potash
|
Phosphate Solutions
|
Innovative Ag Solutions
|
Other
Activities
|
Reconciliation
|
Consolidated
|
|
$ millions
|
For the year ended December 31, 2016
|
|||||||
Sales to external parties
|
1,111
|
1,213
|
2,082
|
632
|
325
|
-
|
5,363
|
Inter-segment sales
|
9
|
125
|
104
|
29
|
15
|
(282)
|
-
|
Total sales
|
1,120
|
1,338
|
2,186
|
661
|
340
|
(282)
|
5,363
|
Segment profit
|
286
|
282
|
224
|
55
|
93
|
(37)
|
903
|
General and administrative expenses
|
(321)
|
||||||
Other expenses not allocated to the segments
|
(585)
|
||||||
Operating loss
|
(3)
|
||||||
Financing expenses, net
|
(132)
|
||||||
Share in earnings of equity-accounted investees
|
18
|
||||||
Loss before income taxes
|
(117)
|
||||||
Capital expenditures
|
38
|
311
|
237
|
7
|
1
|
58
|
652
|
Depreciation, amortization and impairment
|
52
|
127
|
203
|
17
|
3
|
4
|
406
|
2018
|
2017
|
2016
|
||||
$
millions
|
% of
sales
|
$
millions
|
% of
sales
|
$
millions
|
% of
sales
|
USA
|
903
|
16
|
1,091
|
20
|
1,070
|
20
|
China
|
848
|
15
|
724
|
13
|
669
|
12
|
Brazil
|
656
|
12
|
594
|
11
|
521
|
10
|
United Kingdom
|
382
|
7
|
328
|
6
|
306
|
6
|
Germany
|
365
|
7
|
378
|
7
|
392
|
7
|
France
|
267
|
5
|
265
|
5
|
226
|
4
|
Spain
|
262
|
5
|
264
|
5
|
258
|
5
|
Israel
|
223
|
4
|
171
|
3
|
237
|
4
|
India
|
211
|
4
|
200
|
4
|
199
|
4
|
Australia
|
126
|
2
|
85
|
2
|
187
|
3
|
All other
|
1,313
|
23
|
1,318
|
24
|
1,298
|
25
|
Total
|
5,556
|
100
|
5,418
|
100
|
5,363
|
100
|
Industrial Products
|
Potash
|
Phosphate Solutions
|
Innovative Ag Solutions
|
Other
Activities
|
Reconciliation
|
Consolidated
|
|
$ millions
|
For the year ended December 31, 2018
|
|||||||
Europe
|
473
|
459
|
719
|
362
|
49
|
(92)
|
1,970
|
Asia
|
399
|
519
|
481
|
105
|
2
|
(18)
|
1,488
|
North America
|
347
|
107
|
405
|
103
|
24
|
(8)
|
978
|
South America
|
21
|
408
|
264
|
21
|
1
|
(3)
|
712
|
Rest of the world
|
56
|
130
|
230
|
150
|
3
|
(161)
|
408
|
Total
|
1,296
|
1,623
|
2,099
|
741
|
79
|
(282)
|
5,556
|
Industrial Products
|
Potash
|
Phosphate Solutions
|
Innovative Ag Solutions
|
Other
Activities
|
Reconciliation
|
Consolidated
|
|
$ millions
|
For the year ended December 31, 2017
|
|||||||
Europe
|
456
|
386
|
749
|
326
|
87
|
(86)
|
1,918
|
Asia
|
351
|
433
|
476
|
100
|
3
|
(21)
|
1,342
|
North America
|
327
|
116
|
369
|
94
|
282
|
(13)
|
1,175
|
South America
|
19
|
347
|
277
|
22
|
5
|
(4)
|
666
|
Rest of the world
|
40
|
101
|
166
|
150
|
7
|
(147)
|
317
|
Total
|
1,193
|
1,383
|
2,037
|
692
|
384
|
(271)
|
5,418
|
Industrial Products
|
Potash
|
Phosphate Solutions
|
Innovative Ag Solutions
|
Other
Activities
|
Reconciliation
|
Consolidated
|
|
$ millions
|
For the year ended December 31, 2016
|
|||||||
Europe
|
424
|
421
|
717
|
319
|
77
|
(95)
|
1,863
|
Asia
|
301
|
396
|
511
|
74
|
6
|
(13)
|
1,275
|
North America
|
330
|
93
|
380
|
110
|
250
|
(22)
|
1,141
|
South America
|
25
|
267
|
274
|
19
|
1
|
2
|
588
|
Rest of the world
|
40
|
161
|
304
|
139
|
6
|
(154)
|
496
|
Total
|
1,120
|
1,338
|
2,186
|
661
|
340
|
(282)
|
5,363
|
For the year ended December 31
|
|||
2018
|
2017
|
2016
|
|
$ millions
|
$ millions
|
$ millions
|
Israel
|
2,841
|
2,548
|
2,470
|
Europe
|
2,198
|
2,119
|
2,124
|
North America
|
831
|
1,045
|
1,045
|
Asia
|
617
|
583
|
556
|
Others
|
211
|
215
|
218
|
6,698
|
6,510
|
6,413
|
|
Intercompany sales
|
(1,142)
|
(1,092)
|
(1,050)
|
Total
|
5,556
|
5,418
|
5,363
|
Europe*
|
834
|
(45)
|
(117)
|
Israel
|
526
|
475
|
304
|
North America
|
74
|
154
|
83
|
Asia
|
52
|
8
|
(41)
|
Others
|
29
|
33
|
(203)
|
Intercompany eliminations
|
4
|
4
|
(29)
|
Total
|
1,519
|
629
|
(3)
|
For the year ended December 31
|
||
2018
|
2017
|
|
$ millions
|
$ millions
|
Israel
|
3,570
|
3,387
|
Europe
|
1,228
|
1,227
|
Asia
|
401
|
455
|
North America
|
309
|
321
|
Other
|
59
|
94
|
Total
|
5,567
|
5,484
|
As at December 31
|
||
2018
|
2017
|
|
$ millions
|
$ millions
|
Finished products
|
772
|
709
|
Work in progress
|
258
|
269
|
Raw materials
|
216
|
212
|
Spare parts
|
143
|
142
|
Total inventories
|
1,389
|
1,332
|
Less – non-current inventories. mainly raw materials (presented in non-current assets)
|
99
|
106
|
Current inventories
|
1,290
|
1,226
|
As at December 31
|
||
2018
|
2017
|
|
$ millions
|
$ millions
|
Government institutions
|
108
|
78
|
Current tax assets
|
79
|
16
|
Prepaid expenses
|
52
|
43
|
Insurance receivables
|
1
|
26
|
Other
|
55
|
62
|
295
|
225
|
2018
|
2017
|
|
$ millions
|
$ millions
|
Current assets
|
192
|
197
|
Non-current assets
|
318
|
367
|
Current liabilities
|
225
|
241
|
Non-current liabilities
|
49
|
215
|
Equity
|
236
|
108
|
2018
|
2017
|
2016
|
|
$ millions
|
$ millions
|
$ millions
|
Sales
|
387
|
363
|
377
|
Operating loss
|
-
|
(21)
|
(78)
|
Depreciation and amortization
|
34
|
34
|
34
|
Operating income (loss) before depreciation and amortization
|
34
|
13
|
(44)
|
Net loss
|
(13)
|
(38)
|
(104)
|
Comprehensive income (loss)
|
3
|
(26)
|
(126)
|
As at December 31
|
||
2018
|
2017
|
|
$ millions
|
$ millions
|
Lease rights
|
102
|
106
|
Non-current inventories
|
99
|
106
|
Surplus in defined benefit plan
|
73
|
89
|
Long-term loan
|
59
|
-
|
Derivatives
|
15
|
64
|
Other
|
9
|
8
|
357
|
373
|
1) |
In December 2017, the Company entered into an agreement to sell its fire safety and oil additives business to SK Invictus Holding L.P., an affiliate of SK Capital (hereinafter – the Buyer). In March 2018, the Company completed the sale transaction for a consideration of $1,010 million, of which $953 million in cash and $57 million in the form of a long-term loan to a subsidiary of the Buyer. As a result, the Company recorded, in the financial statements of 2018, a capital gain of $841 million (net of transaction expenses), under "other income" in the statement of income.
the table below presents
the book value of the sold assets and liabilities
.
|
2018
|
|
$ millions
|
Cash and cash equivalents
|
1
|
Trade and other receivables
|
34
|
Inventories
|
59
|
Property, plant and equipment
|
26
|
Intangible assets
|
64
|
Trade payables and other current liabilities
|
(28)
|
Deferred tax liabilities
|
(3)
|
Net assets and liabilities
|
153
|
Consideration received in cash (*)
|
938
|
Income tax paid
|
(35)
|
Cash disposed of
|
(1)
|
Net cash inflow
|
902
|
2) |
In June 2018, the Company entered into an agreement for the sale of the assets and business of its subsidiary, Rovita, for no consideration (hereinafter – the Agreement). Rovita produces commodity milk protein products, using by-products from the whey protein business of Prolactal, which is part of the Phosphate Solutions segment. In July 2018, the company completed the sales transaction and as a result, recognized a loss deriving from the write-off of all Rovita’s assets, in the amount of $16 million ($12 million after tax), under “other expenses” in the statement of income.
|
Land, roads and buildings
|
Installations and equipment
|
Dikes and evaporating ponds
|
Heavy mechanical equipment
|
Furniture, vehicles and equipment
|
Plants under construction and spare parts for installations (1)
|
Total
|
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
Cost
|
|||||||
Balance as at January 1, 2018
|
844
|
5,788
|
1,888
|
150
|
242
|
898
|
9,810
|
Additions
|
42
|
789
|
100
|
5
|
20
|
(367)
|
589
|
Disposals
|
(2)
|
(19)
|
-
|
(2)
|
(7)
|
-
|
(30)
|
Translation differences
|
(23)
|
(76)
|
(13)
|
-
|
(4)
|
(16)
|
(132)
|
Balance as at December 31, 2018
|
861
|
6,482
|
1,975
|
153
|
251
|
515
|
10,237
|
Accumulated depreciation
|
|||||||
Balance as at January 1, 2018
|
451
|
3,520
|
1,053
|
84
|
181
|
-
|
5,289
|
Depreciation for the year
|
24
|
234
|
96
|
7
|
12
|
-
|
373
|
Impairment
|
5
|
5
|
-
|
-
|
1
|
-
|
11
|
Disposals
|
(1)
|
(16)
|
-
|
(2)
|
(8)
|
-
|
(27)
|
Translation differences
|
(11)
|
(50)
|
(10)
|
-
|
(1)
|
-
|
(72)
|
Balance as at December 31, 2018
|
468
|
3,693
|
1,139
|
89
|
185
|
-
|
5,574
|
Depreciated balance as at December 31, 2018
|
393
|
2,789
|
836
|
64
|
66
|
515
|
4,663
|
Land, roads and buildings
|
Installations and equipment
|
Dikes and evaporating ponds
|
Heavy mechanical equipment
|
Furniture, vehicles and equipment
|
Plants under construction and spare parts for installations (1)
|
Total
|
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
Cost
|
|||||||
Balance as at January 1, 2017
|
763
|
5,408
|
1,715
|
149
|
244
|
879
|
9,158
|
Additions
|
42
|
302
|
140
|
7
|
13
|
(14)
|
490
|
Disposals
|
(6)
|
(28)
|
-
|
(12)
|
(17)
|
-
|
(63)
|
Translation differences
|
49
|
136
|
33
|
7
|
9
|
35
|
269
|
Reclassification to assets held for sale
|
(4)
|
(30)
|
-
|
(1)
|
(7)
|
(2)
|
(44)
|
Balance as at December 31, 2017
|
844
|
5,788
|
1,888
|
150
|
242
|
898
|
9,810
|
Accumulated depreciation
|
|||||||
Balance as at January 1, 2017
|
409
|
3,232
|
944
|
83
|
181
|
-
|
4,849
|
Depreciation for the year
|
23
|
227
|
84
|
7
|
14
|
-
|
355
|
Impairment
|
-
|
13
|
-
|
-
|
-
|
-
|
13
|
Disposals
|
(4)
|
(23)
|
-
|
(12)
|
(17)
|
-
|
(56)
|
Translation differences
|
24
|
85
|
25
|
7
|
6
|
-
|
147
|
Reclassification to assets held for sale
|
(1)
|
(14)
|
-
|
(1)
|
(3)
|
-
|
(19)
|
Balance as at December 31, 2017
|
451
|
3,520
|
1,053
|
84
|
181
|
-
|
5,289
|
Depreciated balance as at December 31, 2017
|
393
|
2,268
|
835
|
66
|
61
|
898
|
4,521
|
A. |
Composition
|
Goodwill
|
Concessions and mining rights
|
Trademarks
|
Technology / patents
|
Customer relationships
|
Exploration and evaluation assets
|
Computer
application
|
Others
|
Total
|
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
Cost
|
|||||||||
Balance as at January 1, 2018
|
348
|
216
|
91
|
80
|
183
|
39
|
76
|
34
|
1,067
|
Additions
|
-
|
-
|
-
|
1
|
-
|
1
|
13
|
1
|
16
|
Disposals
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(2)
|
(2)
|
Translation differences
|
(17)
|
(6)
|
(3)
|
(6)
|
(5)
|
(1)
|
(2)
|
-
|
(40)
|
Balance as at December 31, 2018
|
331
|
210
|
88
|
75
|
178
|
39
|
87
|
33
|
1,041
|
Amortization and impairment losses
|
|||||||||
Balance as at January 1, 2018
|
22
|
63
|
24
|
35
|
94
|
25
|
61
|
21
|
345
|
Amortization for the year
|
-
|
5
|
3
|
5
|
10
|
1
|
4
|
2
|
30
|
Impairment
|
-
|
-
|
-
|
3
|
3
|
-
|
-
|
-
|
6
|
Disposals
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(1)
|
(1)
|
Translation differences
|
-
|
-
|
(1)
|
(4)
|
(2)
|
(1)
|
(2)
|
-
|
(10)
|
Balance as at December 31, 2018
|
22
|
68
|
26
|
39
|
105
|
25
|
63
|
22
|
370
|
Amortized Balance as at December 31 ,2018
|
309
|
142
|
62
|
36
|
73
|
14
|
24
|
11
|
671
|
A. |
Composition (cont’d)
|
Goodwill
|
Concessions and mining rights
|
Trademarks
|
Technology / patents
|
Customer relationships
|
Exploration and evaluation assets
|
Computer
application
|
Others
|
Total
|
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
Cost
|
|||||||||
Balance as at January 1, 2017
|
398
|
205
|
86
|
80
|
214
|
35
|
65
|
76
|
1,159
|
Additions
|
-
|
-
|
-
|
3
|
-
|
1
|
10
|
3
|
17
|
Discontinuance of consolidation
|
(55)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(55)
|
Translation differences
|
16
|
11
|
7
|
7
|
16
|
3
|
2
|
1
|
63
|
Reclassification to assets held for sale
|
(11)
|
-
|
(2)
|
(10)
|
(47)
|
-
|
(1)
|
(46)
|
(117)
|
Balance as at December 31, 2017
|
348
|
216
|
91
|
80
|
183
|
39
|
76
|
34
|
1,067
|
Amortization and impairment losses
|
|||||||||
Balance as at January 1, 2017
|
21
|
57
|
19
|
34
|
88
|
9
|
57
|
50
|
335
|
Amortization for the year
|
-
|
6
|
3
|
5
|
12
|
1
|
3
|
5
|
35
|
Impairment
|
-
|
-
|
1
|
-
|
-
|
14
|
-
|
-
|
15
|
Translation differences
|
1
|
-
|
1
|
3
|
5
|
1
|
2
|
1
|
14
|
Reclassification to assets held for sale
|
-
|
-
|
-
|
(7)
|
(11)
|
-
|
(1)
|
(35)
|
(54)
|
-
|
|||||||||
Balance as at December 31, 2017
|
22
|
63
|
24
|
35
|
94
|
25
|
61
|
21
|
345
|
Amortized Balance as at December 31 ,2017
|
326
|
153
|
67
|
45
|
89
|
14
|
15
|
13
|
722
|
As at December 31
|
||
2018
|
2017
|
|
$ millions
|
$ millions
|
Intangible assets having a defined useful life
|
332
|
365
|
Intangible assets having an indefinite useful life
|
339
|
357
|
671
|
722
|
As at December 31
|
||
2018
|
2017
|
|
$ millions
|
$ millions
|
Goodwill
|
||
Phosphate Solutions
|
127
|
140
|
Industrial Products
|
92
|
93
|
Innovative Ag. Solutions
|
71
|
73
|
Potash
|
19
|
20
|
309
|
326
|
|
Trademarks
|
||
Industrial Products, United States
|
13
|
13
|
Phosphate Solutions, United States
|
12
|
12
|
Industrial Products, Europe
|
5
|
6
|
30
|
31
|
|
339
|
357
|
As at December 31, 2018
|
As at December 31, 2017
|
|||
Assets
|
Liabilities
|
Assets
|
Liabilities
|
|
$ millions
|
$ millions
|
Included in current assets and liabilities:
|
||||
Foreign currency and interest derivative instruments
|
13
|
(16)
|
1
|
(3)
|
Derivative instruments on energy and marine transport
|
-
|
(5)
|
4
|
-
|
13
|
(21)
|
5
|
(3)
|
|
Included in non-current assets and liabilities:
|
||||
Foreign currency and interest derivative instruments
|
15
|
-
|
64
|
(3)
|
A. |
Composition
|
As at December 31
|
||
2018
|
2017
|
|
$ millions
|
$ millions
|
Short-term credit
|
||
|
||
From financial institutions
|
544
|
635
|
From the parent company
|
-
|
175
|
544
|
810
|
|
Current maturities
|
||
Long-term loans from financial institutions
|
32
|
12
|
Long-term loans from others
|
34
|
-
|
Total Short-Term Credit
|
610
|
822
|
Long- term debt and debentures
|
||
Loans from financial institutions
|
377
|
786
|
Other loans
|
35
|
98
|
412
|
884
|
|
Less – current maturities
|
66
|
12
|
346
|
872
|
|
Marketable debentures
|
1,195
|
1,241
|
Non-marketable debentures
|
274
|
275
|
Total Long- term debt and debentures
|
1,815
|
2,388
|
As at December 31
|
||
2018
|
2017
|
|
$ millions
|
$ millions
|
Balance as at January 1
|
3,227
|
3,399
|
Changes from financing cash flows
|
||
Receipt of long-term debt
|
1,746
|
966
|
Repayment of long-term debt
|
(2,115)
|
(1,387)
|
Repayment of short-term credit, net of receipt
|
(283)
|
147
|
Interest paid
|
(103)
|
(111)
|
Total net financing cash flows
|
(755)
|
(385)
|
Effect of changes in foreign exchange rates
|
(63)
|
101
|
Other changes
|
33
|
112
|
Balance as at December 31
|
2,442
|
3,227
|
As at December 31
|
||
2018
|
2017
|
|
$ millions
|
$ millions
|
Second year
|
17
|
261
|
Third year
|
273
|
18
|
Fourth year
|
113
|
213
|
Fifth year
|
308
|
644
|
Sixth year and thereafter
|
1,104
|
1,252
|
1,815
|
2,388
|
Financial Covenants (1)
|
Financial Ratio Required under the Agreement
|
Financial Ratio December 31,
|
2018
|
Total shareholder's equity
|
Equity greater than 2,000 million dollars
|
3,781 million dollars
|
The Ratio of the EBITDA to the net interest expenses
|
Equal to or greater than 3.5
|
11.17
|
Ratio of the net financial debt to EBITDA (2)
|
Less than 4.0
|
1.62
|
Ratio of certain subsidiaries loans to the total assets of the consolidated company
|
Less than 10%
|
1.87%
|
(1) | Examination of compliance with the above‑mentioned financial covenants is made as required based on the Company's consolidated financial statements. As at December 31, 2018, the Company complies with its financial covenants. |
(2) |
According to the Company’s covenants, the required ratio of the net financial debt to EBITDA as of
January 1
, 2019 will be reduced to 3.5.
|
Year ended December 31,
|
|||
2018
|
2017
|
2016
|
|
$ millions
|
$ millions
|
$ millions
|
Carrying amount of the transferred assets
|
332
|
331
|
331
|
Fair value of the associated liabilities
|
332
|
331
|
331
|
Net position *
|
-
|
-
|
-
|
Instrument type
|
Loan date
|
Original principal (millions)
|
Currency
|
Carrying amount
($ millions)
|
Interest rate
|
Principal repayment date
|
Additional information
|
Loan-Israeli institutions
|
November 2013
|
300
|
Israeli Shekel
|
67
|
4.74% (1)
|
2015-2024
(annual installment)
|
Partially prepaid
|
Debentures (private offering) – 3 series
|
January 2014
|
84
145
46
|
U.S Dollar
|
84
144
46
|
4.55%
5.16%
5.31%
|
January 2021
January 2024
January 2026
|
|
Loan-international institutions
|
July 2014
|
27
|
Euro
|
25
|
2.33%
|
2019-2024
|
Partially prepaid
|
Debentures - Series D
|
December 2014
|
800
|
U.S Dollar
|
182
|
4.50%
|
December 2024
|
(2)
|
Loan - European Bank
|
December 2014
|
161
|
Brazilian Real
|
19
|
CDI+1.35%
|
2015-2021
(Semiannual installment)
|
|
Debentures - Series E
|
April 2016
|
1,569
|
Israeli Shekel
|
416
|
2.45%
|
2021- 2024
(annual installment)
|
|
Loan - others
|
April - October, 2016
|
600
|
Chinese Yuan Renminbi
|
29
|
5.23%
|
2019
|
(3)
|
Loan - Asian Banks
|
June - October, 2018
|
600
|
Chinese Yuan Renminbi
|
87
|
4.79% - 5.44%
|
2019
|
|
Loan - Asian Bank
|
April 2018
|
400
|
Chinese Yuan Renminbi
|
58
|
CNH Hibor + 0.50%
|
2019
|
|
Debentures - Series F
|
May 2018
|
600
|
U.S Dollar
|
596
|
6.38%
|
May 2038
|
(4)
|
Loan - European Bank
|
December 2018
|
70
|
U.S Dollar
|
70
|
Libor + 0.66%
|
December 2021
|
(1) |
From April 2018, in accordance with the loan agreement, there has been a decrease in the interest rate, from 4.94% to 4.74%.
|
(2) |
Debentures Series D
|
(3) |
Loans from others
|
(4) |
Debentures-Series F
|
Issuer
|
European bank (1)
|
Group of twelve international banks (2)
|
European bank (3)
|
Date of the credit facility
|
March 2014
|
March 2015
|
December 2016
|
Date of credit facility termination
|
March 2019
|
March 2023
|
May 2025
|
The amount of the credit facility
|
USD 35 million
Euro 100 million
|
USD 1,200 million
|
USD 100 million
|
Credit facility has been utilized
|
Euro 40 million
|
USD 200 million
|
USD 70 million
|
Interest rate
|
Up to 33% use of the credit: Libor/Euribor + 0.70%.
From 33% to 66% use of the credit: Libor/Euribor + 0.80%
66% or more use of the credit: Libor/Euribor + 0.95%
|
Libor + 0.45% + spread
|
|
Loan currency type
|
USD and Euro loans
|
USD and Euro loans
|
USD loans
|
Pledges and restrictions
|
Financial covenants - see Section D, a cross-default mechanism and a negative pledge.
|
Financial covenants - see Section D, a cross-default mechanism and a negative pledge.
|
Financial covenants - see Section D and a negative pledge.
|
Non-utilization fee
|
0.32%
|
0.21%
|
0.30%
|
(1) |
After the date of the report, the Company elected not to realize the option of revolving credit facility extension, and to repay the utilized credit facility on the date of its termination.
|
(2) |
In October 2018, the Company entered into an agreement according to which, its commitment under certain revolving credit facility agreements will be reduced by a total aggregate amount of $655 million, to an amount of $1.2 billion.
|
(3) |
In June 2018, the maturity date of the credit facility was extended to 2025. In November 2018, the credit facility was reduced from $136 million to $100 million. As at the date of the report, the Company utilized $70 million of that credit facility.
|
1)
|
The Group has undertaken various obligations in respect of loans and credit received from non‑Israeli banks, including a negative pledge whereby the Group, committed, among other things, in favor of the lenders, to limit guarantees and indemnities to third parties (other than the guarantees in respect to subsidiaries) up to an agreed amount for $550 million. The Group has also undertaken to grant loans only to subsidiaries and to associated companies in which it holds at least 25% of the voting rights – not more than stipulated by the agreement with the banks. ICL has further committed not to grant any credit, other than in the ordinary course of business, and not to register any charges, including rights of lien, except those defined in the agreement as “liens permitted to be registered” on its existing and future assets and income. For further information regarding to the covenants in respect of these loans, see item D above.
|
2)
|
In the third quarter of 2018, YPH JV entered into loan agreements in the total amount of RMB 500 million ($74 million) with the Bank of China. Since the partner (YTH) provided the bank with a full guarantee against the said loan, the Company pledged a portion of its shares in YPH JV (22%), which represents its part of the debt to YTH (RMB 250 million). The pledge agreement does not include restrictions on, among others, management of YPH JV's operations. The realization of the pledge will take place only if the guarantee is forfeited. For further information relating to loan for Bank of China, see item F above.
|
3)
|
As
at December 31, 2018
the total guarantees the Company provided were
about $79
million.
|
As at December 31
|
||
2018
|
2017
|
|
$ millions
|
$ millions
|
Employees
|
284
|
269
|
Accrued expenses
|
85
|
83
|
Governmental (mainly in respect of royalties) (1)
|
61
|
67
|
Current tax liabilities
|
112
|
88
|
Others
|
105
|
88
|
647
|
595
|
(1) |
See Note 20.
|
a) |
Some of the Company’s Israeli subsidiaries are “Industrial Enterprise”, as defined in the above‑mentioned law. In respect of buildings, machinery and equipment owned and used by any "Industrial Enterprise", the Company is entitled to claim accelerated depreciation as provided by the Income Tax Regulations – Adjustments for Inflation (Depreciation Rates), 1986 which allow accelerated depreciation to any "Industrial Enterprise" as of the tax year in which each asset is first placed in service.
|
b) |
The Industrial Enterprises owned by some of the Company's Israeli subsidiaries have a common line of production and, therefore, they file, together with the Company, a consolidated tax return in accordance with Section 23 of the Law for the Encouragement of Industry. Accordingly, each of the said companies is entitled to offset its tax losses against the taxable income of the other companies.
|
1) |
The price for a unit of bromine (tonne) provided in the transaction;
|
2) |
The normative price of a unit of bromine. The normative price of a unit of bromine is the total sales of the downstream products produced less the operating expenses attributable to the downstream activities, without the acquisition cost of the bromine, and less an amount equal to 12% of the total revenues of the downstream products produced as part of the downstream activities, where the result is divided by the number of bromine units used to produce the downstream products sold.
|
1) |
The price for a unit of phosphate (tonne) provided in the transaction;
|
2) |
The normative price of a unit of phosphate. The “normative price” of a unit of phosphate is the total sales of the downstream products produced less the operating expenses attributable to the downstream activities, without the acquisition cost of the phosphate rock, and less an amount equal to 12% of the total revenues of the downstream products produced as part of the downstream activities, where the result is divided by the number of phosphate units used to produce the downstream products sold.
|
3) |
The production and operating costs attributable to a unit of phosphate.
|
Country
|
Tax rate
|
Note
|
Brazil
|
34%
|
|
Germany
|
29%
|
|
United States
|
26%
|
(1)
|
Netherlands
|
25%
|
(3)
|
Spain
|
25%
|
|
China
|
25%
|
|
United Kingdom
|
19%
|
(2)
|
(1) |
The tax rate above includes federal and states tax. In December 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (hereinafter - the Tax Act). The Tax Act significantly revises the future ongoing U.S. federal corporate income tax by, among other things, lowering U.S. corporate income tax rates and implementing a territorial tax system. The lower corporate income tax rates are effective as of January 1, 2018.
The Company examined the effects of the Tax Act's implementation and found that the main impact is the re‑measurement of the deferred tax assets and liabilities to incorporate the lower Federal corporate tax rate of 21% and as a result, in the financial statements of 2017, the Company reduced the balances of the assets and liabilities for deferred taxes, in the net amount of $13 million
.
|
(2) |
The tax rate in the UK was reduced to 19% effective from April 1, 2017 and 17% commencing from April 1, 2020.
|
(3) |
The tax rates in the Netherlands will be reduced, in stages, by the total of 4% by 2021, as follows: 1% in 2019, 1.5% in 2020 and 1.5% in 2021. In 2021, The tax rate will be 21%.
|
1) |
The Company and the main operational companies in Israel (DSW, Rotem, Bromine, DSM, BCL and F&C), along with most of the other companies in Israel, have received final tax assessments up to and including 2011. The main subsidiaries outside of Israel have final tax assessments up to and including 2011
and 2012
.
|
2) |
Israel - In December 2018, the Israeli Tax Authorities (hereinafter - the ITA) rejected the company's objection relating to an assessment issued to the Company and to certain Israeli subsidiaries, and demanded an additional tax payment, for the years 2012‑2014, in the amount of $73 million. The Company disputes the assessment and filed an appeal to the Jerusalem District Court. In the Company’s estimation, it is more likely than not that its claims will be accepted.
|
3) |
The company's subsidiary in Belgium recognized a notion deduction on its capital based on its interpretation of the Belgian tax law, which was validated by the Court of Appeals in Belgium. The tax authorities dispute the eligibility of the deduction by appealing to the Supreme Court against the Court of Appeals' resolution and issuing tax assessments in a total amount of $27 million for the years commencing 2010. The Company believes, it is more likely than not that its tax position will also be accepted by the Supreme Court.
|
4) |
Currently, the Company is also under tax audits in Spain and Germany for the years 2012‑2015. As at the date of the report, there are no additional tax payment requests from the tax authorities, excluding immaterial amounts in Germany. The Company believes that the provisions in its books are sufficient.
|
In respect of financial position
|
In respect
of carry forward tax losses
|
Total
|
||||
Depreciable property,
plant and equipment and intangible assets
|
Inventories
|
Provisions for employee benefits
|
Other
|
|||
$ millions
|
Balance as at January 1, 2017
|
(374)
|
45
|
75
|
2
|
99
|
(153)
|
Changes in 2017:
|
||||||
Amounts recorded in the statement of income
|
74
|
(17)
|
1
|
11
|
(36)
|
33
|
Change in tax rate
|
13
|
-
|
-
|
-
|
-
|
13
|
Amounts recorded to a capital reserve
|
-
|
-
|
3
|
5
|
-
|
8
|
Translation differences
|
(6)
|
-
|
5
|
-
|
1
|
-
|
Transfer to the group assets held for sale
|
2
|
-
|
-
|
1
|
-
|
3
|
Balance as at December 31, 2017
|
(291)
|
28
|
84
|
19
|
64
|
(96)
|
Changes in 2018:
|
||||||
Amounts recorded in the statement of income
|
(123)
|
(2)
|
(6)
|
-
|
55
|
(76)
|
Amounts recorded to a capital reserve
|
-
|
-
|
(3)
|
2
|
-
|
(1)
|
Translation differences
|
2
|
-
|
(1)
|
(1)
|
(2)
|
(2)
|
Balance as at December 31, 2018
|
(412)
|
26
|
74
|
20
|
117
|
(175)
|
As at December 31
|
||
2018
|
2017
|
|
$ millions
|
$ millions
|
Euro
|
22
|
33
|
British Pound
|
21
|
22
|
U.S Dollar
|
(7)
|
10
|
Israeli Shekels
|
(204)
|
(166)
|
Other
|
(7)
|
5
|
(175)
|
(96)
|
Current taxes
|
53
|
208
|
68
|
Deferred taxes
|
76
|
(23)
|
(45)
|
Taxes in respect of prior years
|
-
|
(27)
|
32
|
129
|
158
|
55
|
For the year ended December 31
|
|||
2018
|
2017
|
2016
|
|
$ millions
|
$ millions
|
$ millions
|
Income (loss) before income taxes, as reported in the statements of income
|
1,364
|
505
|
(117)
|
Statutory tax rate (in Israel)
|
23%
|
24%
|
25%
|
Theoretical tax expense (income)
|
314
|
121
|
(29)
|
Add (less) – the tax effect of:
|
|||
Tax benefits deriving from the Law for Encouragement of Capital Investments net of natural Resources Tax
|
(20)
|
(4)
|
(3)
|
Differences deriving from additional deduction and different tax rates applicable to foreign subsidiaries (1)
|
(186)
|
23
|
(38)
|
Income taxes from intercompany dividend distribution
|
-
|
18
|
-
|
Deductible temporary differences for which deferred taxes assets were not recorded and non–deductible expenses
|
24
|
15
|
135
|
Taxes in respect of prior years
|
-
|
(27)
|
32
|
Impact of change in tax rates
|
-
|
(13)
|
(32)
|
Differences in measurement basis (mainly ILS vs USD)
|
(11)
|
18
|
1
|
Other differences
|
8
|
7
|
(11)
|
Taxes on income included in the income statements
|
129
|
158
|
55
|
(1) |
Mainly related to the exempt income resulting from the sale of the fire safety and oil additives business in March 2018. For additional information see Note 10.
|
For the year ended December 31
|
|||
2018
|
2017
|
2016
|
|
$ millions
|
$ millions
|
$ millions
|
Tax recorded in other comprehensive income
|
|||
Actuarial gains from defined benefit plan
|
(3)
|
3
|
8
|
Change in investments at fair value through other comprehensive income
|
-
|
5
|
(5)
|
Taxes in respect of exchange rate differences on equity loan to a subsidiary included in translation adjustment
|
2
|
(5)
|
(1)
|
Total
|
(1)
|
3
|
2
|
As at December 31
|
||
2018
|
2017
|
|
$ millions
|
$ millions
|
Fair value of plan assets
|
518
|
631
|
Termination benefits
|
(111)
|
(142)
|
Defined benefit obligation
|
(860)
|
(1,068)
|
(453)
|
(579)
|
As at December 31
|
||
2018
|
2017
|
|
$ millions
|
$ millions
|
Equity instruments
|
||
With quoted market price
|
200
|
197
|
Debt instruments
|
||
With quoted market price
|
164
|
179
|
Without quoted market price
|
119
|
145
|
283
|
324
|
|
Deposits with insurance companies
|
35
|
110
|
518
|
631
|
a) |
Under collective labor agreements, the Group companies in Israel make current deposits in outside pension plans for some of the employees. These plans generally provide full severance pay coverage.
|
b) |
The Group companies in Israel make current deposits in insurance policies in respect of employees holding management positions. These policies provide coverage for the severance pay liability in respect of the said personnel. Under employment agreements, subject to certain limitations, these insurance policies are the property of the employees. The amounts funded in respect of these policies are not reflected in the statements of financial position since they are not under the control and management of the Group.
|
c) |
As to the balance of the liabilities that are not funded, as mention above, a provision is recorded in the financial statements based on an actuarial calculation.
|
1) |
Some of the Group’s employees in and outside of Israel (some of whom have already left the Group) have defined benefit pension plans for their retirement, which are controlled by the Company. Generally, according to the terms of the plans, as stated, the employees are entitled to receive pension payments based on, among other things, their number of years of service (in certain cases up to 70% of their last base salary) or computed, in certain cases, based on a fixed salary. Some employees of a subsidiary in Israel are entitled to early retirement if they meet certain conditions, including age and seniority at the time of retirement.
|
In addition, some Group companies have entered into plans with funds – and with a pension fund for some of the employees – under which such companies make current deposits with that fund which releases them from their liability for making a pension payment under the labor agreements to all of their employees upon reaching a retirement age. The amounts funded are not reflected in the statements of financial position since they are not under the control and management of the Group companies.
|
2) |
In May 2018, a collective labor agreement was signed between Dead Sea Works Ltd. (hereinafter - DSW)
and the DSW’s Workers Council, the New General Organization of Workers in Israel and the Histadrut’s Negev District branch, for a period of five years (hereinafter – the Agreement), commencing on October 1, 2017, the termination date of the previous labor agreement. The key provisions of the Agreement are as follows:
|
a) Arrangement of wage increases to the employees to whom the Agreement applies; b) completion of execution of the DSW efficiency plan by September 30, 2021, in accordance with the provisions specified in the Agreement; c) during the efficiency period, mentioned above, no collective dismissals shall be implemented; d) the declared labor disputes are cancelled and throughout the Agreement period appropriate labor relations shall be maintained and no actions shall be taken which may cause a work disruption; e) payment of a signing bonus upon signing of the Agreement.
|
Considering the aforesaid, in the financial statements for 2018, the Company recognized an expense in the amount of $5 million due to the signing bonus, under "salary expenses" in the statement of income.
|
3) |
In January 2018, considering the Company's decision to discontinue the production of potash at ICL Boulby and to commence full production of Polysulphate in the second half of 2018, a personnel reduction's plan was approved. As a result, the Company recorded, in its financial statements of 2018, an increase of about $7 million under "provision for employee benefits".
|
Fair value of plan assets
|
Defined benefit obligation
|
Defined benefit obligation, net
|
||||
2018
|
2017
|
2018
|
2017
|
2018
|
2017
|
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
Balance as at January 1
|
631
|
552
|
(1,068)
|
(934)
|
(437)
|
(382)
|
Income (costs) included in profit or loss:
|
||||||
Current service costs
|
-
|
-
|
(24)
|
(24)
|
(24)
|
(24)
|
Interest income (costs)
|
14
|
17
|
(26)
|
(29)
|
(12)
|
(12)
|
Past service cost
|
-
|
-
|
7
|
-
|
7
|
-
|
Effect of movements in exchange rates, net
|
(17)
|
23
|
37
|
(39)
|
20
|
(16)
|
Included in other comprehensive income:
|
||||||
Actuarial gains (losses) deriving from changes in financial assumptions
|
-
|
-
|
71
|
(42)
|
71
|
(42)
|
Other actuarial gains (losses)
|
(15)
|
25
|
-
|
-
|
(15)
|
25
|
Change in respect to translation differences, net
|
(19)
|
36
|
21
|
(65)
|
2
|
(29)
|
Other movements:
|
||||||
Benefits paid
|
(38)
|
(36)
|
73
|
64
|
35
|
28
|
Conversion to defined contribution plans
|
(49)
|
-
|
49
|
-
|
-
|
-
|
Transferred to assets held for sale
|
-
|
-
|
-
|
1
|
-
|
1
|
Employer contribution
|
11
|
14
|
-
|
-
|
11
|
14
|
Balance as at December 31
|
518
|
631
|
(860)
|
(1,068)
|
(342)
|
(437)
|
For the year ended December 31
|
|||
2018
|
2017
|
2016
|
|
%
|
%
|
%
|
Discount rate as at December 31
|
3.0
|
2.7
|
2.9
|
Future salary increases
|
3.3
|
3.2
|
2.6
|
Future pension increase
|
2.2
|
2.2
|
2.2
|
December 2018
|
||||
Decrease 10%
|
Decrease
5%
|
Increase
5%
|
Increase
10%
|
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
Significant actuarial assumptions
|
||||
Salary increase
|
18
|
9
|
(9)
|
(18)
|
Discount rate
|
(32)
|
(16)
|
16
|
32
|
Mortality table
|
(17)
|
(9)
|
9
|
17
|
Restoration's site and equipment's dismantling
|
Legal claims
|
Other
|
Total
|
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
Balance as at January 1, 2018
|
194
|
28
|
49
|
271
|
Provisions recorded during the period (1)
|
25
|
2
|
-
|
27
|
Provisions reversed during the period
|
(3)
|
-
|
(6)
|
(9)
|
Payments during the period
|
(6)
|
(11)
|
-
|
(17)
|
Translation differences
|
(5)
|
(1)
|
-
|
(6)
|
Balance as at December 31, 2018
|
205
|
18
|
43
|
266
|
(1) |
For additional information, see Note 20.
|
(1) |
Several of the Group’s subsidiaries have entered into agreements with suppliers for the purchase of raw materials and energy in the ordinary course of business, for various periods ending on December 31, 2023. As of December 31, 2018, the total amount of the commitments under the said purchase periods of the agreements is about $2.67 billion. This item takes into consideration part of the agreements described below.
|
(2) |
Several of the Group’s subsidiaries have entered into agreements with suppliers for the acquisition of property, plant and equipment. As at December 31, 2018, the subsidiaries have capital purchase commitments of about $368 million. This item takes into consideration part of the agreements described below.
|
(3) |
In October 2017, Dead Sea Works (hereinafter - DSW) signed an agreement, the cost of which for ICL is $280 million, for the execution of the first stage of the Salt Harvesting Project, with a contracting company Holland Shallow Seas Dredging Ltd., which includes, among others, the construction of a special dredger that is designed to execute the salt harvesting. The dredger is expected to enter into service towards the end of 2019. For further information - see item C(2).
|
(4) |
In 2017 and 2018, DSW signed agreements with several execution and infrastructure companies, in a total amount of $160 million (out of the total project cost of about $250 million), for construction of the new pumping station (hereinafter - the P-9 Pumping Station). The P-9 Pumping Station is expected to commence its operation during the year 2020. For further information – see item C(2).
|
(5) |
Subsequent to the date of the report, in
February 2019, the Company signed agreements for the sale of two office buildings, located in Be'er Sheva, Israel, for a total consideration of NIS 78 million ($21 million). The carrying amount of the two buildings is $7.3 million. Concurrent with the sale agreements, the Company signed lease agreements for the said buildings, for a period of 10 years with an option to terminate after four years. In accordance with IFRS16, since the above‑mentioned transactions meet the definition of sale and leaseback, part of the expected profit will be deferred by being deducted from the right‑to‑use asset.
|
(6) |
In 2012, the Company started the construction of a new cogeneration power station (EPC) in Sodom, Israel (hereinafter – the Station). The Station has a production capacity of about 330
tonnes
of steam per hour and about 230 MW, which supply electricity and steam requirements for the production plants at the Sodom site and for third party customers. In August 2018, the process of certification approval was completed, and the Power Station started operating in full. The Company intends to operate the Station concurrently with the existing power station, which will continue operating on a partial basis in a "hot back‑up" format, for production of electricity and steam. The total power produced at both stations can reach up to 245 MW.
|
(6) |
(cont'd)
|
(7) |
In February 2018, the Company entered into two supply agreements with Tamar and “Leviathan” reservoir (hereinafter – the Agreements), to secure its gas supply needs until the end of 2025 or until the entry of the “Karish” and “Tanin” reservoirs into service, whichever occurs first. The gas price in the Agreements is in accordance with the gas price formulas stipulated under the government’s gas outline. The Company anticipates that the scope of the annual gas consumption will be about 0.75 BCM.
|
(8) |
The Articles of Association of the Company and its Israeli subsidiaries include provisions that permit exemption, indemnification and insurance of the liability of officers, all in accordance with the provisions of the Israeli Companies Law.
|
(1) |
Dead Sea Works Ltd. (hereinafter – DSW)
|
(1) |
Dead Sea Works Ltd. (hereinafter – DSW) (Cont’d)
|
(2) |
Rotem Amfert Ltd. (hereinafter – “Rotem”)
|
a) |
Rotem Field (including the Hatrurim Field) – valid up to the end of 2021.
|
b) |
Zafir Field (Oron‑Zin) – valid up to the end of 2021.
|
(3) |
Spain
|
(4) |
United Kingdom
|
A. |
The mining rights of a subsidiary in the United Kingdom (hereinafter – ICL Boulby), are based on approximately 114 mining leases and licenses for extracting various minerals, in addition to numerous easements and rights of way from private owners of land under which ICL Boulby operates, and mining rights under the North Sea granted by the British Crown (Crown Estates), which includes provisions to explore and exploit the resources of the Polysulphate mineral. The said mining rights cover a total area of about 374 square kilometers. As at the date of this report, all the lease periods, licenses, easements and rights of way are effective until 2038. In 2018 and 2017, the mining royalties amounted to $1.3 million and $2 million, respectively.
|
B. |
A UK subsidiary from ICL Innovative Ag Solutions segment (hereinafter – Everris UK), has peat mines in the UK (Creca, Nutberry and Douglas Water). Peat is used as a raw material for production of detached beds for soil improvement and use as soil substitutes in growing media. The Nutberry and Douglas Water mining sites are owned by Everris UK, while the Creca mine is held under a long‑term lease. The mining permits are granted by the local authorities and are renewed after examination of the local authorities. The mining permits were granted up to the end of 2024.
|
(5) |
China
|
(5) |
China (cont'd)
|
(1) |
Ecology
|
A. |
In 2015, a request was filed for certification of a claim as a class action, in the District Court in Tel‑Aviv–Jaffa, against eleven defendants, including a subsidiary, Fertilizers and Chemical Ltd., in respect of claims relating to air pollution in Haifa Bay and for the harm allegedly caused from it to the residents of the Haifa Bay area. The amount of the claim is about NIS 13.4 billion (about $3.5 billion). In the Company’s estimation, based on the factual material provided to it and the relevant court decision, it is more likely than not that the plaintiffs’ contentions will be rejected.
|
B. |
In connection with the 2017 event of the partial collapse of the dyke in Pond 3, which is used for accumulation of phosphogypsum water that is created as part of the production processes in Rotem plants in Israel, the Company is taking action to rectify environmental impacts caused to the Ashalim Stream and its surrounding area, to the extent required. The Company’s actions are being carried out in full coordination and close cooperation with the Israeli environmental authorities. The Company is committed to the matter of environmental protection, and for years has worked closely with the Israeli environmental protection authorities to maintain the Negev’s natural reserves in the area of its facilities. As at the date of this report, the event is being investigated by the Ministry of Environmental Protection and the Nature and Natural Parks Authority. In 2017, the Company recognized restoration costs, in immaterial amounts, that were incurred in the short term. Several applications for certification of claims as class actions were filed against the Company (see item C below) contending, among others, that the Company should bear the restoration costs in the long‑term. In light of the complexity of the process and the uncertainty regarding the final restoration plans to be determined by the relevant authorities, the Company is unable at this stage to estimate the expected costs of the restoration work, as stated. The Company is in contact with its insurance carriers to activate the insurance policies in respect of the matters described above.
|
(1) |
Ecology (cont'd)
|
B. |
(cont’d)
|
C. |
In July and August 2017, three applications for certification of claims as class actions were filed against the Company, as a result of a partial collapse of the dyke in the evaporation pond of Rotem Amfert Israel, which caused contamination of the Ashalim Stream and its surrounding area. The claimants contend that the Company breached various provisions of the environmental laws, including, the provisions of the Law for Prevention of Environmental Hazards, the Water Law as well as provisions of the Torts Ordinance, breach of a statutory duty and negligence. In the framework of the first application, the Court was requested to instruct the Company to rectify the harm caused as a result of its omissions in order to prevent recurrence of the damage caused as well as to grant a monetary remedy for non‑pecuniary damages. The monetary remedy was not defined, however, according to the claimants, the amount of the personal claim is NIS 1,000 ($267) for each resident of the State of Israel, which totals approximately 8.68 million persons. In the framework of the second application, the Court was requested to grant a monetary remedy in an amount of no less than NIS 250 million ($67 million), and concurrently to award personal compensation in the amount of NIS 2,000 ($534) for each resident of the State of Israel, this being in respect of non‑pecuniary damages. Furthermore, the Court was requested to instruct the Company to comply with the relevant laws and the rules provided thereunder. As part of the third application, the Court was requested to instruct the Company, among other things, to prepare plans for removal of the pollution, restoration of the Ashalim Stream and its surrounding area, for control and prevention of recurrence of the damage caused, to pay monetary relief to the class of injured parties, in the amount of NIS 202.5 million ($54 million), and to provide compensation by means of restoring the natural values impaired and returning the area to its former condition. On May 1, 2018, the Nature and Parks Authority (hereinafter – NPA) filed a motion with the Be’er Sheva District Court to strike the three applications mentioned above as, according to NPA, it is the entity most suitable to serve as the representative plaintiff in a class action in this regard.
|
(1) |
Ecology (cont'd)
|
D. |
In March 2018, an application for certification of a claim as a class action was filed with the District Court in Be’er Sheva by two groups: the first class constituting the entire public in the State of Israel and the second class constituting visitors of Bokek stream and the Dead Sea (hereinafter – the Applicants), against the subsidiaries, Rotem Amfert Negev Ltd. and Periclase Dead Sea Ltd. (hereinafter – the Respondents).
|
(1) |
Ecology (cont'd)
|
D. |
(cont’d)
|
E. |
In October 2018, an application for certification of a class action was filed with the Beer Sheva Magistrate Court against Dead Sea Works Ltd. and Dead Sea Bromine Company Ltd., with respect to a bromine leak that occurred in June 2018, within the premises of Dead Sea Works. According to the plaintiff, the alleged air pollution caused an environmental hazard and a health risk to passersby and to those present in the vicinity of the plant, as well as in the settlements Neot Hakikar and Ein Tamar, and the blocking of Route 90. According to the statement of claim, the Court is requested to award compensation for the alleged damages, in the total amount of about NIS 1.5 million (about $0.4 million). In December 2018, the parties signed a settlement agreement at immaterial amounts to conclude the application proceeding for certification of a class action. The agreement is subject to the Court's approval.
|
(2) |
Increase in level of Pond 5 (hereinafter – the Pond)
|
(2) |
Increase in level of Pond 5 (hereinafter – the Pond) (cont'd)
|
a. |
The planning and execution of the Salt Harvesting Project will be performed by DSW.
|
b. |
The Salt Harvesting Project as well as the project for the new pumping station that is to be constructed (hereinafter – the P-9 Pumping Station), constitute an Israeli national infrastructure project that will be promoted by the Israeli Committee for National Infrastructures.
|
c. |
Starting from January 1, 2017, the water level in the pond will not rise above 15.1 meters in DSW’s network (about 390 meters below sea level). DSW will be required to pay compensation in respect of any damages caused, if at all, as a result of a rise of the water level beyond the level determined. In the case of a material deviation from the timetables for the execution of the Salt Harvesting Project as a result of a requirement for changes by the planning institutions, as a result of which the Plan is not approved on time, or due
to
a decision of a judicial tribunal that caused a delay of at least one year in provision of effect to the Salt Harvesting Project by the planning institutions, without the Company having violated its obligations, the Company will be permitted to request raising of the water level above that stated above.
|
(2) |
Increase in level of Pond 5 (hereinafter – the Pond) (cont'd)
|
d. |
Increase in the rate of the royalties from 5% to 10% of sales, for quantities of chloride potash DSW sells in excess of 1.5 million
tonnes
annually. This increase applies to sales starting January 1, 2012. In July 2012, as part of the agreement, the Government committed that at this time it sees no need to make additional changes to its specific fiscal policy regarding mining from the quarries at the Dead Sea, including the commercial utilization thereof and, accordingly, at this time, it will not initiate and will even object to, as applicable, proposed laws regarding this matter. The Company’s consent to the increase of the rate of the royalties is contingent on implementation of the Government of Israel’s decision.
|
(3) |
Spain
|
A. |
The subsidiary in Spain (hereinafter – ICL Iberia) has two potash production centers – Suria and Sallent. As part of the efficiency plan, the Company intends to consolidate the activities of ICL Iberia into one site by means of expanding the Suria production site and discontinuing the mining activities on the Sallent site. The mining activities in Spain require an environmental mining license and an urban license.
|
(3) |
Spain (cont'd)
|
B. |
Further to the court decision received in 2016 providing that ICL Iberia bears sole responsibility for contamination of the water in certain wells on Suria and Sallent sites (due to an over concentration of salt), in January 2018, claims were received from several owners of the land surrounding the wells, whereby ICL Iberia is required to compensate them for their damages, in the aggregate amount of $22 million. In the Company's estimation, it is more likely than not that
it
will
be required to compensate the owners in the amount of
$12 million.
Accordingly, in 2017 a provision was recorded.
|
(4) |
In December 2018, an application for certification of a class action was filed with the Tel Aviv District Court against the Company, Israel Corporation, and office holders, including directors who held office during the said dates which are stated in the application, with respect to the manner in which the IT (the Harmonization) project was managed and terminated. According to the allegations made in the Application, the Company failed to properly report negative developments which occurred on certain dates during the said IT project whose failure caused the company immense financial damages.
|
(4) |
(cont'd)
|
(5) |
In July 2018, an application for certification of a class action was filed with the Central District Court against the Company and its subsidiaries, Rotem Amfert Negev Ltd. and Fertilizers and Chemicals Ltd. (jointly hereinafter – the Defendants). The causes of action are the alleged exploitation of the Defendants' monopolistic position to charge consumers in Israel excessive and unfair prices for products classified as "solid phosphate fertilizer" between 2011 and 2018, contrary to the provisions of the Restrictive Trade Practices Law, and unjust enrichment at the expense of the plaintiff and the represented group. The representative plaintiff is a Kibbutz member who grows various plants and trees in his yard and in a nearby orchard. The represented group includes all the consumers who purchased, directly or indirectly, solid phosphate fertilizer products manufactured by the Defendants, or farming produce fertilized with solid phosphate fertilizer or food products that include such farming produce as stated above, in the years 2011-2018 (hereinafter – the Represented Group).
|
(6) |
In 2015, an appeal was filed in the Israeli Court for Water Matters by Adam Teva V’Din - Israeli Association for Environmental Protection (ATD) wherein the Court was requested to order the Government Water and Sewage Authority to issue a production license to DSW pursuant to the Water Law with respect to the transfer of water from the North Basin of the Dead Sea to the evaporation ponds in the Sea’s South Basin in order to regulate and supervise, within the framework of the production license, transfer of the water, as stated, in connection with certain aspects, including limitation of the quantities transferred.
|
(6) |
(cont'd)
|
(7) |
In September 2017, a decision of the District Court in Beer Sheva was received regarding a dispute between the National Company for Roads in Israel and DSW, whereby the Company is to participate in restoration of the bridges and bear responsibility for the damage caused as a result of leakage of chemical materials from DSW’s trucks. In October 2017, DSW filed an appeal in the Supreme Court of the District Court’s decision, and in November 2017, the National Company for Roads in Israel filed a counter appeal. In November 2018, the parties agreed to start a mediation process.
Considering the early stage of the proceeding, there is a difficulty in estimating its chances.
|
(8) |
Following the discontinuation of the Harmonization Project (global ERP system), the Company entered into a mediation proceeding with the lead supplier in the Project (
hereinafter -
IBM Israel), for settlement of mutual monetary disputes that arose upon the said discontinuation. In December 2018, following the termination of the mediation proceeding, under which the Company had paid an immaterial amount, the Company filed a lawsuit in the Tel Aviv District Court, against IBM Israel, in the amount of $300 million (about NIS 1
.
1 billion), for compensation of the damages incurred to the Company due to IBM’s failure to meet its undertakings within the Project, which led to the failure of the Project.
Considering
the early stages of the proceedings, there is a difficulty in estimating the certainty of the outcome.
|
(9) |
In October 2018, a petition was filed to the International Trade Administration of the U.S. Department of Commerce and the U.S. International Trade Commission by a US Magnesium company (hereinafter - US Magnesium), to impose antidumping and countervailing duties on imports of magnesium from Israel. US Magnesium claims that imports of magnesium produced in Israel by Dead Sea Magnesium Ltd. are being subsidized and sold at less than fair value in the U.S. market. The US Department of Commerce is expected to issue its preliminary determination with respect to subsidies on May 2, 2019.
|
(10) |
In addition to the contingent liabilities, as stated above, as at the
reporting
date, the contingent liabilities regarding the matters of environmental protection and legal claims, which are pending against the Group, are in immaterial amounts. It is noted that part of the above claims is covered by insurance. According to the Company’s estimation, the provisions recognized in its financial statements are sufficient.
|
As at December 31, 2018
|
As at December 31, 2017
|
|||
Authorized
|
Issued and paid
|
Authorized
|
Issued and paid
|
Number of Ordinary shares of Israeli Shekel 1 par value (in millions)
|
1,485
|
* 1,305
|
1,485
|
* 1,303
|
Number of Special State share of Israeli Shekel 1 par value
|
1
|
1
|
1
|
1
|
Number of Outstanding Shares (in millions)
|
As at January 1, 2017
|
1,301
|
Issuance of shares
|
2
|
As at December 31, 2017
|
1,303
|
Issuance of shares
|
2
|
As at December 31, 2018
|
1,305
|
1. |
The ordinary shares confer upon their holders voting rights (including appointment of directors by a simple majority at General Meetings of the shareholders), the right to participate in shareholders’ meetings, the right to receive profits and the right to a share in excess assets upon liquidation of ICL.
|
2. |
The Special State of Israel Share, held by the State of Israel in order to safeguard matters of vital interest of the State of Israel, confers upon it special rights to make decisions, among other things, on the following matters:
|
- |
Sale or transfer of Company assets, which are “vital” to the State of Israel not in the ordinary course of business.
|
- |
Voluntary liquidation, change or reorganization of the organizational structure of ICL or merger (excluding mergers of entities controlled by ICL that would not impair the rights or power of the Government, as holder of the Special State Share).
|
- |
Any acquisition or holding of 14% or more of the issued share capital of ICL.
|
- |
The acquisition or holding of 25% or more of the issued share capital of ICL (including augmentation of an existing holding up to 25%), even if there was previously an understanding regarding a holding of less than 25%.
|
- |
Any percentage of holding of the Company’s shares, which confers upon its holder the right, ability or actual possibility to appoint, directly or indirectly, such number of the Company’s directors equal to half or more of the Company’s directors actually appointed.
|
1. |
Non-marketable options
|
Grant date
|
Employees entitled
|
Number of instruments (thousands)
|
Issuance's details
|
Instrument terms
|
Vesting conditions
|
Expiration date
|
August 6, 2014
|
Officers and senior employees
|
3,993
|
An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan, to 450 ICL officers and senior employees in Israel and overseas.
|
Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company. In case of on the exercise date the closing price of an ordinary share is higher than twice the exercise price (the “Share Value Cap”), the number of the exercised shares will be reduced so that the product of the exercised shares actually issued to an offeree multiplied by the share closing price will equal to the product of the number of exercised options multiplied by the Share Value Cap.
|
3 equal tranches:
(1) One third on December 1, 2016
(2) One third on December 1, 2017
(3) One third on December 1, 2018
|
Two years from the vesting date.
|
December 11, 2014
|
Former CEO
|
367
|
An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan.
|
|||
May 12, 2015
|
Officers and senior employees
|
6,729
|
An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan, to 550 ICL officers and senior employees in Israel and overseas.
|
Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company.
|
3 equal tranches:
(1) one third at the end of 12 months after the grant date
(2) one third at the end of 24 months after the grant date
(3) one third at the end of 36 months after the grant date
|
The first and second tranches is at the end of 36 months after the grant date for the third tranche is at the end of 48 months after the grant date.
|
June 29, 2015
|
Former CEO
|
530
|
An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan.
|
|||
Former Chairman of BOD
|
404
|
|||||
June 30, 2016
|
Officers and senior employees
|
3,035
|
An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan, to 90 ICL officers and senior employees in Israel and overseas.
|
June 30, 2023
|
||
September 5, 2016
|
Former CEO
|
625
|
An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan.
|
|||
Chairman of BOD
|
186
|
|||||
February 14, 2017
|
Former CEO
|
114
|
An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan.
|
February 14, 2024
|
||
June 20, 2017
|
Officers and senior employees
|
6,868
|
An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan to 498 ICL officers and senior employees in Israel and overseas.
|
June 20, 2024
|
||
August 2, 2017
|
Chairman of BOD
|
165
|
An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan.
|
1. |
Non-marketable options (cont'd)
|
Grant date
|
Employees entitled
|
Number of instruments (thousands)
|
Issuance's details
|
Instrument terms
|
Vesting conditions
|
Expiration date
|
March 6, 2018
|
Officers and senior employees
|
5,554
|
An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan (as amended) to 508 ICL officers and senior employees in Israel and overseas, ICL CEO and Chairman of the BOD.
|
Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company.
|
3 equal tranches:
(1) one third at the end of 12 months after the grant date
(2) one third at the end of 24 months after the grant date
(3) one third at the end of 36 months after the grant date
|
March 6, 2025
|
May 14, 2018
|
CEO
|
385
|
May 14, 2025
|
|||
August 20, 2018
|
Chairman of BOD
|
403
|
August 20, 2025
|
2014 Plan
|
|||||
Granted 2014
|
Granted 2015
|
Granted 2016
|
Granted 2017
|
Granted 2018
|
Share price (in $)
|
8.2
|
7.0
|
3.9
|
4.5
|
4.4
|
CPI-linked exercise price (in $)
|
8.4
|
7.2
|
4.3
|
4.3
|
4.3
|
Expected volatility:
|
|||||
First tranche
|
29.40%
|
25.40%
|
30.51%
|
31.88%
|
28.86%
|
Second tranche
|
31.20%
|
25.40%
|
30.51%
|
31.88%
|
28.86%
|
Third tranche
|
40.80%
|
28.80%
|
30.51%
|
31.88%
|
28.86%
|
Expected life of options (in years):
|
|||||
First tranche
|
4.3
|
3.0
|
7.0
|
7.0
|
7.0
|
Second tranche
|
5.3
|
3.0
|
7.0
|
7.0
|
7.0
|
Third tranche
|
6.3
|
4.0
|
7.0
|
7.0
|
7.0
|
Risk-free interest rate:
|
|||||
First tranche
|
(0.17)%
|
(1.00)%
|
0.01%
|
0.37%
|
0.03%
|
Second tranche
|
0.05%
|
(1.00)%
|
0.01%
|
0.37%
|
0.03%
|
Third tranche
|
0.24%
|
(0.88)%
|
0.01%
|
0.37%
|
0.03%
|
Fair value (in $ millions)
|
8.4
|
9.0
|
4.0
|
11.3
|
8.8
|
Weighted average grant date fair value per option (in $)
|
1.9
|
1.2
|
1.1
|
1.6
|
1.4
|
1. |
Non-marketable options (cont'd)
|
Number of options (in millions)
|
|
2014 Plan
|
Balance as at January 1, 2017
|
14
|
Movement in 2017:
|
|
Granted during the year
|
7
|
Forfeited during the year
|
(1)
|
Total options outstanding as at December 31, 2017
|
20
|
Movement in 2018:
|
|
Granted during the year
|
6
|
Expired during the year
|
(6)
|
Forfeited during the year
|
(1)
|
Exercised during the year
|
(1)
|
Total options outstanding as at December 31, 2018
|
18
|
December 31, 2018
|
December 31, 2017
|
December 31, 2016
|
Granted 2014 US Dollar
|
6.77
|
7.43
|
6.81
|
Granted 2015 US Dollar
|
6.92
|
7.59
|
6.95
|
Granted 2016 US Dollar
|
4.21
|
4.68
|
4.35
|
Granted 2017 US Dollar
|
3.89
|
4.35
|
-
|
Granted 2018 US Dollar
|
3.89
|
-
|
-
|
December 31, 2018
|
December 31, 2017
|
December 31, 2016
|
Number of options exercisable (In Millions)
|
11
|
12
|
10
|
Weighted average exercise price in Israeli Shekel
|
18.53
|
22.56
|
30.49
|
Weighted average exercise price in US Dollar
|
4.94
|
6.51
|
7.93
|
December 31, 2018
|
December 31, 2017
|
December 31, 2016
|
Range of exercise price in Israeli Shekel
|
14.26-25.93
|
15.01-26.3
|
16.59-40.78
|
Range of exercise price in US Dollar
|
3.81-6.92
|
4.33-7.59
|
4.31-10.61
|
December 31, 2018
|
December 31, 2017
|
December 31, 2016
|
Average remaining contractual life
|
3.90
|
2.60
|
2.40
|
2. |
Restricted shares
|
Grant date
|
Employees entitled
|
Number of instruments (thousands)
|
Vesting conditions (*)
|
Instrument terms
|
Additional Information
|
Fair value at the grant date (Million)
|
August 6, 2014
|
Officers and senior employees
|
922
|
3 equal tranches:
(1) One third on December 1, 2016
(2) One third on December 1, 2017
(3) One third on December 1, 2018
|
An issuance for no consideration, under the 2014 Equity Compensation Plan, to 450 ICL officers and senior employees in Israel and overseas.
|
The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the date approval of the BOD and/or the date of the approval of the General Meeting where required).
|
8.4
|
December 11, 2014
|
Former CEO
|
86
|
An issuance for no consideration, under the 2014 Equity Compensation Plan.
|
|||
February 26, 2015
|
ICL’s Directors (excluding ICL's CEO)
|
99
|
3 tranches:
(1) 50% will vest August 28, 2015
(2) 25% will vest February 26, 2017
(3) 25% will vest February 26, 2018
|
An issuance for no consideration, under the 2014 Equity Compensation Plan, to 11 ICL Directors.
|
0.7
|
|
May 12, 2015
|
Officers and senior employees
|
1,194
|
3 equal tranches:
(1) one third at the end of 12 months after the grant date
(2) one third at the end of 24 months after the grant date
(3) one third at the end of 36 months after the grant date
|
An issuance for no consideration, under the 2014 Equity Compensation Plan, to 550 ICL officers and senior employees in Israel and overseas.
|
9.7
|
|
June 29, 2015
|
Former CEO
|
90
|
An issuance for no consideration, under the 2014 Equity Compensation Plan.
|
|||
Former Chairman of the BOD
|
68
|
|||||
December 23, 2015
|
ICL’s Directors (excluding ICL's CEO & Chairman of the BOD)
|
121
|
3 equal tranches:
(1) One third on December 23, 2016
(2) One third on December 23, 2017
(3) One third on December 23, 2018
|
An issuance for no consideration, under the 2014 Equity Compensation Plan, to 8 ICL Directors.
|
0.5
|
2. |
Restricted shares (cont’d)
|
Grant date
|
Employees entitled
|
Number of instruments (thousands)
|
Vesting conditions (*)
|
Instrument terms
|
Additional Information
|
Fair value at the grant date (Million)
|
June 30, 2016
|
Officers and senior employees
|
990
|
3 equal tranches:
(1) one third at the end of 12 months after the grant date
(2) one third at the end of 24 months after the grant date
(3) one third at the end of 36 months after the grant date
|
An issuance for no consideration, under the 2014 Equity Compensation Plan, to 90 ICL officers and senior employees in Israel and overseas.
|
The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the date approval of the BOD and/or the date of the approval of the General Meeting where required).
|
4.8
|
September 5, 2016
|
Chairman of the BOD
|
55
|
An issuance for no consideration, under the 2014 Equity Compensation Plan.
|
|||
Former CEO
|
185
|
|||||
January 3, 2017
|
ICL’s Directors (excluding ICL's Chairman of the BOD)
|
146
|
An issuance for no consideration, under the 2014 Equity Compensation Plan, to 8 ICL Directors.
The value includes a reduction of 5% from the value of the equity compensation, pursuant to the decision of the directors in March 2016, to reduce their annual compensation for 2016 and 2017.
|
0.6
|
||
February 14, 2017
|
Former CEO
|
38
|
An issuance for no consideration, under the 2014 Equity Compensation Plan.
|
0.2
|
||
June 20, 2017
|
Officers and Senior employees
|
2,211
|
An issuance for no consideration, under the 2014 Equity Compensation Plan, to 494 ICL officers and senior employees in Israel and overseas.
|
10
|
||
August 2, 2017
|
Chairman of BOD
|
53
|
An issuance for no consideration, under the 2014 Equity Compensation Plan.
|
0.3
|
||
January 10, 2018
|
ICL’s Directors (excluding ICL's CEO & Chairman of the BOD)
|
137
|
An issuance for no consideration, under the 2014 Equity Compensation Plan, to 7 ICL Directors.
|
0.6
|
3. |
Restricted shares (cont’d)
|
Grant date
|
Employees entitled
|
Number of instruments (thousands)
|
Vesting conditions (*)
|
Instrument terms
|
Additional Information
|
Fair value at the grant date (Million)
|
March 6, 2018
|
Officers and senior employees
|
1,726
|
3 equal tranches:
(1) one third at the end of 12 months after the grant date
(2) one third at the end of 24 months after the grant date
(3) one third at the end of 36 months after the grant date
|
An issuance for no consideration, under the 2014 Equity Compensation Plan (as amended).
|
The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the date approval of the BOD and/or the date of the approval of the General Meeting where required).
|
8
|
May 14, 2018
|
CEO
|
121
|
0.6
|
|||
August 20, 2018
|
Chairman of BOD
|
47
|
0.2
|
|||
ICL’s Directors (excluding ICL's CEO & Chairman of the BOD)
|
88
|
Acceleration at January 2019.
|
0.4
|
Board of Directors decision date
to distribute
the dividend
|
Actual date of
distribution of
the dividend
|
Gross amount of the dividend
distributed
(in millions of $)
|
Net amount of
the distribution
(net of the
subsidiary’s share)
(in millions of $)
|
Amount of
the dividend
per share
(in $)
|
March 15, 2016
|
April 18, 2016
|
67
|
67
|
0.05
|
May 17, 2016
|
June 22, 2016
|
35
|
35
|
0.03
|
August 9, 2016
|
September 27, 2016
|
60
|
60
|
0.05
|
November 22, 2016
|
January 4, 2017
|
60
|
60
|
0.05
|
February 14, 2017
|
April 4, 2017
|
57
|
57
|
0.04
|
May 9, 2017
|
June 20, 2017
|
34
|
32
|
0.03
|
August 2, 2017
|
September 13, 2017
|
32
|
32
|
0.02
|
November 7, 2017
|
December 20, 2017
|
57
|
56
|
0.04
|
February 13, 2018
|
March 14, 2018
|
70
|
69
|
0.05
|
May 10, 2018
|
June 20, 2018
|
52
|
51
|
0.04
|
July 31, 2018
|
September 4, 2018
|
56
|
56
|
0.04
|
October 31, 2018
|
December 19, 2018
|
66
|
65
|
0.05
|
February 5, 2019 (after the reporting date)*
|
March 13, 2019
|
62
|
61
|
0.05
|
1) |
During 2008 and 2009 22.4 million shares were acquired by the Company under a purchase plan, for a total consideration of approximately $258 million. Total shares held by the company and it's subsidiaries are 24.5 million.
|
2) |
In determining the amount of retained earnings available for distribution as a dividend pursuant to the Israeli Companies Law, a deduction must be made from the balance of the retained earnings the amount of self‑acquisitions (that are presented separately in the “treasury shares” category in the equity section).
|
For the year ended December 31
|
|||
2018
|
2017
|
2016
|
|
$ millions
|
$ millions
|
$ millions
|
Sales
|
5,556
|
5,418
|
5,363
|
Cost of sales
|
|||
Materials
|
1,643
|
1,504
|
1,546
|
Cost of labor
|
791
|
777
|
753
|
Depreciation and amortization
|
384
|
363
|
317
|
Energy
|
349
|
343
|
315
|
Other
|
535
|
759
|
772
|
3,702
|
3,746
|
3,703
|
For the year ended December 31
|
|||
2018
|
2017
|
2016
|
|
$ millions
|
$ millions
|
$ millions
|
Selling, transport and marketing expenses
|
|||
Transport
|
553
|
497
|
475
|
Cost of labor
|
125
|
122
|
119
|
Other
|
120
|
127
|
128
|
798
|
746
|
722
|
|
General and administrative expenses
|
|||
Cost of labor
|
172
|
170
|
188
|
Professional Services
|
44
|
49
|
77
|
Other
|
41
|
42
|
56
|
257
|
261
|
321
|
|
Research and development expenses, net
|
|||
Cost of labor
|
38
|
40
|
48
|
Other
|
17
|
15
|
25
|
55
|
55
|
73
|
Other income
|
|||
Capital gain
|
841
|
54
|
-
|
Past service cost
|
7
|
-
|
14
|
Retroactive electricity charges
|
-
|
6
|
16
|
Insurance compensation
|
-
|
30
|
30
|
Other
|
11
|
19
|
11
|
Other income recorded in the income statements
|
859
|
109
|
71
|
Other expenses
|
|||
Provision for legal claims
|
31
|
31
|
21
|
Impairment of assets
|
19
|
32
|
489
|
Provision for historical waste removal and site closure costs
|
18
|
-
|
51
|
Provision for early retirement and dismissal of employees
|
7
|
20
|
39
|
Environment related provisions
|
1
|
7
|
-
|
Other
|
8
|
-
|
18
|
Other expenses recorded in the income statements
|
84
|
90
|
618
|
For the year ended December 31
|
|||
2018
|
2017
|
2016
|
|
$ millions
|
$ millions
|
$ millions
|
Financing income and expenses
|
|||
Financing income:
|
|||
Financing income recorded in relation to employee benefits
|
7
|
-
|
-
|
Net change in fair value of derivative financial instruments
|
-
|
104
|
24
|
Net gain from changes in exchange rates and interest income
|
49
|
1
|
1
|
56
|
105
|
25
|
|
Financing expenses:
|
|||
Interest expenses to banks and others
|
117
|
120
|
151
|
Financing expenses in relation to employee benefits
|
-
|
38
|
17
|
Banks and finance institutions commissions (mainly commission on early repayment of loans)
|
18
|
16
|
4
|
Net change in fair value of derivative financial instruments
|
101
|
-
|
-
|
Net loss from changes in exchange rates
|
-
|
78
|
7
|
Financing expenses
|
236
|
252
|
179
|
Net of borrowing costs capitalized
|
22
|
23
|
22
|
214
|
229
|
157
|
|
Net financing expenses recorded in the income statements
|
158
|
124
|
132
|
As at December 31, 2018
|
|||||
Financial assets
|
Financial liabilities
|
||||
Measured at fair value through the statement of income
|
Measured at fair value through the statement of comprehensive income
|
Measured at amortized cost
|
Measured at fair value through the statement of income
|
Measured at amortized cost
|
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
Cash and cash equivalents
|
-
|
-
|
121
|
-
|
-
|
Short-term investments and deposits
|
-
|
-
|
92
|
-
|
-
|
Trade receivables
|
-
|
-
|
990
|
-
|
-
|
Other receivables
|
13
|
-
|
30
|
-
|
-
|
Investments at fair value through other comprehensive income
|
-
|
145
|
-
|
-
|
-
|
Other non-current assets
|
15
|
-
|
66
|
-
|
-
|
Total financial assets
|
28
|
145
|
1,299
|
-
|
-
|
Short term credit
|
-
|
-
|
-
|
-
|
(610)
|
Trade payables
|
-
|
-
|
-
|
-
|
(715)
|
Other current liabilities
|
-
|
-
|
-
|
(21)
|
(330)
|
Long-term debt and debentures
|
-
|
-
|
-
|
-
|
(1,815)
|
Other non-current liabilities
|
-
|
-
|
-
|
-
|
(6)
|
Total financial liabilities
|
-
|
-
|
-
|
(21)
|
(3,476)
|
Total financial instruments, net
|
28
|
145
|
1,299
|
(21)
|
(3,476)
|
As at December 31, 2017
|
||||||
Financial assets
|
Financial liabilities
|
|||||
Measured at fair value through the statement of income
|
Measured at fair value through the statement of comprehensive income
|
Measured at amortized cost
|
Measured at fair value through the statement of income
|
Measured at amortized cost
|
||
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
Cash and cash equivalents
|
-
|
-
|
83
|
-
|
-
|
Short-term investments and deposits
|
-
|
-
|
90
|
-
|
-
|
Trade receivables
|
-
|
-
|
932
|
-
|
-
|
Other receivables
|
5
|
-
|
81
|
-
|
-
|
Investments at fair value through other comprehensive income
|
-
|
212
|
-
|
-
|
-
|
Other non-current assets
|
64
|
-
|
9
|
-
|
-
|
Total financial assets
|
69
|
212
|
1,195
|
-
|
-
|
Short term credit
|
-
|
-
|
-
|
-
|
(822)
|
Trade payables
|
-
|
-
|
-
|
-
|
(790)
|
Other current liabilities
|
-
|
-
|
-
|
(3)
|
(311)
|
Long-term debt and debentures
|
-
|
-
|
-
|
-
|
(2,388)
|
Other non-current liabilities
|
-
|
-
|
-
|
(3)
|
(1)
|
Total financial liabilities
|
-
|
-
|
-
|
(6)
|
(4,312)
|
Total financial instruments, net
|
69
|
212
|
1,195
|
(6)
|
(4,312)
|
As at December 31
|
||
Carrying amount ($ millions)
|
||
2018
|
2017
|
Cash and cash equivalents
|
121
|
83
|
Short term investments and deposits
|
92
|
90
|
Trade receivables
|
990
|
932
|
Other receivables
|
43
|
86
|
Investments at fair value through other comprehensive income
|
145
|
212
|
Other non-current assets
|
81
|
73
|
1,472
|
1,476
|
Western Europe
|
294
|
332
|
Asia
|
342
|
293
|
North America
|
150
|
131
|
South America
|
106
|
70
|
Israel
|
72
|
70
|
Other
|
26
|
36
|
990
|
932
|
As at December 31
|
||||
2018
|
2017
|
|||
Gross
|
Impairment
|
Gross
|
Impairment
|
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
Not past due
|
829
|
-
|
785
|
-
|
Past due up to 3 months
|
114
|
-
|
125
|
-
|
Past due 3 to 12 months
|
38
|
(1)
|
23
|
(6)
|
Past due over 12 months
|
12
|
(2)
|
10
|
(5)
|
993
|
(3)
|
943
|
(11)
|
2018
|
2017
|
|
$ millions
|
$ millions
|
Balance as at January 1
|
11
|
6
|
Additional allowance
|
1
|
5
|
Write offs
|
(7)
|
(1)
|
Reversals
|
(1)
|
-
|
Changes due to translation differences
|
(1)
|
1
|
Balance as at December 31
|
3
|
11
|
As at December 31, 2018
|
|||||
Carrying amount
|
12 months or less
|
1-2 years
|
3-5 years
|
More than 5 years
|
|
$ millions
|
Non-derivative financial liabilities
|
|||||
Short term credit (not including current maturities)
|
544
|
556
|
-
|
-
|
-
|
Trade payables
|
715
|
715
|
-
|
-
|
-
|
Other current liabilities
|
330
|
330
|
-
|
-
|
-
|
Long-term debt and debentures
|
1,881
|
152
|
453
|
1,084
|
1,166
|
3,470
|
1,753
|
453
|
1,084
|
1,166
|
|
Financial liabilities – derivative instruments utilized for economic hedging
|
|||||
Foreign currency and interest derivative instruments
|
16
|
16
|
-
|
-
|
-
|
Derivative instruments on energy and marine transport
|
5
|
4
|
1
|
-
|
-
|
21
|
20
|
1
|
-
|
-
|
As at December 31, 2017
|
|||||
Carrying amount
|
12 months or less
|
1-2 years
|
3-5 years
|
More than 5 years
|
|
$ millions
|
Non-derivative financial liabilities
|
|||||
Short term credit (not including current maturities)
|
810
|
822
|
-
|
-
|
-
|
Trade payables
|
790
|
790
|
-
|
-
|
-
|
Other current liabilities
|
310
|
310
|
-
|
-
|
-
|
Long-term debt and debentures
|
2,400
|
102
|
345
|
1,085
|
1,358
|
4,310
|
2,024
|
345
|
1,085
|
1,358
|
|
Financial liabilities – derivative instruments utilized for economic hedging
|
|||||
Foreign currency and interest derivative instruments
|
6
|
3
|
-
|
-
|
3
|
As at December 31
|
||
2018
|
2017
|
|
$ millions
|
$ millions
|
Fixed rate instruments:
|
|
|
Financial assets
|
151
|
88
|
Financial liabilities
|
(1,728)
|
(1,800)
|
(1,577)
|
(1,712)
|
|
Variable rate instruments
|
||
Financial assets
|
128
|
97
|
Financial liabilities
|
(714)
|
(1,428)
|
(586)
|
(1,331)
|
As at December 31, 2018
|
||||
Impact on profit (loss)
|
||||
Decrease of 1% in interest
|
Decrease of 0.5% in interest
|
Increase of 0.5% in interest
|
Increase of 1% in interest
|
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
Changes in U.S Dollar interest
|
||||
Non-derivative instruments
|
(1)
|
(1)
|
1
|
1
|
SWAP instruments
|
(18)
|
(9)
|
9
|
18
|
(19)
|
(10)
|
10
|
19
|
|
Changes in Israeli Shekel interest
|
||||
SWAP instruments
|
19
|
10
|
(10)
|
(19)
|
As at December 31, 2018
|
||||
Carrying amount (fair value)
|
Stated amount
|
Maturity date
|
Interest rate range
|
|
$ millions
|
$ millions
|
Years
|
%
|
As at December 31, 2017
|
||||
Carrying amount (fair value)
|
Stated amount
|
Maturity date
|
Interest rate range
|
|
$ millions
|
$ millions
|
Years
|
%
|
U.S Dollar
|
||||
SWAP contracts from variable interest to fixed interest
|
(3)
|
350
|
2018-2024
|
1.36% - 2.6%
|
Israeli Shekel
|
||||
SWAP contracts from fixed ILS interest to fixed USD interest
|
64
|
489
|
1/3/2024
|
2.45% - 4.74%
|
Euro
|
||||
SWAP contracts from variable USD interest to fixed EUR interest
|
(1)
|
51
|
15/8/2018
|
1-month Libor
|
As at December 31
|
||
Impact on profit (loss)
|
||
2018
|
2017
|
|
$ millions
|
$ millions
|
Non-derivative financial instruments
|
||
U.S Dollar/Euro
|
(64)
|
(9)
|
U.S Dollar/Israeli Shekel
|
92
|
92
|
U.S Dollar/British Pound
|
(3)
|
3
|
U.S Dollar/Chinese Yuan
|
(12)
|
(4)
|
U.S Dollar/Turkey Lira
|
(1)
|
(1)
|
As at December 31, 2018
|
||||
Increase 10%
|
Increase 5%
|
Decrease 5%
|
Decrease 10%
|
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
Euro/ U.S Dollar
|
||||
Forward transactions
|
9
|
4
|
(4)
|
(8)
|
Options
|
5
|
2
|
(2)
|
(4)
|
SWAP
|
34
|
17
|
(17)
|
(34)
|
U.S Dollar/Israeli Shekel
|
||||
Forward transactions
|
(32)
|
(17)
|
19
|
39
|
Options
|
(75)
|
(41)
|
19
|
43
|
SWAP
|
(48)
|
(25)
|
28
|
58
|
British Pound/U.S Dollar
|
||||
Forward transactions
|
(4)
|
(2)
|
2
|
3
|
Options
|
(1)
|
(1)
|
-
|
1
|
U.S Dollar/Chinese Yuan Renminbi
|
||||
Forward transactions
|
(3)
|
(1)
|
2
|
3
|
British Pound/Euro
|
||||
Forward transactions
|
(4)
|
(2)
|
2
|
4
|
As at December 31, 2018
|
|||
Carrying amount
|
Stated amount
|
Average
|
|
$ millions
|
$ millions
|
exchange rate
|
Forward contracts
|
|||
U.S Dollar/Israeli Shekel
|
2
|
352
|
3.7
|
Euro/U.S Dollar
|
2
|
86
|
1.2
|
Euro/British Pound
|
1
|
19
|
0.9
|
U.S Dollar/British Pound
|
-
|
32
|
1.3
|
U.S Dollar/Chinese Yuan Renminbi
|
-
|
29
|
6.5
|
Other
|
-
|
37
|
-
|
Currency and interest SWAPs
|
|||
U.S Dollar/Israeli Shekel
|
15
|
486
|
3.7
|
Euro/U.S Dollar
|
(1)
|
334
|
1.1
|
Put options
|
|||
U.S Dollar/Israeli Shekel
|
1
|
695
|
3.6
|
Euro/U.S Dollar
|
2
|
45
|
1.2
|
U.S Dollar/Japanese Yen
|
-
|
3
|
114.3
|
U.S Dollar/British Pound
|
-
|
11
|
1.3
|
Call options
|
|||
U.S Dollar/Israeli Shekel
|
(15)
|
695
|
3.6
|
Euro/U.S Dollar
|
-
|
45
|
1.2
|
U.S Dollar/Japanese Yen
|
-
|
3
|
114.3
|
U.S Dollar/British Pound
|
-
|
11
|
1.3
|
As at December 31, 2017
|
|||
Carrying amount
|
Stated amount
|
Average exchange rete
|
|
$ millions
|
$ millions
|
Forward contracts
|
|||
U.S Dollar/Israeli Shekel
|
2
|
430
|
3.5
|
Euro/U.S Dollar
|
(3)
|
320
|
1.2
|
Euro/British Pound
|
-
|
20
|
0.9
|
U.S Dollar/British Pound
|
-
|
24
|
1.3
|
U.S Dollar/Chinese Yuan Renminbi
|
(1)
|
33
|
6.7
|
Other
|
-
|
33
|
-
|
Currency and interest SWAPs
|
|||
U.S Dollar/Israeli Shekel
|
64
|
489
|
3.7
|
Put options
|
|||
U.S Dollar/Israeli Shekel
|
5
|
525
|
3.4
|
Euro/U.S Dollar
|
-
|
63
|
1.2
|
U.S Dollar/Japanese Yen
|
-
|
3
|
115.5
|
Call options
|
|||
U.S Dollar/Israeli Shekel
|
(1)
|
525
|
3.4
|
Euro/U.S Dollar
|
(2)
|
63
|
1.2
|
U.S Dollar/Japanese Yen
|
-
|
3
|
115.5
|
As at December 31, 2018
|
|||||||
US Dollar
|
Euro
|
British Pound
|
Israeli Shekel
|
Brazilian Real
|
Chinese Yuan Renminbi
|
Others
|
Non-derivative instruments:
|
|||||||
Cash and cash equivalents
|
41
|
21
|
4
|
2
|
5
|
37
|
11
|
Short term investments and deposits
|
74
|
3
|
-
|
-
|
-
|
12
|
3
|
Trade receivables
|
516
|
222
|
60
|
60
|
25
|
72
|
35
|
Other receivables
|
6
|
12
|
-
|
12
|
-
|
-
|
-
|
Investments at fair value through other comprehensive income
|
-
|
-
|
-
|
-
|
-
|
145
|
-
|
Other non-current assets
|
60
|
1
|
-
|
1
|
4
|
-
|
-
|
Total financial assets
|
697
|
259
|
64
|
75
|
34
|
266
|
49
|
Short-term credit
|
201
|
166
|
19
|
34
|
6
|
184
|
-
|
Trade payables
|
150
|
188
|
23
|
265
|
11
|
72
|
6
|
Other current liabilities
|
55
|
46
|
7
|
192
|
2
|
19
|
9
|
Long term debt, debentures and others
|
1,322
|
5
|
-
|
480
|
13
|
1
|
-
|
Total financial liabilities
|
1,728
|
405
|
49
|
971
|
32
|
276
|
15
|
Total non-derivative financial instruments, net
|
(1,031)
|
(146)
|
15
|
(896)
|
2
|
(10)
|
34
|
Derivative instruments:
|
|||||||
Forward transactions
|
-
|
86
|
51
|
352
|
-
|
29
|
37
|
Cylinder
|
-
|
45
|
11
|
695
|
-
|
-
|
3
|
SWAPS – U.S Dollar into Israeli Shekel
|
-
|
-
|
-
|
486
|
-
|
-
|
-
|
SWAPS – U.S Dollar into Euro
|
-
|
334
|
-
|
-
|
-
|
-
|
-
|
Total derivative instruments
|
-
|
465
|
62
|
1,533
|
-
|
29
|
40
|
Net exposure
|
(1,031)
|
319
|
77
|
637
|
2
|
19
|
74
|
As at December 31, 2017
|
|||||||
US Dollar
|
Euro
|
British Pound
|
Israeli Shekel
|
Brazilian Real
|
Chinese Yuan Renminbi
|
Others
|
Non-derivative instruments:
|
|||||||
Cash and cash equivalents
|
19
|
18
|
7
|
1
|
7
|
22
|
9
|
Short term investments and deposits
|
82
|
1
|
-
|
-
|
-
|
5
|
2
|
Trade receivables
|
419
|
246
|
48
|
59
|
31
|
92
|
37
|
Other receivables
|
40
|
1
|
-
|
39
|
-
|
-
|
1
|
Investments at fair value through other comprehensive income
|
-
|
-
|
-
|
-
|
-
|
212
|
-
|
Other non-current assets
|
5
|
1
|
-
|
-
|
3
|
-
|
-
|
Total financial assets
|
565
|
267
|
55
|
99
|
41
|
331
|
49
|
Short-term credit
|
427
|
158
|
20
|
36
|
8
|
173
|
-
|
Trade payables
|
187
|
182
|
23
|
289
|
15
|
85
|
9
|
Other current liabilities
|
95
|
77
|
15
|
96
|
2
|
21
|
5
|
Long term debt, debentures and others
|
1,721
|
29
|
-
|
522
|
22
|
98
|
-
|
Total financial liabilities
|
2,430
|
446
|
58
|
943
|
47
|
377
|
14
|
Total non-derivative financial instruments, net
|
(1,865)
|
(179)
|
(3)
|
(844)
|
(6)
|
(46)
|
35
|
Derivative instruments:
|
|||||||
Forward transactions
|
-
|
320
|
44
|
430
|
-
|
33
|
33
|
Cylinder
|
-
|
63
|
-
|
525
|
-
|
-
|
3
|
Total derivative instruments
|
-
|
383
|
44
|
955
|
-
|
33
|
36
|
Net exposure
|
(1,865)
|
204
|
41
|
111
|
(6)
|
(13)
|
71
|
As at December 31, 2018
|
As at December 31, 2017
|
|||
Carrying amount
|
Fair value
|
Carrying amount
|
Fair value
|
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
Loans bearing fixed interest (1)
|
238
|
244
|
271
|
279
|
Debentures bearing fixed interest
|
||||
Marketable (2)
|
1,201
|
1,217
|
1,247
|
1,291
|
Non-marketable (3)
|
281
|
279
|
281
|
288
|
1,720
|
1,740
|
1,799
|
1,858
|
As at December 31, 2018
|
|
Level 2
|
|
$ millions
|
Investments at fair value through other comprehensive income (1)
|
145
|
Derivatives used for economic hedging, net
|
7
|
152
|
As at December 31, 2017
|
|
Level 2
|
|
$ millions
|
Investments at fair value through other comprehensive income (1)
|
212
|
Derivatives used for economic hedging, net
|
63
|
275
|
For the year ended December 31
|
|||
2018
|
2017
|
2016
|
|
$ millions
|
$ millions
|
$ millions
|
Earnings (losses) attributed to the shareholders of the Company
|
1,240
|
364
|
(122)
|
For the year ended December 31
|
|||
2018
|
2017
|
2016
|
|
Shares thousands
|
Shares thousands
|
Shares thousands
|
Balance as at January 1
|
1,276,238
|
1,274,298
|
1,272,516
|
Shares issued during the year
|
73
|
1,054
|
-
|
Shares vested
|
898
|
720
|
779
|
Weighted average number of ordinary shares used in computation of the basic earnings per share
|
1,277,209
|
1,276,072
|
1,273,295
|
For the year ended December 31
|
|||
2018
|
2017
|
2016
|
|
Shares thousands
|
Shares thousands
|
Shares thousands
|
Weighted average number of ordinary shares used in the computation of the basic earnings per share
|
1,277,209
|
1,276,072
|
1,273,295
|
Effect of stock options and restricted shares
|
2,572
|
925
|
-
|
Weighted average number of ordinary shares used in the computation of the diluted earnings per share
|
1,279,781
|
1,276,997
|
1,273,295
|
A. |
Parent company and subsidiaries
|
Short-term benefits
|
11
|
8
|
Post-employment benefits
|
1
|
1
|
Share-based payments
|
4
|
4
|
Total *
|
16
|
13
|
* To interested parties employed by the Company
|
5
|
4
|
* To interested parties not employed by the Company
|
1
|
1
|
Sales
|
5
|
8
|
35
|
Cost of sales
|
19
|
97
|
113
|
Selling, transport and marketing expenses
|
7
|
8
|
7
|
Financing expenses (income), net
|
3
|
(9)
|
-
|
General and administrative expenses
|
1
|
1
|
1
|
Management fees to the parent company
|
1
|
1
|
1
|
(1) |
A subsidiary in the Phosphate Solutions segment is engaged in a long-term agreement with Nutrien, for acquisition of food‑quality phosphoric acid. The agreement is in effect until the end of 2018. In October 2017, the Company signed a new agreement with Nutrien for acquisition of phosphoric acid commencing January 2019 up to 2025. Nutrien was an interested party up to January 2018.
|
(2) |
In 2013, the Company's Board of Directors authorized certain subsidiaries in Israel to purchase electricity from OPC Rotem (a company related to the Company’s controlling shareholder).
|
(3) |
On January 17, 2018, our Audit and Accounting Committee and our Board of Directors approved, and on April 24, 2018, our General Meeting of shareholders approved, the renewed management agreement effective retroactively as of January 1, 2018, for an additional term of three years, expiring on December 31, 2020. According to the renewed management agreement, the annual management fee paid to Israel Corp for each calendar year, shall not exceed $1
million
plus VAT. Such amount includes the overall value of the cash and equity compensation for the service of our directors whom are office holders of Israel Corp., and any and all prior or other compensation arrangements relating to such directors were cancelled. In addition, the renewed agreement was amended so as to no longer include an increase of management fees to a threshold of $3.5 million plus VAT in case an executive chairman of the Board is appointed on behalf of Israel Corporation. All other provisions of the management agreement remained unchanged. According to the decision of the General Meeting of our shareholders, the Audit & Accounting Committee will annually examine the reasonableness of the Management Fees paid in the previous year against the Management Services actually provided by Israel Corp to the Company in the same year. On February 4 and 25, 2019, the Audit & Accounting Committee examined the management services that were actually rendered in 2018 against the management fees paid in that year and concluded that the fees were reasonable
|
(4) |
In March 2017, ICL's Audit and Accounting Committee and its Board of Directors approved a framework agreement with the controlling shareholder, Israel Corporation Ltd. (hereinafter – Israel Corp.), for three years, according to which Israel Corp. can deposit, occasionally, an amount of up to $150 million in short‑term U.S. dollar or shekel deposits in ICL subject to ICL’s approval. In August 2017, the terms of the framework agreement were expanded to up to $250 million. The terms and conditions of the deposits, including the interest rate, will be determined on the date of the deposits. The deposits will be received by ICL without security. In
fourth quarter of
2017,
the Company
received
short-term
loans, in
a total
amount of $175 million, for a period of 6 months, bearing interest at an annual rate of 1.72%–1.99
%, which were repaid in
the first quarter of 2018
.
|
(5) |
In
December 2017, the Company, Oil Refineries Ltd. (a public company controlled by Israel Corporation Ltd.) and OPC Energy Ltd. (a public company that is controlled indirectly by one of the Company’s controlling shareholders) signed individual agreements with Energean Israel Limited for supply of natural gas. The company share will be up to 13 BCM of natural gas over a period of 15 years, in the total amount of about $1.9 billion. For
further
information see Note 20.
|
As at December 31
|
||
2018
|
2017
|
|
$ millions
|
$ millions
|
Other current assets
|
28
|
38
|
Other current liabilities
|
7
|
191
|
Ownership interest in its subsidiary and investee companies for the year ended December 31
|
|||
Name of company
|
Principal location of the company’s activity
|
2018
|
2017
|
ICL Israel Ltd.
|
Israel
|
100.00%
|
100.00%
|
Dead Sea Works Ltd.
|
Israel
|
100.00%
|
100.00%
|
Dead Sea Bromine Company Ltd.
|
Israel
|
100.00%
|
100.00%
|
Rotem Amfert Negev Ltd.
|
Israel
|
100.00%
|
100.00%
|
Mifalei Tovala Ltd.
|
Israel
|
100.00%
|
100.00%
|
Dead Sea Magnesium Ltd.
|
Israel
|
100.00%
|
100.00%
|
Ashli Chemicals (Holland) B.V.
|
Israel
|
100.00%
|
100.00%
|
Bromine Compounds Ltd.
|
Israel
|
100.00%
|
100.00%
|
Tetrabrom Technologies Ltd.*
|
Israel
|
0.00%
|
100.00%
|
Fertilizers and Chemicals Ltd.
|
Israel
|
100.00%
|
100.00%
|
Iberpotash S.A.
|
Spain
|
100.00%
|
100.00%
|
Fuentes Fertilizantes S.L.
|
Spain
|
100.00%
|
100.00%
|
ICL Europe Coöperatief U.A.
|
The Netherlands
|
100.00%
|
100.00%
|
ICL-IP Europe B.V.
|
The Netherlands
|
100.00%
|
100.00%
|
ICL IP Terneuzen B.V.
|
The Netherlands
|
100.00%
|
100.00%
|
ICL Fertilizers Europe C.V.
|
The Netherlands
|
100.00%
|
100.00%
|
ICL Finance B.V.
|
The Netherlands
|
100.00%
|
100.00%
|
Everris International B.V.
|
The Netherlands
|
100.00%
|
100.00%
|
ICL Puriphos B.V.
|
The Netherlands
|
100.00%
|
100.00%
|
ICL-IP America Inc.
|
United States of America
|
100.00%
|
100.00%
|
ICL Specialty Products Inc.
|
United States of America
|
100.00%
|
100.00%
|
Everris N.A. Inc.
|
United States of America
|
100.00%
|
100.00%
|
Phosphorus Derivatives Inc.**
|
United States of America
|
0.00%
|
100.00%
|
BK Giulini GmbH
|
Germany
|
100.00%
|
100.00%
|
ICL Holding Germany GmbH
|
Germany
|
100.00%
|
100.00%
|
ICL I.P. Bitterfeld GmbH
|
Germany
|
100.00%
|
100.00%
|
Rovita GmbH
|
Germany
|
100.00%
|
100.00%
|
Prolactal GmbH
|
Austria
|
100.00%
|
100.00%
|
Cleveland Potash Ltd.
|
United Kingdom
|
100.00%
|
100.00%
|
ICL Brasil, Ltda.
|
Brazil
|
100.00%
|
100.00%
|
ICL (Shanghai) Investment Co. Ltd.
|
China
|
100.00%
|
100.00%
|
Yunnan Phosphate Haikou Co. Ltd.
|
China
|
50.00%
|
50.00%
|
Sinobrom Compounds Co. Ltd., China
|
China
|
75.00%
|
75.00%
|
ICL Asia Ltd.
|
Hong Kong
|
100.00%
|
100.00%
|
ICL Trading (HK) Ltd.
|
Hong Kong
|
100.00%
|
100.00%
|
Allana Potash Afar PLC***
|
Ethiopia
|
100.00%
|
100.00%
|
ICL Finance B.V.
PO Box 313 1000 AH Amsterdam The Netherlands
Israel Chemicals Limited
Millennium Tower, 23 Aranha st. Tel-Aviv 6107025 Israel |
ICL Finance Inc.
1220 N. Market Street Suite 808, City of Wilmington County of New Castle, Delaware United States of America |
1 |
We refer to the Facility Agreement. Words and expressions defined in the Facility Agreement shall have the same meanings in this letter.
|
2 |
We write as Agent under the Facility Agreement and with the consent of all of the Lenders.
|
3 |
In this letter
Effective Date
means the first day of the Interest Period following the date on which we receive:
|
(a) |
a copy of this letter duly executed by you;
|
(b) |
a copy of the new agency Fee Letter duly executed by you; and
|
(c) |
the following documents in form and substance satisfactory to us:
|
(i) |
a legal opinion of:
|
(aa) |
Dentons UK and Middle East LLP, legal advisers to the Agent in England;
|
(bb) |
Houthoff Buruma London B.V., legal advisers to the Agent in the Netherlands;
|
(cc) |
Aner Berger, Advocates, legal advisers to the Parent in Israel; and
|
(dd) |
Mcguire Woods, legal advisers to the Agent who are providing, among other opinions, a capacity and authority opinion in respect of ICL Finance Inc. as a Delaware incorporated entity; and
|
(ii) |
the relevant constitutional and corporate authorisation documents required to support the issuance of legal opinions in form and substance satisfactory to the Agent listed in sub-paragraph (i) above,
|
(aa) |
the Agent must (and does so with the consent of all Parties) notify Bank of America Merrill Lynch International Limited (in its capacity as a prospective Lender) of a relevant Loan three Business Days prior to the proposed Utilisation Date that is due to be immediately on or following the Effective Date (and only for such Utilisation Date) so that Bank of America Merrill Lynch International Limited as New Lender can adhere to its obligations under Clause 5.4 (
Lenders' participation
) of the Facility Agreement on the Effective Date. For the avoidance of doubt, the relevant Utilisation Request shall be forward-looking to reflect the adjusted Commitments (if applicable) as at such proposed Utilisation Date, with all the conditions pursuant to Clause 4 (
Conditions of Utilisation
) needing to met for such Utilisation;
|
(bb) |
no Loan is outstanding on the Effective Date; and
|
(cc) |
such date is no later than 31 December 2018.
|
4 |
With effect from the Effective Date the Facility Agreement will be amended as follows:
|
(a) |
the definition of 'Amendment Letter' shall be included in clause 1.1 (
Definitions
) of the Facility Agreement:
|
(b) |
the existing definition of 'Commitment' will be deleted in its entirety and be replaced with the following in clause 1.1 (
Definitions
) of the Facility Agreement:
|
(a) |
in relation to a Lender listed in Schedule 1 (
The Original Lenders
), the amount in US Dollars set opposite its name under the heading "Commitment" in Schedule 1 (
The Original Lenders
) and the amount of any other Commitment transferred to it under this Agreement; and
|
(b) |
in relation to any other Lender, the amount in US Dollars of any Commitment transferred to it under this Agreement
|
(c) |
the existing definition of 'First Maturity Date' will be deleted in its entirety and be replaced with the following definition in clause 1.1 (
Definitions
) of the Facility Agreement:
|
(d) |
the existing definition of 'Total Commitments' will be deleted in its entirety and be replaced with the following definition in clause 1.1 (
Definitions
) of the Facility Agreement and all other references to 'US$1,705,000,000' shall be replaced with 'US$1,200,000,000' throughout the Facility Agreement:
|
(e) |
the following new clause 1.2.5 will be inserted into the Facility Agreement:
|
(f) |
clause 7.2 (
Extension Option
) of the Facility Agreement will be deleted in its entirety and be replaced with the following in clause 7.2 (
Extension Option
) of the Facility Agreement:
|
'7.2.1 |
The Borrower may by notice to the Agent (the
Initial Extension Request
) not more than 60 days and not less than 35 days before the first anniversary of the date of the Amendment Letter, request that the First Maturity Date be extended for a further period to the Second Maturity Date.
|
7.2.2 |
The Borrower may by notice to the Agent (the
Ultimate Extension Request
) no more than 60 days and not less than 35 days before the second anniversary of the Amendment Letter, request that the Termination Date:
|
(a) |
with respect to Lenders who have agreed to the Initial Extension Request, be extended for a further period to the Third Maturity Date; and/or
|
(b) |
if no Initial Extension Request has been made, or with respect to Lenders who refused the Initial Extension Request:
|
(i) |
be extended for a period of one year to the Second Maturity Date; or
|
(ii) |
be extended for a period of two years to the Third Maturity Date,
|
7.2.3 |
The Agent must promptly notify the Lenders of any Initial Extension Request or Ultimate Extension Request (an
Extension Request
).
|
7.2.4 |
Each Lender may, in its absolute discretion, decide whether or not to accept the Extension Request. Each Lender that agrees to an Extension Request by the date falling 15 days before the relevant anniversary of the date of the Amendment Letter, will extend its Commitment for a further period of one year or two years, as applicable, from the then current Termination Date and the applicable Termination Date with respect to the Commitment of that Lender will be extended accordingly.
|
7.2.5 |
If any Lender fails to reply to an Extension Request on or before the date falling 15 days before the relevant anniversary of the date of the Amendment Letter, it will be deemed to have refused that Extension Request and its Commitments will not be extended.
|
7.2.6 |
If one or more (but not all) of the Lenders agree to an Extension Request, then the Agent must notify the Borrower and the Lenders which have agreed to the extension, identifying in that notification which Lenders have not agreed to the Extension Request.
|
7.2.8 |
The Borrower may, on the basis that one or more of the Lenders has or have not agreed to the Extension Request and no later than the date falling 5 days before the relevant anniversary of the date of the Amendment Letter, withdraw the request by notice to the Agent which will promptly notify the Lenders.
|
7.2.9 |
The Borrower shall pay the Extension Fee to the Agent for the account of each Lender that has accepted the relevant Extension Request.'
|
(g) |
the table in Schedule 1 (
The Original Lenders
) to the Facility Agreement will be deleted in its entirety and be replaced with the following table. Furthermore, any reference to 'BNP Paribas Fortis SA/NV, Netherlands Branch' in the Finance Documents shall be replaced with 'BNP Paribas SA, Netherlands Branch':
|
Banco Bilbao Vizcaya Argentaria, S.A.
|
100,000,000
|
Bank of America Merrill Lynch International Limited
|
100,000,000
|
Barclays Bank PLC
|
100,000,000
|
BNP Paribas SA, Netherlands Branch
|
100,000,000
|
Citibank, N.A.
|
100,000,000
|
Commerzbank Aktiengesellschaft, Filiale Luxemburg
|
100,000,000
|
Coöperatieve Centrale Raiffeissen-Boerenleenbank B.A. (trading as Rabobank)
|
100,000,000
|
Crédit Agricole Corporate and Investment Bank
|
100,000,000
|
HSBC Bank Plc
|
100,000,000
|
MUFG Bank, Ltd.
|
100,000,000
|
Sumitomo Mitsui Banking Corporation Europe Limited
|
100,000,000
|
UniCredit Bank Austria AG
|
100,000,000
|
Total
|
US$1,200,000,000
|
5 |
Without prejudice to the rights of any Finance Party which have arisen on or before the Effective Date:
|
(a) |
each Obligor confirms that, on and after the Effective Date the Facility Agreement (as amended by this letter), and the other Finance Documents, will remain in full force and effect; and
|
(b) |
each Guarantor confirms that, on and after the Effective Date, its guarantee, undertaking and indemnity under Clause 18 (
Guarantee and indemnity
) of the Facility Agreement will remain in full force and effect and will extend to each Obligor's obligations under the Finance Documents (as amended by this letter).
|
6 |
To the extent that a Guarantor's guarantee, undertaking or indemnity under Clause 18 (
Guarantee and indemnity
) of the Facility Agreement is not, for any reason, enforceable on or after the Effective Date in relation to each Obligor's obligations under the Finance Documents (as amended by this letter), that Guarantor guarantees to, undertakes with and indemnifies each Finance Party on the terms of those clauses in relation to those obligations on and after the Effective Date.
|
7 |
The representations and warranties set out in Clause 19 (
Representations
) of the Facility Agreement are deemed to be repeated by each Obligor by reference to the facts and circumstances then existing on:
|
8 |
Save as set out under paragraphs 4 and 13, nothing in this letter shall be deemed to be:
|
(a) |
an amendment to the terms of any Finance Document;
|
(b) |
a waiver or consent by the Lenders to any breach or potential breach (present or future) of any provision of the Finance Documents; or
|
(c) |
any waiver of a Default or Event of Default (however described).
|
9 |
The Borrower shall:
|
(a) |
within five Business Days of demand of the Agent, reimburse the Agent for the amount of all costs and expenses (including legal fees) reasonably incurred by it in connection with this letter; and
|
(b) |
on the Effective Date, pay to the Agent for the account of the Lenders (including Bank of America Merrill Lynch International Limited as New Lender) an upfront fee of US$1,200,000.
|
10 |
This letter is a Finance Document.
|
11 |
Clauses 38 (
Counterparts
) to 40 (
Enforcement
) (inclusive) of the Facility Agreement shall apply to this letter as they apply to the Facility Agreement.
|
12 |
Other than a Lender, a person who is not a party to this letter has no right under the Contracts (Rights of Third Parties) Act 1999 to enforce or to enjoy the benefit of any term of this letter.
|
13 |
By Bank of America Merrill Lynch International Limited signing and dating the acceptance on the enclosed copy of this letter and returning it to us, Bank of America Merrill Lynch International Limited confirms as New Lender:
|
(a) |
its agreement to the terms of this letter;
|
(b) |
that it shall become a Party as a "Lender"; and
|
(c) |
that it will assume the same obligations to the other Finance Parties as it would have been under if it was an Original Lender.
|
14 |
By the Obligors signing and dating the acceptance on the enclosed copy of this letter and returning it to us, the Obligors confirm:
|
(a) |
their agreement to the terms of this letter (including, for the avoidance of doubt, Bank of America Merrill Lynch International Limited becoming a Party as a "Lender"); and
|
(b) |
that no Default is continuing.
|
/s/ Chris Sims
|
/s/ Yulchrlo Iwamoto
|
|
Vice President
|
Assistant Vice President
|
/s/ Marina Heilika
|
|
Director, Corporate and Investment banking
|
/s/ Ron Mulder
|
/s/ Coby Ben Hamou
|
|
ICL Europe Tax & Treasury Director
|
VP, CFO Europe
|
|
Authorised signatory
|
Authorised signatory
|
|
Date:
October 29, 2018
|
Date:
October 29, 2018
|
/s/ Michael Hazzan
|
/s/ Lisa Haimovitz
|
|
SVP, Corporate Finance
|
SVP, Global General Counsel
|
Authorised signatory
|
Authorised signatory
|
|
Date:
October 29, 2018
|
Date:
October 29, 2018
|
/s/ Paul Schlessman
|
/s/ John Laaker
|
|
President
|
Treasurer
|
|
Authorised signatory
|
Authorised signatory
|
|
Date:
October 29, 2018
|
Date:
October 29, 2018
|
|
1.
|
I have reviewed this annual report on Form 20-F of Israel Chemicals Ltd.;
|
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;
|
|
4.
|
The company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:
|
|
(a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
|
(b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
|
(c)
|
Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
|
(d)
|
Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and
|
|
5.
|
The company’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent functions):
|
|
(a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and
|
|
(b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting.
|
Date: February 26, 2019
|
/s/
Raviv Zoller
|
Raviv Zoller
ICL President and CEO
|
|
1.
|
I have reviewed this annual report on Form 20-F of Israel Chemicals Ltd.;
|
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;
|
|
4.
|
The company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:
|
|
(a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
|
(b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
|
(c)
|
Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
|
(d)
|
Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and
|
|
5.
|
The company’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent functions):
|
|
(a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and
|
|
(b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting.
|
Date: February 26, 2019
|
/s/ Kobi Altman
|
|
Kobi Altman
Chief Financial Officer
|
Name of Subsidiary / Investee company
|
Jurisdiction of Incorporation
|
Agro-Vant
|
Israel
|
Bromine Compounds Ltd.,
|
Israel
|
Chemada Fine Chemicals Ltd.
|
Israel
|
Dead Sea Bromine Company Ltd.
|
Israel
|
Dead Sea Magnesium Ltd.
|
Israel
|
Dead Sea Periclase Fused Products Co.
|
Israel
|
Dead Sea Periclase Ltd.
|
Israel
|
Dead Sea Works Ltd.
|
Israel
|
Edom Mining and Development Ltd.
(the operations were transferred to
Rotem)
|
Israel
|
Fertilizers and Chemicals Ltd.
|
Israel
|
ICL Innovation Ltd
|
Israel
|
ICL Israel Ltd.
|
Israel
|
Industrial Chemical Equipment Ltd.
|
Israel
|
Israel Light Metal Initiative Ltd.
|
Israel
|
Keter Tovala Ltd (
the operations were transferred to
Rotem)
|
Israel
|
M.M.M. Company United Landfill, Industries (1998), Ltd.
|
Israel
|
Mifalei Tovala Ltd.,
|
Israel
|
Novetide Ltd.
|
Israel
|
P.A.M.A. Ltd (Energy Resources Development)
|
Israel
|
Potassium Nitrate Ltd.
|
Israel
|
Revivim in the Bay Water Environment Ltd.
|
Israel
|
Rotem Amfert Negev Ltd.
|
Israel
|
Sherut Integrated transportation services 2013 Ltd.
|
Israel
|
Sherut Rail & Road Transportation Services 1990 Registered Partnership in Israel
|
Israel
|
Tami (IMI) Institute for R&D Ltd.
|
Israel
|
Tami Nano Innovation Lab Ltd.
|
Israel
|
B.K. Giulini Argentina S.A
|
Argentina
|
Everris Australia Pty Ltd.
|
Australia
|
Fibrisol Service Australia Pty. Ltd.
|
Australia
|
Prolactal GmbH
|
Austria
|
ICL Belgium (Sales) N.V.
|
Belgium
|
ICL Belgium NV
|
Belgium
|
Bromisa Industrial e Commercial Ltda.
|
Brazil
|
ICL Brazil, Ltda.
|
Brazil
|
Rotem Do Brasil Ltda.
|
Brazil
|
Allana Potash Corp.
|
Canada
|
Name of Subsidiary / Investee company
|
Jurisdiction of Incorporation
|
ICL Investment Co. Ltd.
|
China
|
ICL Trading (HK) Ltd.
|
China
|
Jiaxing I.C.L. Chemical Co. Ltd.
|
China
|
Lianyungang Dead Sea Bromine Compounds Co. Ltd
|
China
|
Shanghai Tari International Food Additive Co. Ltd.,
|
China
|
Sinobrom Compounds Co. Ltd.
|
China
|
Yunnan BK Giulini Tianchuang Phosphate Co. Ltd.,
|
China
|
Yunnan ICL YTH Phosphate Research and Technology Center Co. Ltd.
|
China
|
Yunnan Phosphate Haikou Co. Ltd.
|
China
|
Yunnan Three Circles Chemicals Co., Ltd., (under liquidation)
|
China
|
Yunnan Yuntianhua Co., Ltd.
|
China
|
Zhangjiagang F.T.Z. ICL Trading Co.
|
China
|
Allana Potash Afar PLC
|
Ethiopia
|
ICL Potash Ethiopia Plc.
|
Ethiopia
|
Nova Potash PLC
|
Ethiopia
|
Potash Afar PLC * under liquidation
|
Ethiopia
|
Rotem Manufacturing Private Limited Company
|
Ethiopia
|
Hagesüd Interspice France S.A.R.L
|
France
|
Scora S.A.S.
|
France
|
Sofima SAS
|
France
|
B.K. Giulini GmbH
|
Germany
|
BKG Finance GmbH
|
Germany
|
BKG Finance Sup GmbH
|
Germany
|
Hagesüd Interspice Gewürzwerke GmbH
|
Germany
|
Hoyerman Chemie GmbH
|
Germany
|
ICL Deutschland Ludwigshafen GmbH
|
Germany
|
ICL Deutschland Vertriebs GmbH
|
Germany
|
ICL Fertilizers Deutschland GmbH,
|
Germany
|
ICL Germany Food and Chemical Specialties GmbH
|
Germany
|
ICL Holding Beschraenkt Haftende O.H.G.
|
Germany
|
ICL Holding Germany GmbH
|
Germany
|
ICL IP Bitterfeld GmbH
|
Germany
|
ICL Ludwigshafen Service GmbH
|
Germany
|
ICL-IP Bitterfeld Grundbesitz GmbH & Co KG
|
Germany
|
Rotem Holding GmbH
|
Germany
|
Rovita GmbH
|
Germany
|
Turris Versicherungvermittlung GmbH
|
Germany
|
Name of Subsidiary / Investee company
|
Jurisdiction of Incorporation
|
A.R.M. Ltd.,
|
Hong Kong
|
B.K. Giulini Leather Chemistry Co. Ltd. (under liquidation)
|
Hong Kong
|
B.K. Giulini Personal Care Co., Ltd. (under liquidation)
|
Hong Kong
|
D.D.F.R Corporation Ltd.
|
Hong Kong
|
ICL Asia Ltd.
|
Hong Kong
|
B.K. Giulini Specialties Private Limited
|
India
|
ICL Fertilizers (India) Private Ltd.
|
India
|
ICL Management and Trading India Private Limited
|
India
|
ICL Italia Treviso SRL,
|
Italy
|
ICL Italy Milano SRL
|
Italy
|
ICL Japan Ltd.
|
Japan
|
Everris Kenya Ltd.
|
Kenya
|
ICL Korea Ltd.
|
Korea
|
Everris Malaysia Sdn. Bhd
|
Malaysia
|
ICL Fosfatos y Aditivos de México S. A. de C.V.
|
Mexico
|
Tari International N.Z. Ltd.
|
New Zealand
|
ICL Polska S.p z.o.o
|
Poland
|
ICL Group Asia Pacific PTE. LTD
|
Singapore
|
ICL Slovakia
|
Slovakia
|
Landchem Ltd.
|
South Africa
|
Absia SL
|
Spain
|
Agrocallejas Mediterranea, S.L Unipersonal
|
Spain
|
Everis Iberica Fertilizers S.L.
|
Spain
|
Fomento y Desarrollo Agrícola S.L
|
Spain
|
Fuentes Fertilizantes S.L.
|
Spain
|
Iberpotash S.A.
|
Spain
|
ICL Iberia Ltd. SCA
|
Spain
|
Logistica de Fertilizers Fuentes S.A.
|
Spain
|
Sal Vesta Iberia S.L.
|
Spain
|
Trafico de Mercancías S.A.
|
Spain
|
Twincap Forsakrings A.B.
|
Sweden
|
ICL Swiss (Zug) GmbH
|
Swiss
|
Intracap Insurance Ltd
|
Switzerland
|
ICL Fertilizers Tanzania Limited
|
Tanzania
|
Name of Subsidiary / Investee company
|
Jurisdiction of Incorporation
|
Amsterdam Fertilizers B.V.
|
The Netherlands
|
Ashli Chemicals (Holland) B.V.
|
The Netherlands
|
Eurocil B.V
|
The Netherlands
|
Everris International B.V.
|
The Netherlands
|
Finacil E.E.I.G. (European Economic Interest Grupen)
|
The Netherlands
|
ICL Europe B.V.
|
The Netherlands
|
ICL Europe Coöperatief U.A.
|
The Netherlands
|
ICL Fertilizers Europe C.V.
|
The Netherlands
|
ICL Finance B.V.,
|
The Netherlands
|
ICL Potash Ethiopia BV
|
The Netherlands
|
ICL Puriphos B.V.
|
The Netherlands
|
ICL-IP Terneuzen B.V
|
The Netherlands
|
Incap B.V.
|
The Netherlands
|
Rotem Kimyevi Maddeler Sanayi ve Ticaret A.S,
|
Turkey
|
Amega Sciences Holdings Ltd.
|
UK
|
Amega Sciences Plc.
|
UK
|
Cleveland Potash Ltd.
|
UK
|
Constantine & Company (Export) Limited
|
UK
|
Everris Ltd.
|
UK
|
Fibrisol Service Ltd.
|
UK
|
ICL UK (Sales) Ltd.
|
UK
|
Nutrient Sciences Ltd.
|
UK
|
B.K. Mercosur S.A.
|
Uruguay
|
Everris NA, Inc.
|
USA
|
ICL Americas LLC
|
USA
|
ICL Finance Inc.
|
USA
|
ICL Group America Inc.
|
USA
|
ICL Specialty products Inc
|
USA
|
ICL Specialty Products North America Inc.
|
USA
|
ICL-IP America Inc.
|
USA
|
1.
|
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and
|
2.
|
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Israel Chemicals Ltd.
|